STN Columbus

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
NEWS
                 CA/CAplus pre-1967 chemical substance index entries enhanced
         DEC 18
NEWS
                 with preparation role
                 CA/CAplus patent kind codes updated
NEWS
     4 DEC 18
NEWS 5 DEC 18
                 MARPAT to CA/Caplus accession number crossover limit increased
         DEC 18
                 MEDLINE updated in preparation for 2007 reload
NEWS 6
      7 DEC 27
                 CA/CAplus enhanced with more pre-1907 records
NEWS
NEWS 8 JAN 08
                 CHEMLIST enhanced with New Zealand Inventory of Chemicals
         JAN 16
                 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 9
NEWS 10
         JAN 16
                 IPC version 2007.01 thesaurus available on STN
NEWS 11
         JAN 16
                 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
                 CA/CAplus updated with revised CAS roles
NEWS 12
         JAN 22
                 CA/CAplus enhanced with patent applications from India
NEWS 13
         JAN 22
                 PHAR reloaded with new search and display fields
CAS Registry Number crossover limit increased to 300,000 in
NEWS 14
        JAN 29
NEWS 15 JAN 29
                 multiple databases
                 PATDPASPC enhanced with Drug Approval numbers
NEWS 16 FEB 15
                 RUSSIAPAT enhanced with pre-1994 records
NEWS 17
        FEB 15
NEWS 18
        FEB 23
                 KOREAPAT enhanced with IPC 8 features and functionality
         FEB 26
                 MEDLINE reloaded with enhancements
NEWS 19
NEWS 20 FEB 26
                 EMBASE enhanced with Clinical Trial Number field
                 TOXCENTER enhanced with reloaded MEDLINE
NEWS 21
        FEB 26
                 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 22
        FEB 26
NEWS 23 FEB 26
                 CAS Registry Number crossover limit increased from 10,000
                 to 300,000 in multiple databases
         MAR 15
                 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 24
         MAR 16
                 CASREACT coverage extended
         MAR 20
                 MARPAT now updated daily
NEWS 26
NEWS 27
         MAR 22
                 LWPI reloaded
NEWS 28
         MAR 30
                 RDISCLOSURE reloaded with enhancements
NEWS 29
         MAR 30
                 INPADOCDB will replace INPADOC on STN
NEWS EXPRESS
              NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP)
              AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
              Welcome Banner and News Items
              For general information regarding STN implementation of IPC 8
 NEWS IPC8
NEWS X25
              X.25 communication option no longer available
Enter NEWS followed by the item number or name to see news on that
specific topic.
  All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
           *JICST-EPLUS - JICST-EPlus File on Sci. & Tech. in Japan 1985-present
  * The files listed above are temporarily unavailable.
```

SINCE FILE

ENTRY

TOTAL

SESSION

FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007

=> file reg

COST IN U.S. DOLLARS

FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3 DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/reqprops.html

```
=> e tamoxifen/cn
                       TAMOTSU V/CN
E1
               1
                       TAMOX - PUREN/CN
E2
               1
                  --> TAMOXIFEN/CN
E3
               1
                       TAMOXIFEN ALCOHOL/CN
E4
                       TAMOXIFEN AZIRIDINE/CN
E5
               1
                       TAMOXIFEN CITRATE/CN
E6
                       TAMOXIFEN HYDROCHLORIDE/CN
E7
               1
                       TAMOXIFEN METHIODIDE/CN
E8
               1
                       TAMOXIFEN N-OXIDE/CN
E9
               1
                       TAMOXIFENOL/CN
E10
               1
                1
                       TAMP/CN
E11
                       TAMPACRYL/CN
E12
               1
=> s e3
                1 TAMOXIFEN/CN
L1
=> d
      ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
      10540-29-1 REGISTRY
RN
      Entered STN: 16 Nov 1984
      Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-
CN
      (CA INDEX NAME)
OTHER CA INDEX NAMES:
      Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
CN
      Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl- (9CI)
Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-
CN
CN
OTHER NAMES:
      (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine
CN
CN
      ICI 47699
      Mammaton
CN
CN
      Tamoxifen
CN
      trans-Tamoxifen
CN
      Z-Tamoxifen
FS
      STEREOSEARCH
      C26 H29 N O
MF
CI
LC
                     ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
      STN Files:
        BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH,
        IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
           (*File contains numerically searchable property data)
```

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7522 REFERENCES IN FILE CA (1907 TO DATE)
176 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7539 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e raloxifene/cn
                       RALOX LC/CN
E1
                1
                       RALOX-A/CN
E2
                1
E3
                1
                   --> RALOXIFENE/CN
                       RALOXIFENE HYDROCHLORIDE/CN
E4
                1
                       RALOZAM/CN
E5
                1
                       RALSTONITE/CN
E6
                       RALSTONITE (ALF2(OH))/CN
RALSTONITE (ALF2(OH).1/2H2O)/CN
E7
                1
E8
                       RALTAT 10/CN
E9
E10
                1
                       RALTITREXED/CN
                       RALUBEN/CN
E11
                1
                       RALUFON CAS-OH/CN
E12
=> \dot{s} e3
                1 RALOXIFENE/CN
L2
=> d
      ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
L2
      84449-90-1 REGISTRY
RN
      Entered STN: 16 Nov 1984
ED
     Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl] - (CA INDEX NAME)
CN
OTHER NAMES:
      Keoxifene
CN
      LY 139481
CN
CN
      Raloxifene
CN
      [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-
      piperidinyl)ethoxy)phenyl]methanone
MF
      C28 H27 N O4 S
CI
      COM
        TN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,
LC
      STN Files:
        MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE,
        TOXCENTER, USAN, USPAT2, USPATFULL
           (*File contains numerically searchable property data)
      Other Sources:
                           WHO
```

1636 REFERENCES IN FILE CA (1907 TO DATE) 35 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA 1643 REFERENCES IN FILE CAPLUS (1907 TO DATE) => e toremifene/cn TORELOR/CN E1 1 E2 1 TOREM/CN E3 1 --> TOREMIFENE/CN E4 1 TOREMIFENE CITRATE/CN TOREMIFENE N-OXIDE/CN E5 1 E6 TORENDRIKITE/CN TORENTAL/CN E7 1 1 TOREPALLOY GW/CN E8 TOREPALLOY HW/CN E9 1 TOREPALLOY UN/CN E10 E11 TOREPALLOY UW/CN TOREPALLOY UW 1A/CN E12 => s e3 1 TOREMIFENE/CN L3 => d L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN 89778-26-7 REGISTRY RN ED Entered STN: 16 Nov 1984 Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,Ndimethyl-(CA INDEX NAME) OTHER CA INDEX NAMES: Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, CN Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-CN dimethyl- (9CI) OTHER NAMES: CN Acapodene . Farestone CN GTx 006 CN CN Toremifene CN Z-Toremifene FS STEREOSEARCH DR 98644-21-4 C26 H28 Cl N O MF CI COM ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, LC STN Files: CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, TOXCENTER,

Double bond geometry as shown.

Other Sources:

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ULIDAT, USAN, USPAT2, USPATFULL

WHO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

661 REFERENCES IN FILE CA (1907 TO DATE)

(*File contains numerically searchable property data)

16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA 666 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e triphenylethylene/cn
                    TRIPHENYLETHOXYMETHYLENEPHOSPHORANE/CN
                    TRIPHENYLETHOXYSILANE/CN
E2
             1 .
E3
             1 --> TRIPHENYLETHYLENE/CN
                    TRIPHENYLETHYLENE ANION RADICAL/CN
E4
                    TRIPHENYLETHYLENE BROMIDE/CN
E5
             1
                    TRIPHENYLETHYLENE DIANION DILITHIUM SALT/CN
E6
             1
                    TRIPHENYLETHYLENE GLYCOL/CN
E7
             1
E8
             1
                    TRIPHENYLETHYLENE OZONIDE/CN
E9
             1
                    TRIPHENYLETHYLPHOSPHONIUM BROMIDE/CN
                    TRIPHENYLETHYLPHOSPHONIUM CHLORIDE/CN
E10
             1
E11
             1
                    TRIPHENYLETHYLPHOSPHONIUM DIHYDROGEN PHOSPHATE/CN
                    TRIPHENYLETHYLPHOSPHONIUM IODIDE/CN
E12
             1
=> s e3
             1 TRIPHENYLETHYLENE/CN
L4
=> d
     ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
L4
     58-72-0 REGISTRY
RN
     Entered STN: 16 Nov 1984
     Benzene, 1,1',1''-(1-ethenyl-2-ylidene)tris- (CA INDEX NAME)
OTHER CA INDEX NAMES:
     Ethylene, triphenyl- (6CI, 8CI)
OTHER NAMES:
     1,1,2-Triphenylethene
CN
     1,1,2-Triphenylethylene
CN
     Benzilidenediphenylmethane
CN
CN
     NSC 17535
CN
     Triphenylethene
     Triphenylethylene
CN
MF
     C20 H16
CI
     COM
       TN Files: ADISNEWS, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, IFICDB, IFIPAT,
T.C
     STN Files:
       IFIUDB, MEDLINE, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources: EINECS**, NDSL**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
Ph 2C === CH - Ph
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
             623 REFERENCES IN FILE CA (1907 TO DATE)
              51 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              624 REFERENCES IN FILE CAPLUS (1907 TO DATE)
              34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
```

```
=> file medline
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
SESSION
FULL ESTIMATED COST
SINCE FILE
ENTRY
SESSION
28.95
29.16
```

FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007

FILE LAST UPDATED: 30 Mar 2007 (20070330/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

```
substance identification.
=> s (antiestrogen or selective estrogen receptor modul? or serm)
          2839 ANTIESTROGEN
        232939 SELECTIVE
         80730 ESTROGEN
        566461 RECEPTOR
        279820 MODUL?
          2359 SELECTIVE ESTROGEN RECEPTOR MODUL?
                 (SELECTIVE (W) ESTROGEN (W) RECEPTOR (W) MODUL?)
          5161 (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
L5
=> d his
     (FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007
                E TAMOXIFEN/CN
              1 S E3
L1
                E RALOXIFENE/CN
L2
              1 S E3
                E TOREMIFENE/CN
L3
              1 S E3
                E TRIPHENYLETHYLENE/CN
T.4
     FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007
L5
           5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
=> s 11 or 12 or 13 or 14
         11703 L1
          1448 L2
           394 L3
            31 L4
         12869 L1 OR L2 OR L3 OR L4
L6
=> s (tamoxifen or raloxifene or toremifene or triphenylethylene)
         15057 TAMOXIFEN
          1934 RALOXIFENE
           493 TOREMIFENE
           265 TRIPHENYLETHYLENE
L7
         16501 (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE)
=> s (hot flash?)
         25185 HOT
         14661 FLASH?
T.B
          1538 (HOT FLASH?)
                 (HOT (W) FLASH?)
=> d his
     (FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007
                E TAMOXIFEN/CN
              1 S E3
Ll
                E RALOXIFENE/CN
L2
              1 S E3
                E TOREMIFENE/CN
L3
              1 S E3
                E TRIPHENYLETHYLENE/CN
L4
              1 S E3
     FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007
L5
           5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
          12869 S L1 OR L2 OR L3 OR L4
L6
          16501 S (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE)
L7
```

L8

1538 S (HOT FLASH?)

This file contains CAS Registry Numbers for easy and accurate

```
=> s 15 and 18
            93 L5 AND L8
=> s 16 or 17
L10
         16501 L6 OR L7
=> s 18 and 110
           182 L8 AND L10
L11
=> d 19 1-93
     ANSWER 1 OF 93
                         MEDLINE on STN
Full Text
     2007013928
AN
                    MEDLINE
DN
     PubMed ID: 17211091
     Therapeutic agents for disorders of bone and calcium metabolism:
TT
     Bazedoxifene.
ΑU
     Chaki Osamu
CS
     Yokohama City University Medical Center, Section of Gynecology.
     Clinical calcium, (2007 Jan) Vol. 17, No. 1, pp. 30-5. Ref: 8
     Journal code: 9433326. ISSN: 0917-5857.
CY
     Japan
     (ENGLISH ABSTRACT)
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Japanese
     Priority Journals
FS
     200703
EM
ED
     Entered STN: 10 Jan 2007
     Last Updated on STN: 24 Mar 2007
     Entered Medline: 23 Mar 2007
L9
     ANSWER 2 OF 93
                        MEDLINE on STN
Full Text
AN
     2006547551
                    MEDLINE
DN
     PubMed ID: 16972744
     [Oncologic indications and contra-indications for hormones use in
ΤI
     Indicaciones y contraindicaciones oncologicas del uso de hormonas en la
     menopausia.
ΑU
     Sarria Jose Antonio
     Universidad Nacional de Cordoba.
SO
     Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), (2005)
     Vol. 62, No. 2 Suppl 1, pp. 59-66.
     Journal code: 8303003. ISSN: 0014-6722.
     Argentina
CY
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
LA
     Spanish
FS
     Priority Journals
EΜ
     200703
    Entered STN: 16 Sep 2006
Last Updated on STN: 9 Mar 2007
ED
     Entered Medline: 8 Mar 2007
     ANSWER 3 OF 93
1.9
                        MEDLINE on STN
Full Text
     2006492805
                    MEDLINE
AΝ
DN
     PubMed ID: 16916481
     A Canadian observational study of the optimal method of transition from
     postmenopausal hormone therapy to raloxifene.
ΑU
     Lorraine Joanne; Lee Bobbie
     Eli Lilly Canada, Toronto ON.
CS
     Journal of obstetrics and gynaecology Canada : JOGC = Journal
SO
     d'obstetrique et gynecologie du Canada : JOGC, (2006 Jul) Vol. 28, No. 7,
     pp. 583-94.
     Journal code: 101126664. ISSN: 1701-2163.
CY
     Canada
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (CLINICAL TRIAL)
```

```
LA
     English
     Priority Journals
FS
EM
     200609
     Entered STN: 19 Aug 2006
ED
     Last Updated on STN: 19 Sep 2006
     Entered Medline: 18 Sep 2006
                         MEDLINE on STN
     ANSWER 4 OF 93
L9
Full Text
     2006293766
                     MEDLINE
AN
     PubMed ID: 16722623
DN
     Novel chromene-derived selective estrogen receptor modulators
TI
     useful for alleviating hot flushes and vaginal dryness.
     Jain Nareshkumar; Kanojia Ramesh M; Xu Jiayi; Jian-Zhong Guo; Pacia
AU
     Emmanuel; Lai Muh-Tsann; Du Fuyong; Musto Amy; Allan George; Hahn DoWon;
     Lundeen Scott; Sui Zhihua
     Johnson & Johnson Pharmaceutical Research & Development LLC, 1000 Route
CS
     202, Raritan, New Jersey 08869, USA.
Journal of medicinal chemistry, (2006 Jun 1) Vol. 49, No. 11, pp. 3056-9.
SO
     Journal code: 9716531. ISSN: 0022-2623.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
EM
     200607
     Entered STN: 26 May 2006
     Last Updated on STN: 13 Jul 2006
     Entered Medline: 12 Jul 2006
     ANSWER 5 OF 93
                         MEDLINE on STN
L9
Full Text
ΑN
     2006264840
                     MEDLINE
     PubMed ID: 16689342
DN
     Hormone replacement therapy.
ΤI
ΑU
     Nozaki Masahiro
     Department of Obstetrics and Gynecology, Graduate School of Medical
CS
     Sciences, Kyushu University.
     Nippon rinsho. Japanese journal of clinical medicine, (2006 Apr) Vol. 64
     Suppl 4, pp. 406-10. Ref: 15
Journal code: 0420546. ISSN: 0047-1852.
CY.
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Japanese
FS
     Priority Journals
EΜ
     200606
     Entered STN: 13 May 2006
ED
     Last Updated on STN: 1 Jul 2006
     Entered Medline: 30 Jun 2006
     ANSWER 6 OF 93
                         MEDLINE on STN
L9
<u>Full Text</u>
AN
     2006067888
                     MEDLINE
DN
     PubMed ID: 16451049
     A selective estrogen receptor modulator for the treatment of hot flushes.
ΤI
     Wallace Owen B; Lauwers Kenneth S; Dodge Jeffrey A; May Scott A; Calvin
     Joel R; Hinklin Ronald; Bryant Henry U; Shetler Pamela K; Adrian Mary D;
     Geiser Andrew G; Sato Masahiko; Burris Thomas P
CS
     Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate
     Center, Indianapolis, IN 46285, USA.. owen.wallace@lilly.com
Journal of medicinal chemistry, (2006 Feb 9) Vol. 49, No. 3, pp. 843-6.
     Journal code: 9716531. ISSN: 0022-2623.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
T.A
     English
FS
     Priority Journals
EM
     200603
     Entered STN: 3 Feb 2006
     Last Updated on STN: 30 Mar 2006
     Entered Medline: 29 Mar 2006
```

1.9

ANSWER 7 OF 93

MEDLINE on STN

```
AN
     2006034876
                      MEDLINE
DN
     PubMed ID: 16422310
     Identifying methodologies in the assessment of treatment effects on the
TI
     repeated occurrences of hot flashes in postmenopausal women.
ΑU
     He Weili; Deng Weiping
     Clinical Biostatistics, Merck Research Laboratories, RY34-A316, 126
CS
     Lincoln Avenue, Rahway, NJ 07065, USA. weili he@merck.com
Clinical trials (London, England), (2005) Vol. 2, No. 6, pp. 497-508.
Journal code: 101197451. ISSN: 1740-7745.
so
     England: United Kingdom
CY
     (COMPARATIVE STUDY)
DT
     Journal; Article; (JOURNAL ARTICLE)
     English
LA
FS
     Priority Journals
EM
     200603
     Entered STN: 21 Jan 2006
     Last Updated on STN: 18 Mar 2006
     Entered Medline: 17 Mar 2006
     ANSWER 8 OF 93
                          MEDLINE on STN
L9
Full Text
                     MEDLINE
     2005550268
AN
     PubMed ID: 16227740
DN
     Experience of high-dose toremifene treatment for postmenopausal women with
TI
     metastatic breast cancer.
     Yamamoto Yutaka; Kawazoe Teru; Iwase Hirotaka
AU
     Dept. of Breast & Endocrine Surgery, Faculty of Medical and Pharmaceutical
CS
     Sciences, Kumamoto University.
     Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Oct) Vol. 32, No. 10,
SO
     pp. 1415-\bar{9}.
     Journal code: 7810034. ISSN: 0385-0684.
CY
     Japan
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     Japanese
LA
FS
     Priority Journals
EΜ
     200511
     Entered STN: 18 Oct 2005
     Last Updated on STN: 9 Nov 2005
     Entered Medline: 8 Nov 2005
                          MEDLINE on STN
     ANSWER 9 OF 93
L9
Full
     Text
                      MEDLINE
AN
     2005390217
     PubMed ID: 16048357
DN
     Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
     Cranney Ann; Adachi Jonathan D
ΑU
     Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
CS
     Drug safety: an international journal of medical toxicology and drug experience, (2005) Vol. 28, No. 8, pp. 721-30. Ref: 74
SO
     Journal code: 9002928. ISSN: 0114-5916.
     New Zealand
CY
     Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
DT
     English
LA
FS
     Priority Journals
EΜ
     200510
     Entered STN: 29 Jul 2005
     Last Updated on STN: 1 Nov 2005
     Entered Medline: 31 Oct 2005
                           MEDLINE on STN
L9
     ANSWER 10 OF 93
Full
     Text
ΑN
     2005265706
                      MEDLINE
     PubMed ID: 15908903
DN
     Treatment of menopause-related mood disturbances.
TI
     Soares Claudio N; Prouty Jennifer; Born Leslie; Steiner Meir
AU
CS
     Department of Psychiatry and Behavioral Neurosciences, McMaster
     University, Hamilton, ON, Canada.
SO
     CNS spectrums, (2005 Jun) Vol. 10, No. 6, pp. 489-97. Ref: 100
     Journal code: 9702877. ISSN: 1092-8529.
```

Full_Text

```
United States
CY
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200510
     Entered STN: 24 May 2005
ED
     Last Updated on STN: 12 Oct 2005
     Entered Medline: 11 Oct 2005
L9
     ANSWER 11 OF 93
                          MEDLINE on STN
Full Text
AN
     2005236210
                     MEDLINE
     PubMed ID: 15772568
DN
     Effects of ospemifene and raloxifene on hormonal status, lipids, genital
ΤI
     tract, and tolerability in postmenopausal women.
     Komi Janne; Lankinen Kari S; Harkonen Pirkko; DeGregorio Michael W; Voipio Sari; Kivinen Seppo; Tuimala Risto; Vihtamaki Tarja; Vihko Kimmo;
ΑU
     Ylikorkala Olavi; Erkkola Risto
CS
     Hormos Medical Corporation, Turku, Finland.
     Menopause (New York, N.Y.), (2005 Mar) Vol. 12, No. 2, pp. 202-9.
SO
     Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
      (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
LA
     Priority Journals
FS
EM
     200507
     Entered STN: 6 May 2005
ED
     Last Updated on STN: 22 Jul 2005
     Entered Medline: 21 Jul 2005
     ANSWER 12 OF 93
                          MEDLINE on STN
1.9
Full Text
     2005072224
                     MEDLINE
AN
     PubMed ID: 15701885
DN
     TAS-108: a novel steroidal antiestrogen.
TΙ
     Buzdar Aman U
AU
     University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030,
CS
     USA.. abuzdar@mdanderson.org
     Clinical cancer research : an official journal of the American Association
SO
     for Cancer Research, (2005 Jan 15) Vol. 11, No. 2 Pt 2, pp. 906s-8s. Ref:
     Journal code: 9502500. ISSN: 1078-0432.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200505
     Entered STN: 10 Feb 2005
ED
     Last Updated on STN: 10 May 2005
     Entered Medline: 6 May 2005
                           MEDLINE on STN
L9
     ANSWER 13 OF 93
Full Text
     2004615625
                     MEDLINE
     PubMed ID: 15592280
DN
     Predictors of hot flushes in postmenopausal women who receive raloxifene
TI
     Aldrighi Jose M; Quail Deborah C; Levy-Frebault Jacques; Aguas Fernanda;
IIA
     Kosian Kurt; Garrido Lurdes; Bosio-Le Goux Brigitte; Sarachaga Max; Graebe
     Alice; Nino Antonio J; Nickelsen Thomas
     Faculdade De Saude Publica Da Universidade De Sao Paulo, Brazil.
     American journal of obstetrics and gynecology, (2004 Dec) Vol. 191, No. 6,
SO
     pp. 1979-88.
     Journal code: 0370476. ISSN: 0002-9378.
CY
     United States
      (CLINICAL TRIAL)
```

DT

```
Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EM
     200501
     Entered STN: 20 Dec 2004
ED
     Last Updated on STN: 28 Jan 2005
     Entered Medline: 27 Jan 2005
     ANSWER 14 OF 93
                          MEDLINE on STN
L9
Full Text
AN
     2004603075
                    MEDLINE
     PubMed ID: 15577140
DN
     Which is the better choice, estrogen or SERMs in postmenopausal women?.
ΤI
     Shintani Masafumi
ΑU
     Department of Obstetrics and Gynecology, Nara Prefectural Mimuro Hospital.
CS
     Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 105-10. Ref: 17 Journal code: 9433326. ISSN: 0917-5857.
SO
CY
     Japan
     (COMPARATIVE STUDY)
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Japanese
FS
     Priority Journals
     200502
EΜ
     Entered STN: 4 Dec 2004
Last Updated on STN: 1 Mar 2005
     Entered Medline: 25 Feb 2005
                          MEDLINE on STN
L9
     ANSWER 15 OF 93
Full Text
     2004603074
                    MEDLINE
AN
     PubMed ID: 15577139
DN
TI
     Safety profile of raloxifene.
     Morii Hirotoshi
ΑU
     Osaka City University.
CS
     Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 100-4. Ref: 22
SO
     Journal code: 9433326. ISSN: 0917-5857.
CY
     Japan
     (ENGLISH ABSTRACT)
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     Japanese
LA
     Priority Journals
FS
     200502
EM
     Entered STN: 4 Dec 2004
     Last Updated on STN: 1 Mar 2005
     Entered Medline: 25 Feb 2005
     ANSWER 16 OF 93
                          MEDLINE on STN
L9
Full Text
     2004530641
                     MEDLINE
AN
     PubMed ID: 15500420
DN
     The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa).
ΤI
     Huntley Alyson
ΑU
     Universities of Exeter and Plymouth, Complementary Medicine, Peninsula
CS
     Medical School, 25 Victoria Park Road, Exeter, EX2 4NT, UK...
     alvson.huntlev@pms.ac.uk
     Expert opinion on drug safety, (2004 Nov) Vol. 3, No. 6, pp. 615-23. Ref:
SO
     Journal code: 101163027. E-ISSN: 1744-764X.
CY
     England: United Kingdom
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
     Priority Journals
FS
     200510
EM
     Entered STN: 26 Oct 2004
ED
     Last Updated on STN: 6 Oct 2005
```

Entered Medline: 5 Oct 2005

```
Ĺ9
     ANSWER 17 OF 93
                          MEDLINE on STN
Full
     Text
     2004425202
AN
                    MEDLINE
DN
     PubMed ID: 15330494
     Belamcanda chinensis and the thereof purified tectorigenin have
     selective estrogen receptor modulator activities.
     Seidlova-Wuttke D; Hesse O; Jarry H; Rimoldi G; Thelen P; Christoffel V;
     Wuttke W
     Department of Clinical and Experimental Endocrinology, University of
CS
     Goettingen, Robert-Koch-Strasse 40, D-37075 Goettingen, Germany.
     Phytomedicine: international journal of phytotherapy and phytopharmacology, (2004 Jul) Vol. 11, No. 5, pp. 392-403.
SO
     Journal code: 9438794. ISSN: 0944-7113.
CY
     Germany: Germany, Federal Republic of
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
LA
     English
     Priority Journals
FS
EM
     200409
     Entered STN: 28 Aug 2004
ED
     Last Updated on STN: 17 Sep 2004
     Entered Medline: 16 Sep 2004
     ANSWER 18 OF 93
                          MEDLINE on STN
L9
Full Text
     2004390355
AN
                    MEDITNE
DN
     PubMed ID: 15295352
     Raloxifene is not associated with biologically relevant changes in hot
ΤI
     flushes in postmenopausal women for whom therapy is appropriate.
     Palacios Santiago; Farias Maria Lucia F; Luebbert Horst; Gomez Gustavo;
ΑU
     Yabur Juan A; Quail Deborah C; Turbi Carmen; Kayath Marcia J; Almeida
     Maria J; Monnig Elisabeth; Nickelsen Thomas
CS
     Instituto Palacios, Madrid, Spain.
     American journal of obstetrics and gynecology, (2004 Jul) Vol. 191, No. 1,
     pp. 121-31.
     Journal code: 0370476. ISSN: 0002-9378.
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EΜ
     200409
     Entered STN: 6 Aug 2004
     Last Updated on STN: 15 Sep 2004
     Entered Medline: 14 Sep 2004
                          MEDLINE on STN
L9
     ANSWER 19 OF 93
Full
     Text
AN
     2004390192
                     MEDLINE
     PubMed ID: 15293890
DN
     Veralipride administered in combination with raloxifene decreases hot
TI
     flushes and improves bone density in early postmenopausal women.
     Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
ΑU
     Department of Pediatrics, Obstetrics and Reproductive Medicine, University
CS
     of Siena, Siena, Italy.
SO
     Gynecological endocrinology : the official journal of the International
     Society of Gynecological Endocrinology, (2004 Apr) Vol. 18, No. 4, pp.
     194-8.
     Journal code: 8807913. ISSN: 0951-3590.
CY
     England: United Kingdom
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     English
LA
     Priority Journals
FS
EΜ
     200408
     Entered STN: 6 Aug 2004
```

Last Updated on STN: 20 Aug 2004 Entered Medline: 19 Aug 2004 MEDLINE on STN L9 ANSWER 20 OF 93 Full Text AN2004188613 MEDLINE PubMed ID: 15084236 DN Isoflavones and women's health. ΤI Powles Trevor ΑU Parkside Hospital, Wimbledon, London.. amccabe@parkside-hospital.co.uk CS Breast cancer research: BCR, (2004) Vol. 6, No. 3, pp. 140-2. Electronic SO Publication: 2004-04-06. Journal code: 100927353. E-ISSN: 1465-542X. CY England: United Kingdom DT Commentary Journal; Article; (JOURNAL ARTICLE) LA English FS Priority Journals FS ISRCTN NCT ISRCTN42940165 EΜ 200407 Entered STN: 16 Apr 2004 ED Last Updated on STN: 28 Jul 2004 Entered Medline: 27 Jul 2004 ANSWER 21 OF 93 MEDLINE on STN L9 Full Text AN 2004171210 MEDLINE DN PubMed ID: 15021446 Transition from estrogen therapy to raloxifene in postmenopausal women: TI effects on treatment satisfaction and the endometrium-a pilot study. AU Davis Susan R; O'Neill Sheila M; Eden John; Baber Rodney; Ekangaki Abie; Stocks Jodie M; Thiebaud Daniel Jean Hailes Foundation, Melbourne, Australia.. CS susan.davis@jeanhailes.org.au Menopause (New York, N.Y.), (2004 Mar-Apr) Vol. 11, No. 2, pp. 167-75. SO Journal code: 9433353. ISSN: 1072-3714. United States DT (CLINICAL TRIAL) (COMPARATIVE STUDY) Journal; Article; (JOURNAL ARTICLE) (MULTICENTER STUDY) (RANDOMIZED CONTROLLED TRIAL) (RESEARCH SUPPORT, NON-U.S. GOV'T) LA English FS Priority Journals EM 200405 Entered STN: 7 Apr 2004 Last Updated on STN: 10 May 2004 Entered Medline: 7 May 2004 1.9 ANSWER 22 OF 93 MEDLINE on STN Full Text AN2004157072 MEDLINE PubMed ID: 15050912 DN ΤI Selective estrogen receptor modulation: concept and consequences in cancer. ΑU Jordan V Craiq Northwestern University, Chicago, IL, USA.. vcjordan@northwestern.edu CS P50 CA089018-04S1 (NCI) SO Cancer cell, (2004 Mar) Vol. 5, No. 3, pp. 207-13. Ref: 56 Journal code: 101130617. ISSN: 1535-6108. CY United States DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.) General Review; (REVIEW) English FS Priority Journals EM 200405 ED Entered STN: 31 Mar 2004

Last Updated on STN: 18 May 2004

Entered Medline: 17 May 2004 L9 ANSWER 23 OF 93 MEDLINE on STN <u>Full</u> Text AN 2004132490 MEDLINE DN PubMed ID: 15025087 ΤI Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women. ΑU Rollins Gina Report on medical guidelines & outcomes research, (2004 Mar 5) Vol. 15, SO No. 5, pp. 7-9. Journal code: 9106372. ISSN: 1050-5636. CY United States DT (COMPARATIVE STUDY) News Announcement LA English FS Health Technology EΜ 200404 Entered STN: 18 Mar 2004 ED Last Updated on STN: 10 Apr 2004 Entered Medline: 9 Apr 2004 ANSWER 24 OF 93 MEDLINE on STN L9 **Full** Text 2004105346 MEDLINE AN DN PubMed ID: 14997058 Pilot study using gabapentin for tamoxifen-induced hot flashes in TI women with breast cancer. Pandya Kishan J; Thummala Anuradha R; Griggs Jennifer J; Rosenblatt Joseph AU D; Sahasrabudhe Deepak M; Guttuso Thomas J; Morrow Gary R; Roscoe Joseph A James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 14642 USA.. kishan pandya@urmc.rochester.edu Breast cancer research and treatment, (2004 Jan) Vol. 83, No. 1, pp. 87-9. Journal code: 8111104. ISSN: 0167-6806. SO CY Netherlands DT(CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) LA English FS Priority Journals 200405 EM ED Entered STN: 4 Mar 2004 Last Updated on STN: 14 May 2004 Entered Medline: 13 May 2004 L9 ANSWER 25 OF 93 MEDLINE on STN Full Text AN 2003588632 MEDLINE DN PubMed ID: 14669536 TΤ [The effects of tamoxifen on the female genital tract]. Tamoxifen en gynaecologische bijwerkingen. ΑU Mourits M J; van der Zee A G; Willemse P H; Hollema H; de Vries E G Afd. Gynaecologische Oncologie, Academisch Ziekenhuis Groningen, CS Hanzeplein 1, 9711 EZ Groningen.. m.j.e.mourits@og.azg.nl Nederlands tijdschrift voor geneeskunde, (2003 Nov 22) Vol. 147, No. 47, SO pp. 2315-20. Ref: 31 Journal code: 0400770. ISSN: 0028-2162. CY Netherlands DT (ENGLISH ABSTRACT) Journal; Article; (JOURNAL ARTICLE) General Review; (REVIEW) LA Dutch FS Priority Journals EM 200401 Entered STN: 16 Dec 2003 ED Last Updated on STN: 9 Jan 2004 Entered Medline: 8 Jan 2004 L9 ANSWER 26 OF 93 MEDLINE on STN Full Text ΑN 2003569139 MEDLINE DN PubMed ID: 14652237

Active tamoxifen metabolite plasma concentrations after coadministration

```
of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
ΑU
     Stearns Vered; Johnson Michael D; Rae James M; Morocho Alan; Novielli
     Antonella; Bhargava Pankaj; Hayes Daniel F; Desta Zeruesenay; Flockhart
     David A
     The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center,
CS
     Georgetown University Medical Center, Washington, DC, USA.
     5T32-GM-08425 (NIGMS)
NC
     R-01 GM56898 (NIGMS)
     U-01 GM61373 (NIGMS)
     Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
SO
     Journal code: 7503089. E-ISSN: 1460-2105.
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     English
LA
FS
     Priority Journals
EM
     200401
ED
     Entered STN: 16 Dec 2003
     Last Updated on STN: 6 Jan 2004
     Entered Medline: 5 Jan 2004
L9
     ANSWER 27 OF 93
                          MEDLINE on STN
Full Text
AN
     2003569130
                    MEDLINE
     PubMed ID: 14652227
DN
ΤI
     A hot flash on tamoxifen metabolism.
     Goetz Matthew P; Loprinzi Charles L
ΑU
     Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
SO
     pp. 1734-5. Ref: 23
     Journal code: 7503089. E-ISSN: 1460-2105.
CY
     United States
DT
     Commentary
     Editorial
     General Review; (REVIEW)
     English
LA
FS
     Priority Journals
EΜ
     200401
     Entered STN: 16 Dec 2003
     Last Updated on STN: 6 Jan 2004
     Entered Medline: 5 Jan 2004
     ANSWER 28 OF 93
L9
                         MEDLINE on STN
Full
     Text
AN
     2003490049
                    MEDLINE
     PubMed ID: 14567481
DN
TI
     Common causes of night sweats in various populations.
ΑU
     Taylor Roslyn D
     American family physician, (2003 Oct 1) Vol. 68, No. 7, pp. 1264.
SO
     Journal code: 1272646. ISSN: 0002-838X.
CY
     United States
DT
     Commentary
     Letter
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EM
     200310
ED
     Entered STN: 22 Oct 2003
     Last Updated on STN: 1 Nov 2003
     Entered Medline: 31 Oct 2003
L9
     ANSWER 29 OF 93
                          MEDLINE on STN
Full Text
     2003476408
AN
                    MEDLINE
     PubMed ID: 14555500
DN
     Fulvestrant in postmenopausal women with advanced breast cancer.
TI
     Bross Peter F; Baird Amy; Chen Gang; Jee Josephine M; Lostritto Richard T; Morse David E; Rosario Liliam A; Williams Gene M; Yang Peiling; Rahman
     Atiqur; Williams Grant; Pazdur Richard
CS
     Division of Oncology Drug Products, Center for Drug Evaluation and
     Research, Food and Drug Administration, Rockville, Maryland 20852, USA.
```

```
Clinical cancer research : an official journal of the American Association
SO
     for Cancer Research, (2003 Oct 1) Vol. 9, No. 12, pp. 4309-17. Ref: 22
     Journal code: 9502500. ISSN: 1078-0432.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200405
ED
     Entered STN: 14 Oct 2003
     Last Updated on STN: 21 May 2004
     Entered Medline: 20 May 2004
L9
     ANSWER 30 OF 93
                          MEDLINE on STN
Full Text
AN
     2003445171
                     MEDLINE
     PubMed ID: 12952416
DN
     Black cohosh acts as a mixed competitive ligand and partial agonist of the
ΤI
     serotonin receptor.
     Burdette Joanna E; Liu Jianghua; Chen Shao-Nong; Fabricant Daniel S;
AII
     Piersen Colleen E; Barker Eric L; Pezzuto John M; Mesecar Andrew; Van
     Breemen Richard B; Farnsworth Norman R; Bolton Judy L
     Department of Medicinal Chemistry and Pharmacognosy and UIC/NIH Center for Botanical and Dietary Supplements Research, College of Pharmacy, 833 South
CS
     Wood Street, University of Illinois at Chicago, Chicago, IL 60612, USA.
     F31 AT 00800 (NCCAM)
NC
     P50 AT 00155 (NCCAM)
     Journal of agricultural and food chemistry, (2003 Sep 10) Vol. 51, No. 19,
SO
     pp. 5661-70.
     Journal code: 0374755. ISSN: 0021-8561.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA
     English
FS
     Priority Journals
EΜ
     200311
     Entered STN: 25 Sep 2003
ED
     Last Updated on STN: 13 Nov 2003
     Entered Medline: 12 Nov 2003
                          MEDLINE on STN
L9
     ANSWER 31 OF 93
Full Text
AΝ
     2003441488
                     MEDLINE
     PubMed ID: 14501605
DN
     Effects of ospemifene, a novel SERM, on hormones, genital tract,
TI
     climacteric symptoms, and quality of life in postmenopausal women: a
     double-blind, randomized trial.
     Rutanen Eeva-Marja; Heikkinen Jorma; Halonen Kaija; Komi Janne;
Lammintausta Risto; Ylikorkala Olavi
ΑIJ
CS
     Department of Obstetrics and Gynecology, Helsinki University Central
     Hospital, Helsinki, Finland.. eeva-marja.rutanen@hus.fi
     Menopause (New York, N.Y.), (2003 Sep-Oct) Vol. 10, No. 5, pp. 433-9.
SO
     Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
      (RANDOMIZED CONTROLLED TRIAL)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
     Priority Journals
FS
EM
     200312
     Entered STN: 23 Sep 2003
ED
     Last Updated on STN: 18 Dec 2003
     Entered Medline: 8 Dec 2003
L9
     ANSWER 32 OF 93
                           MEDLINE on STN
Full Text
     2003415716
AN
                     MEDLINE
     PubMed ID: 12954049
DN
     Discovery and preclinical characterization of (+)-3-[4-(1-
TI
     piperidinoethoxy) phenyl] spiro[indene- 1,1'-indane] -5,5'-diol
     hydrochloride: a promising nonsteroidal estrogen receptor agonist for hot
```

```
flush.
     Watanabe Nobuhide; Ikeno Akihisa; Minato Hisao; Nakagawa Hiroshi;
ΑU
     Kohayakawa Chie; Tsuji Jun-ichi
     Chemistry Research Laboratories, Dainippon Pharmaceutical Co., Ltd.,
CS
     Enoki-cho 33-94, Suita, Osaka 564-0053, Japan.. nobuhide-
     watanabe@dainippon-pharm.co.jp
     Journal of medicinal chemistry, (2003 Sep 11) Vol. 46, No. 19, pp. 3961-4.
SO
     Journal code: 9716531. ISSN: 0022-2623.
CY
     United States
DT
     (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
     Priority Journals
FS
EM
     200311
     Entered STN: 5 Sep 2003
ED
     Last Updated on STN: 11 Nov 2003
     Entered Medline: 10 Nov 2003
     ANSWER 33 OF 93
                          MEDLINE on STN
L9
Full Text
AN
     2003390761
                     MEDLINE
DN
     PubMed ID: 12928005
TI
     Arzoxifene as therapy for endometrial cancer.
     Burke Thomas W; Walker Cheryl L
ΑU
     Department of Gynecologic Oncology, The University of Texas M. D. Anderson
CS
     Cancer Center, Houston, TX 77030, USA.. <u>tburke@mdanderson.org</u>
Gynecologic oncology, (2003 Aug) Vol. 90, No. 2 Pt 2, pp. S40-6.
Journal code: 0365304. ISSN: 0090-8258.
SO
                                                                            Ref: 55
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LΑ
     English
FS
     Priority Journals
     200309
EΜ
     Entered STN: 21 Aug 2003
ED
     Last Updated on STN: 1 Oct 2003
     Entered Medline: 30 Sep 2003
     ANSWER 34 OF 93
                          MEDLINE on STN
L9
Full Text
     2003381095
AN
                     MEDLINE
     PubMed ID: 12916292
DN
TI
     Selective estrogen-receptor modulators.
ΑŪ
     Cosman Felicia
     Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA..
CS
     cosmanf@helenhayeshosp.org
     Clinics in geriatric medicine, (2003 May) Vol. 19, No. 2, pp. 371-9. Ref:
SO
     58
     Journal code: 8603766. ISSN: 0749-0690.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LΑ
FS
     Priority Journals
ĖΜ
     200310
     Entered STN: 15 Aug 2003
     Last Updated on STN: 3 Oct 2003
     Entered Medline: 2 Oct 2003
     ANSWER 35 OF 93
                          MEDLINE on STN
L9
Full Text
     2003373456
                     MEDLINE
AN
DN
     PubMed ID: 12851517
TI
     Prevention of osteoporosis and uterine effects in postmenopausal women
     taking raloxifene for 5 years.
     Jolly Elaine E; Bjarnason Nina H; Neven Patrick; Plouffe Leo Jr; Johnston
     C Conrad Jr; Watts Steven D; Arnaud Claude D; Mason Timothy M; Crans
     Gerald; Akers Robin; Draper Michael W
     Department of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa,
CS
SO
     Menopause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 337-44.
```

Journal code: 9433353. ISSN: 1072-3714.

```
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
     Priority Journals
FS
EΜ
     200310
ED
     Entered STN: 12 Aug 2003
     Last Updated on STN: 8 Oct 2003
     Entered Medline: 7 Oct 2003
L9
     ANSWER 36 OF 93
                          MEDLINE on STN
Full Text
     2003370970
                    MEDLINE
AN
DN
     PubMed ID: 12808384
     Anti-osteoporotic medications: traditional and nontraditional.
TΙ
ΑU
     Cohen David P
     Department of Obstetrics and Gynecology, University of Chicago, Illinois
CS
     60637, USA.. dcohen@babies.bsd.uchicago.edu
     Clinical obstetrics and gynecology, (2003 Jun) Vol. 46, No. 2, pp. 341-8.
     Ref: 29
     Journal code: 0070014. ISSN: 0009-9201.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200309
     Entered STN: 9 Aug 2003
ED
     Last Updated on STN: 23 Sep 2003
     Entered Medline: 22 Sep 2003
L9
     ANSWER 37 OF 93
                          MEDLINE on STN
Full Text
AN
     2003294123
                    MEDLINE
DN
     PubMed ID: 12821343
     A phase II trial of arzoxifene, a selective estrogen response modulator,
     in patients with recurrent or advanced endometrial cancer.
     McMeekin D Scott; Gordon Alan; Fowler Jeffrey; Melemed Allen; Buller
ΑU
     Richard; Burke Thomas; Bloss Jeffery; Sabbatini Paul
     University of Oklahoma, Oklahoma City, OK 73190, USA...
CS
     scott-mcmeekin@ouhsc.edu
     Gynecologic oncology, (2003 Jul) Vol. 90, No. 1, pp. 64-9. Journal code: 0365304. ISSN: 0090-8258.
SO
CY
     United States
     (CLINICAL TRIAL)
DT
     (CLINICAL TRIAL, PHASE II)
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     English
LA
     Priority Journals
FS
EM
     200307
ED
     Entered STN: 25 Jun 2003
     Last Updated on STN: 25 Jul 2003
     Entered Medline: 24 Jul 2003
L9
     ANSWER 38 OF 93
                          MEDLINE on STN
Full Text
     2003278012
                    MEDLINE
AN
DN
     PubMed ID: 12804015
ΤI
     Efficacy of soyfoods and soybean isoflavone supplements for alleviating
     menopausal symptoms is positively related to initial hot flush frequency.
    Messina Mark; Hughes Claude
Department of Nutrition, Loma Linda University, Loma Linda, CA 92350,
ΑU
CS
     USA.. markm@olympus.net
SO
     Journal of medicinal food, (2003 Spring) Vol. 6, No. 1, pp. 1-11. Ref: 86
     Journal code: 9812512. ISSN: 1096-620X.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
T.A
     English
```

```
FS
     Priority Journals
ΕM
     200310
     Entered STN: 14 Jun 2003
Last Updated on STN: 8 Oct 2003
ED
     Entered Medline: 7 Oct 2003
     ANSWER 39 OF 93
                          MEDLINE on STN
L9
Full Text
                     MEDLINE
     2003134335
AN
     PubMed ID: 12648026
DN
     Pharmacokinetics of selective estrogen receptor modulators.
     Morello Karla C; Wurz Gregory T; DeGregorio Michael W
ΑU
     Department of Internal Medicine, University of California, Davis,
     Sacramento, California 95817, USA.
     Clinical pharmacokinetics, (2003) Vol. 42, No. 4, pp. 361-72. Ref: 73
so
     Journal code: 7606849. ISSN: 0312-5963.
CY
     New Zealand
     Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
DT
LA
     English
FS
     Priority Journals
     200306
EΜ
     Entered STN: 22 Mar 2003
Last Updated on STN: 12 Jun 2003
ED
     Entered Medline: 11 Jun 2003
     ANSWER 40 OF 93
                          MEDLINE on STN
L9
Full Text
AN
     2003113346
                     MEDLINE
     PubMed ID: 12626034
DN
ΤI
     Hormone replacement therapy in women with a history of breast cancer.
ΑU
     Ylikorkala O; Metsa-Heikkila M
     Department of Obstetrics and Gynecology, Helsinki University Central
     Hospital, Helsinki, Finland.
SO
     Gynecological endocrinology: the official journal of the International
     Society of Gynecological Endocrinology, (2002 Dec) Vol. 16, No. 6, pp.
     469-78. Ref: 73
Journal code: 8807913. ISSN: 0951-3590.
     England: United Kingdom
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
     English
LA
     Priority Journals
FS
EΜ
     200306
ED
     Entered STN: 11 Mar 2003
     Last Updated on STN: 28 Jun 2003
     Entered Medline: 27 Jun 2003
     ANSWER 41 OF 93
                        MEDLINE on STN
L9
Full Text
AN
     2003097716
                     MEDLINE
DN
     PubMed ID: 12609561
     The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a
     double-blind placebo-controlled study: effects on menopause symptoms and
     bone markers.
ΑU
     Wuttke W; Seidlova-Wuttke D; Gorkow C
     Department of Clinical and Experimental Endocrinology, University of
CS
     Gottingen, Robert-Koch-Strasse 40, 37075 Gottingen, Germany...
     ufkendo@med.uni-qoettingen.de
     Maturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S67-77.
so
     Journal code: 7807333. ISSN: 0378-5122.
     Ireland
CY
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
LA
FS
     Priority Journals
     200307
EΜ
ED
     Entered STN: 2 Mar 2003
     Last Updated on STN: 18 Jul 2003
```

Entered Medline: 17 Jul 2003 L9 ANSWER 42 OF 93 MEDLINE on STN <u>Full</u> <u>Text</u> AN 2003097710 MEDLINE PubMed ID: 12609555 DN Phytoestrogens: endocrine disrupters or replacement for hormone TI replacement therapy?. Wuttke Wolfgang; Jarry Hubertus; Becker Tamara; Schultens Alexander; ΑU Christoffel Volker; Gorkow Christoph; Seidlova-Wuttke Dana Department of Clinical and Experimental Endocrinology, University of CS Gottingen, Robert-Koch-Strasse 40, 37075 Gottingen, Germany... ufkendo@med.unigoettingen.de
Maturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S9-20. Ref: 59 SO Journal code: 7807333. ISSN: 0378-5122. CY Journal; Article; (JOURNAL ARTICLE) DT General Review; (REVIEW) LA English FS Priority Journals EM 200307 Entered STN: 2 Mar 2003 ED Last Updated on STN: 18 Jul 2003 Entered Medline: 17 Jul 2003 ANSWER 43 OF 93 MEDLINE on STN L9 Full Text AN 2002739799 MEDLINE DN PubMed ID: 12456626 Effectiveness of combined GnRH analogue plus raloxifene administration in ΤI the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Palomba Stefano; Russo Tiziana; Orio Francesco Jr; Tauchmanova Libuse; Zupi Errico; Panici Pier Luigi Benedetti; Nappi Carmine; Colao Annamaria; ΑU Lombardi Gaetano; Zullo Fulvio Department of Obstetrics Gynecology, University 'Magna Graecia' of CS Catanzaro, Catanzaro.. stefanopalomba@tin.it Human reproduction (Oxford, England), (2002 Dec) Vol. 17, No. 12, pp. SO 3213-9. Journal code: 8701199. ISSN: 0268-1161. England: United Kingdom CY DT (CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL) English LΑ FS Priority Journals EΜ 200306 Entered STN: 31 Dec 2002 Last Updated on STN: 5 Jun 2003 Entered Medline: 4 Jun 2003 L9 ANSWER 44 OF 93 MEDLINE on STN Text Full AN 2002728697 MEDLINE PubMed ID: 12490735 DN FDA drug approval summaries: fulvestrant. ΤI Bross Peter F; Cohen Martin H; Williams Grant A; Pazdur Richard ΑU Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, MD 20857, USA.. brossp@cder.fda.gov SO The oncologist, (2002) Vol. 7, No. 6, pp. 477-80. Journal code: 9607837. ISSN: 1083-7159.

CY

DT LA

FS

EΜ

ED

United States

Priority Journals

Entered STN: 20 Dec 2002

Last Updated on STN: 7 Feb 2003 Entered Medline: 6 Feb 2003

English

200302

Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

```
L9 ·
     ANSWER 45 OF 93
                         MEDLINE on STN-
Full Text
AN
     2002683049
                    MEDLINE
     PubMed ID: 12443837
DN
     Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal
TI
     maturation index, and hormonal status in healthy postmenopausal women.
     Voipio S K; Komi J; Kangas L; Halonen K; DeGregorio M W; Erkkola R U
ΑU
     Department of Obstetrics and Gynecology, Turku University Central
CS
     Hospital, FIN-20520, Turku, Finland.
Maturitas, (2002 Nov 20) Vol. 43, No. 3, pp. 207-14.
SO
     Journal code: 7807333. ISSN: 0378-5122.
CY
     Ireland
     (CLINICAL TRIAL)
DT
     (CLINICAL TRIAL, PHASE I)
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
LA
     English
FS
     Priority Journals
EΜ
     200303
     Entered STN: 22 Nov 2002
ED
     Last Updated on STN: 31 Mar 2003
     Entered Medline: 28 Mar 2003
     ANSWER 46 OF 93
                          MEDLINE on STN
L9
Full
     <u>Text</u>
     2002634715
AN
                    MEDLINE
DN
     PubMed ID: 12394205
ΤI
     Tamoxifen as an ergogenic agent in women body builders.
ΑU
     Seehusen Dean A; Glorioso John E
     Department of Family Practice and Emergency Medical Services, Tripler Army
CS
     Medical Center, Hawaii 96859, USA.
     Clinical journal of sport medicine : official journal of the Canadian
SO
     Academy of Sport Medicine, (2002 Sep) Vol. 12, No. 5, pp. 313-4.
     Journal code: 9103300. ISSN: 1050-642X.
CY
     United States
     (CASE REPORTS)
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
     200211
EM
ED
     Entered STN: 24 Oct 2002
     Last Updated on STN: 13 Dec 2002
     Entered Medline: 12 Nov 2002
L9
     ANSWER 47 OF 93
                          MEDLINE on STN
Full
     Text
ΑN
     2002629431
                    MEDLINE
DN
     PubMed ID: 12387278
     ACOG Practice Bulletin: Clinical Management Guidelines for
TI
     Obstetrician-Gynecologists: Number 39, October 2002. Selective
     estrogen receptor modulators.
ΑU
     Anonymous
     American College of Obstetricians and Gynecologists.
CS
     Obstetrics and gynecology, (2002 Oct) Vol. 100, No. 4, pp. 835-43.
SO
     Journal code: 0401101. ISSN: 0029-7844.
     United States
CY
DТ
     (GUIDELINE)
     Journal; Article; (JOURNAL ARTICLE)
     (PRACTICE GUIDELINE)
     English
LΑ
FS
     Abridged Index Medicus Journals; Priority Journals
EΜ
     200211
ED
     Entered STN: 22 Oct 2002
     Last Updated on STN: 13 Dec 2002
     Entered Medline: 7 Nov 2002
L9
     ANSWER 48 OF 93
                          MEDLINE on STN
Full
     Text
AN
     2002443702
                    MEDLINE
DN
     PubMed ID: 12202467
TI
     Meta-analyses of therapies for postmenopausal osteoporosis. IV.
     Meta-analysis of raloxifene for the prevention and treatment of
```

```
postmenopausal osteoporosis.
ΑU
     Cranney Ann; Tugwell Peter; Zytaruk Nicole; Robinson Vivian; Weaver Bruce;
     Adachi Jonathan; Wells George; Shea Beverley; Guyatt Gordon
Osteoporosis Methodology Group and The Osteoporosis Research Advisory
CS
     Group.
     Endocrine reviews, (2002 Aug) Vol. 23, No. 4, pp. 524-8. Ref: 19
SO
     Journal code: 8006258. ISSN: 0163-769X.
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
      (META-ANALYSIS)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
     200302
EΜ
ED
     Entered STN: 31 Aug 2002
     Last Updated on STN: 3 Apr 2003
     Entered Medline: 7 Feb 2003
     ANSWER 49 OF 93
L9
                           MEDLINE on STN .
Full Text
AN
     2002431393
                     MEDLINE
DN
     PubMed ID: 12188398
TΤ
     Climacteric: concept, consequence and care.
     Taechakraichana Nimit; Jaisamrarn Unnop; Panyakhamlerd Krasean;
AU
     Chaikittisilpa Sukanya; Limpaphayom Khunying Kobchitt
CS
     Department of Obstetrics and Gynecology, Faculty of Medicine,
     Chulalongkorn University, Bangkok, Thailand.
     Journal of the Medical Association of Thailand = Chotmainet thangphaet,
SO
     (2002 Jun) Vol. 85 Suppl 1, pp. S1-15. Ref: 74
     Journal code: 7507216. ISSN: 0125-2208.
CY
     Thailand
     Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
DT
LA
     English
FS
     Priority Journals
ΕM
     200209
     Entered STN: 22 Aug 2002
ED
     Last Updated on STN: 18 Sep 2002
     Entered Medline: 17 Sep 2002
L9
     ANSWER 50 OF 93
                           MEDLINE on STN
<u>Full</u>
     <u>Text</u>
     2002354979
                     MEDLINE
AN
     PubMed ID: 12098608
ΤI
     SERMs: current status and future trends.
     Morello Karla C; Wurz Gregory T; DeGregorio Michael W
Department of Internal Medicine, Division of Hematology/Oncology, Cancer
ΑU
CS
     Center, University of California, Davis, 4501 X Street Room 3016,
     Sacramento, CA 95817, USA.
SO
     Critical reviews in oncology/hematology, (2002 Jul) Vol. 43, No. 1, pp.
     63-76. Ref: 99
Journal code: 8916049. ISSN: 1040-8428.
CY
     Ireland
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LΑ
     English
FS
     Priority Journals
     200307
     Entered STN: 7 Jul 2002
     Last Updated on STN: 11 Dec 2002
     Entered Medline: 11 Jul 2003
     ANSWER 51 OF 93
L9
                           MEDLINE on STN
Full Text
AN
     2002350308
                     MEDLINE
     PubMed ID: 12093250
DN
ΤI
     Chemoprevention of breast cancer: a summary of the evidence for the U.S.
     Preventive Services Task Force.
AU
     Kinsinger Linda S; Harris Russell; Woolf Steven H; Sox Harold C; Lohr
     Kathleen N
CS
     Cecil G. Sheps Center for Health Services Research, Program on Prevention,
```

```
CB# 7508, Wing D, Room 383, University of North Carolina School of
     Medicine, Chapel Hill, NC 27599-7508, USA.
NC
     290-97-0011
     Annals of internal medicine, (2002 Jul 2) Vol. 137, No. 1, pp. 59-69.
SO
     Ref: 73
     Journal code: 0372351. E-ISSN: 1539-3704.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     General Review; (REVIEW)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EΜ
     200207
     Entered STN: 3 Jul 2002
ED
     Last Updated on STN: 18 Jul 2002
     Entered Medline: 10 Jul 2002
L9
     ANSWER 52 OF 93
                          MEDLINE on STN
Full Text
     2002249322
AN
                     MEDLINE
DN
     PubMed ID: 11988138
ΤI
     Raloxifene is associated with less side effects than tamoxifen in women
     with early breast cancer: a questionnaire study from one physician's
     practice.
     Rohatqi Nitin; Blau Robbin; Lower Elyse E
ΑU
     Department of Internal Medicine, Division of Hematology/Oncology,
CS
     University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0562,
     Journal of women's health & gender-based medicine, (2002 Apr) Vol. 11, No.
SO
     3, pp. 291-301.
     Journal code: 100888719. ISSN: 1524-6094.
CY
     United States
DT
     (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS.
     Priority Journals
EΜ
     200206
     Entered STN: 5 May 2002
ED
     Last Updated on STN: 20 Jun 2002
     Entered Medline: 19 Jun 2002
L9
     ANSWER 53 OF 93
                          MEDLINE on STN
Full
    <u>Text</u>
     2002230023
                    MEDLINE
AN
DN
     PubMed ID: 11966388
     A 60-year-old woman trying to discontinue hormone replacement therapy.
TΙ
ΑU
     Grady Deborah
     University of California, San Francisco, 74 New Montgomery St, Suite 600,
CS
     San Francisco, CA 94105, USA.. dgrady@itsa.ucsf.edu
SO
     JAMA: the journal of the American Medical Association, (2002 Apr 24) Vol.
     287, No. 16, pp. 2130-7.
     Journal code: 7501160. ISSN: 0098-7484.
CY
     United States
     (CASE REPORTS)
     Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EΜ
     200205
ED
     Entered STN: 23 Apr 2002
     Last Updated on STN: 14 Dec 2002
     Entered Medline: 2 May 2002
     ANSWER 54 OF 93
L9
                          MEDLINE on STN
Full Text
AN
     2002205258
                    MEDLINE
DN
     PubMed ID: 11937433
TI
     Complementary/alternative therapies for reducing hot flashes in
     prostate cancer patients: reevaluating the existing indirect data from
     studies of breast cancer and postmenopausal women.
     Moyad Mark A
AU
CS
     Department of Urology, University of Michigan Medical Center, Ann Arbor,
```

```
Michigan 48109-0330, USA.. <u>moyad@umich.edu</u>
Urology, (2002 Apr) Vol. 59, No. 4 Suppl 1, pp. 20-33. Ref: 148
SO
     Journal code: 0366151. E-ISSN: 1527-9995.
     United States
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
     Priority Journals
FS
     200204
EM
     Entered STN: 9 Apr 2002
ED
     Last Updated on STN: 12 Apr 2002
     Entered Medline: 10 Apr 2002
     ANSWER 55 OF 93
                           MEDLINE on STN
L9
     Text
Full
ΑN
     2002189514
                      MEDLINE
     PubMed ID: 11921648
DN
ΤI
      [Hormone replacement therapy in peri- and postmenopause. Routine use is
     not indicated].
     Hormonersatztherapie in der Peri- und Postmenopause. Ein routinemassiger
     Einsatz ist nicht indiziert.
     Emons G; Westphalen S
ΑU
     Klinik fur Gynakologie und Geburtshilfe, Georg-August-Universitat
     Gottingen.. emons@med.uni-goettingen.de
     MMW Fortschritte der Medizin, (2002 Feb 28) Vol. 144, No. 9, pp. 30-3. Journal code: 100893959. ISSN: 1438-3276.
SO
     Germany: Germany, Federal Republic of
CY
DT
      (COMPARATIVE STUDY)
      (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
LA
     German
     Priority Journals
FS
ΕM
     200204
     Entered STN: 3 Apr 2002
ED
     Last Updated on STN: 30 Apr 2002
     Entered Medline: 29 Apr 2002
L9
     ANSWER 56 OF 93
                           MEDLINE on STN
Full Text
AN
     2002172483
                      MEDLINE
DN
     PubMed ID: 11906441
TI
     Chemoprevention for high-risk women: tamoxifen and beyond.
ΑU
     Fabian C J; Kimler B F
     University of Kansas Medical Center, Kansas City, Kansas 66160, USA..
CS
     cfabian@kumc.edu
SO
     The breast journal, (2001 Sep-Oct) Vol. 7, No. 5, pp. 311-20. Ref: 117
     Journal code: 9505539. ISSN: 1075-122X.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DΤ
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200204
     Entered STN: 22 Mar 2002
ED
     Last Updated on STN: 19 Apr 2002
     Entered Medline: 18 Apr 2002
L9
     ANSWER 57 OF 93
                           MEDLINE on STN
Full Text
     2002112745
AN
DN
     PubMed ID: 11845111
ΤI
     Use of alternatives to estrogen for treatment of menopause.
ΑU
     Pinkerton J V; Santen R
     Department of Obstetrics/Gynecology and the Women's Place, and The Department of Medicine, Division of Endocrinology, University of Virginia
CS
     Health System, Charlottesville, Virginia, USA.
Minerva endocrinologica, (2002 Mar) Vol. 27, No. 1, pp. 21-41. Ref: 100
     Journal code: 8406505. ISSN: 0391-1977.
CY
     Italv
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     English
```

```
Priority Journals
EM
     200206
     Entered STN: 15 Feb 2002
Last Updated on STN: 4 Jun 2002
ED
     Entered Medline: 3 Jun 2002
     ANSWER 58 OF 93
                          MEDLINE on STN
L9
Full
     Text
     2002069894
AN
                     MEDLINE
DN
     PubMed ID: 11795370
     Developing a SERM: stringent preclinical selection criteria leading to
     an acceptable candidate (WAY-140424) for clinical evaluation.
ΑU
     Komm B S; Lyttle C R
     Women's Health Research Institute, Wyeth-Ayerst Research, Collegeville,
CS
     Pennsylvania 19426, USA. . kommb@war.wyeth.com
     Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp.
SO
     317-26. Ref: 166
Journal code: 7506858. ISSN: 0077-8923.
CY
     United States
ידת
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LA
FS
     Priority Journals
EΜ
     200202
     Entered STN: 25 Jan 2002
ED
     Last Updated on STN: 22 Feb 2002
     Entered Medline: 21 Feb 2002
L9
     ANSWER 59 OF 93
                          MEDLINE on STN
Full Text
AN
     2002069890
                     MEDLINE
DN
     PubMed ID: 11795366
ΤI
     Raloxifene: risks and benefits.
ΑU
     Barrett-Connor E
     Department of Family and Preventive Medicine, University of California,
CS
     San Diego, La Jolla 92093, USA.. ebarrettconnor@ucsd.edu
     Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp.
SO
     295-303. Ref: 23
     Journal code: 7506858. ISSN: 0077-8923.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EM
     200202
ED
     Entered STN: 25 Jan 2002
     Last Updated on STN: 22 Feb 2002
     Entered Medline: 21 Feb 2002
T.9
     ANSWER 60 OF 93
                          MEDLINE on STN
Full Text
     2002069886
                     MEDLINE
AN
     PubMed ID: 11795362
What would be the properties of an ideal SERM?.
DN
ΤI
     Anthony M; Williams J K; Dunn B K
ΑU
     Georgetown University Medical Center, Washington, DC 20007, USA.
CS
SO
     Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp.
     261-78. Ref: 123
Journal code: 7506858. ISSN: 0077-8923.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
     Priority Journals
FS
EM
     200202
     Entered STN: 25 Jan 2002
ED
     Last Updated on STN: 22 Feb 2002
     Entered Medline: 21 Feb 2002
L9
     ANSWER 61 OF 93
                          MEDLINE on STN
Full Text
     2002069883
```

MEDLINE

```
PubMed ID: 11795359
      Effect of selective estrogen receptor modulators on reproductive
TΤ
      tissues other than endometrium.
ΑU
      Hendrix S L; McNeeley S G
      Department of Obstetrics and Gynecology, Wayne State University/Hutzel
CS
      Hospital, Detroit, Michigan 48201, USA. shendrix@med.wayne.edu
Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp.
SO
      243-50. Ref: 31
Journal code: 7506858. ISSN: 0077-8923.
      United States
CY
      Journal; Article; (JOURNAL ARTICLE)
DT
      General Review; (REVIEW)
      English
LA
FS
      Priority Journals
ΕM
      200202
ED
      Entered STN: 25 Jan 2002
      Last Updated on STN: 22 Feb 2002
      Entered Medline: 21 Feb 2002
L9
      ANSWER 62 OF 93
                             MEDLINE on STN
Full Text
      2002069870
                       MEDLINE
AN
      PubMed ID: 11795346
Quality of life and tamoxifen in a breast cancer prevention trial: a
DN
TΙ
      summary of findings from the NSABP P-1 study. National Surgical Adjuvant
      Breast and Bowel Project.
AU
      Day R
      Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA. (National Surgical Adjuvant Breast
      and Bowel Projet P-1 study (NSABP-1)). day@nsabp.pitt.edu
SO
      Annals of the New York Academy of Sciences, (2001 Dec) Vol. 949, pp.
      143-50.
      Journal code: 7506858. ISSN: 0077-8923.
      United States
CY
DТ
      (CLINICAL TRIAL)
      (CONTROLLED CLINICAL TRIAL)
      Journal; Article; (JOURNAL ARTICLE)
      (MULTICENTER STUDY)
LA
      English
FS
      Priority Journals
      200202
EM
      Entered STN: 25 Jan 2002
ED
     Last Updated on STN: 22 Feb 2002
Entered Medline: 21 Feb 2002
L9
      ANSWER 63 OF 93
                             MEDLINE on STN
Full Text
AN
      2002060340
                       MEDLINE
      PubMed ID: 11779264
DN
      Serum estradiol level and risk of breast cancer during treatment with
      raloxifene.
      Cummings Steven R; Duong Tu; Kenyon Emily; Cauley Jane A; Whitehead
AII
      Malcolm; Krueger Kathryn A
      Coordinating Center, University of California, Suite 600, 74 New
CS
     Montgomery St, San Francisco, CA 94105, USA. (Multiple Outcomes of Raloxifene Evaluation (MORE) Trial). scummings@psg.ucsf.edu
      JAMA: the journal of the American Medical Association, (2002 Jan 9) Vol.
SO
      287, No. 2, pp. 216-20.
Journal code: 7501160. ISSN: 0098-7484.
CY
      United States
DТ
      (CLINICAL TRIAL)
      Journal; Article; (JOURNAL ARTICLE)
      (RANDOMIZED CONTROLLED TRIAL)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
      English
IΔ
FS
      Abridged Index Medicus Journals; Priority Journals
ΕM
      200202
ED
      Entered STN: 25 Jan 2002
      Last Updated on STN: 3 Apr 2003
      Entered Medline: 5 Feb 2002
L9
      ANSWER 64 OF 93
                             MEDLINE on STN
```

```
Full Text
AN
     2001542165
                     MEDLINE
     PubMed ID: 11589065
DN
     Selective estrogen-receptor modulators in 2001.
TI
     O'Regan R M; Gradishar W J
ΑU
     Division of Hematology and Medical Oncology, Robert H. Lurie Comprehensive
CS
     Cancer Center, Northwestern University, Chicago, Illinois, USA.
Oncology (Williston Park, N.Y.), (2001 Sep) Vol. 15, No. 9, pp. 1177-85, 1189-90; discussion 1190-4.
SO
     Journal code: 8712059. ISSN: 0890-9091.
     United States
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     200201
ED
     Entered STN: 9 Oct 2001
     Last Updated on STN: 25 Jan 2002
     Entered Medline: 7 Jan 2002
     ANSWER 65 OF 93
                          MEDLINE on STN
L9
Full Text
AN
     2001536554
                     MEDLINE
     PubMed ID: 11584060
DN
     Selective estrogen receptor modulation and reduction in risk of
TI
     breast cancer, osteoporosis, and coronary heart disease.
ΑU
     Jordan V C; Gapstur S; Morrow M
     Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA..
CS
     vcjordan@nwu.edu
NC
     CA89018-01 (NCI)
     Journal of the National Cancer Institute, (2001 Oct 3) Vol. 93, No. 19,
SO
     pp. 1449-57. Ref: 96
     Journal code: 7503089. ISSN: 0027-8874.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
     (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     General Review; (REVIEW)
     English
LA
FS
     Priority Journals
EM
     200112
ED
     Entered STN: 4 Oct 2001
     Last Updated on STN: 22 Jan 2002
     Entered Medline: 4 Dec 2001
L9
     ANSWER 66 OF 93
                           MEDLINE on STN
Full Text
AN
     2001515400
                     MEDLINE
     PubMed ID: 11332140
DN
     The role of hormone replacement therapy in women with a previous diagnosis
ΤI
     of breast cancer and a review of possible alternatives.
ΑU
     Pritchard K I
     Division of Clinical Trials and Epidemiology, Toronto-Sunnybrook Regional
CS
     Cancer Centre, Toronto, Canada.
     Annals of oncology : official journal of the European Society for Medical
SO
     Oncology / ESMO, (2001 Mar) Vol. 12, No. 3, pp. 301-10. Ref: 89
     Journal code: 9007735. ISSN: 0923-7534.
CY
     Netherlands
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
FS
     Priority Journals
EΜ
     200109
ED
     Entered STN: 24 Sep 2001
     Last Updated on STN: 24 Sep 2001
     Entered Medline: 20 Sep 2001
L9
     ANSWER 67 OF 93
                           MEDLINE on STN
Full Text
AN
     2001477639
                     MEDLINE
DN
     PubMed ID: 11521122
TI
     Alternatives for women through menopause.
```

```
ΑU
     Gass M L; Taylor M B
     Department of Obstetrics and Gynecology, University Menopause and
CS
     Osteoporosis Center, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
SO
     American journal of obstetrics and gynecology, (2001 Aug) Vol. 185, No. 2
     Suppl, pp. S47-56. Ref: 67
     Journal code: 0370476. ISSN: 0002-9378.
     United States
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EM
     200109
ED
     Entered STN: 27 Aug 2001
     Last Updated on STN: 17 Sep 2001
     Entered Medline: 13 Sep 2001
     ANSWER 68 OF 93
                          MEDLINE on STN
L9
Full Text
     2001460389
                     MEDITNE
ΑN
DN
     PubMed ID: 11348629
     Effect of tibolone and raloxifene on the tail temperature of
TI
     oestrogen-deficient rats.
     Berendsen H H; Weekers A H; Kloosterboer H J
ΑU
     Pharmacology Department, NV Organon, P.O. Box 20, 5340 BH, Oss,
CS
     Netherlands.. <u>H.Berendsen@organon.oss.akzonobel.nl</u>
     European journal of pharmacology, (2001 May 4) Vol. 419, No. 1, pp. 47-54.
SO
     Journal code: 1254354. ISSN: 0014-2999.
CY
     Netherlands
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
EΜ
     200108
     Entered STN: 20 Aug 2001
ED
     Last Updated on STN: 20 Aug 2001
     Entered Medline: 16 Aug 2001
L9
     ANSWER 69 OF 93
                          MEDLINE on STN
Full Text
AN
     2001441220
                     MEDLINE
DN
     PubMed ID: 11486708
ΤI
     Selective estrogen receptor modulation: the search for an ideal
     hormonal therapy for breast cancer.
ΑU
     Dhingra K
CS
     Hoffmann-La Roche, Inc., Nutley, New Jersey 07110, USA..
     kapil.dhingra@Roche.com
     Cancer investigation, (2001) Vol. 19, No. 6, pp. 649-59. Ref: 67 Journal code: 8307154. ISSN: 0735-7907.
SO
     United States
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
     200108
EM
     Entered STN: 13 Aug 2001
     Last Updated on STN: 27 Aug 2001
     Entered Medline: 23 Aug 2001
     ANSWER 70 OF 93
L9
                          MEDLINE on STN
Full Text
AN
     2001334440
                     MEDLINE
DN
     PubMed ID: 11402436
ΤI
     Tamoxifen to raloxifene and beyond.
     O'Regan R M; Jordan V C
ΑU
     Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer
     Center, Northwestern University Medical School, 303 E Chicago Ave.,
     Chicago, IL 60611, USA..
     Seminars in oncology, (2001 Jun) Vol. 28, No. 3, pp. 260-73. Ref: 119 Journal code: 0420432. ISSN: 0093-7754.
SO
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
```

```
LA
     English
FS
     Priority Journals
EM
     200107
ED
     Entered STN: 16 Jul 2001
     Last Updated on STN: 16 Jul 2001
     Entered Medline: 12 Jul 2001
     ANSWER 71 OF 93
                           MEDLINE on STN
L9
Full
     Text
AN
     2001304783
                      MEDLINE
     PubMed ID: 11108432
DN
ΤI
     Clinical pharmacokinetics of toremifene.
     Taras T L; Wurz G T; Linares G R; DeGregorio M W
ΑU
     Department of Internal Medicine, Cancer Center, University of California,
     Davis, Sacramento 95817, USA.
NC.
     T32ES07059 (NIEHS)
     Clinical pharmacokinetics, (2000 Nov) Vol. 39, No. 5, pp. 327-34. Ref: 26
SO
     Journal code: 7606849. ISSN: 0312-5963.
CY
     New Zealand
     Journal; Article; (JOURNAL ARTICLE)
DT
      (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     General Review; (REVIEW)
LA
     English
     Priority Journals
FS
EΜ
     200105
     Entered STN: 4 Jun 2001
ED
     Last Updated on STN: 4 Jun 2001
     Entered Medline: 31 May 2001
     ANSWER 72 OF 93
                           MEDLINE on STN
L9
Full Text
AN
     2001236869
                      MEDLINE
     PubMed ID: 11283133
DN
     Phase I study of a third-generation selective estrogen receptor
TI
     modulator, LY353381.HCL, in metastatic breast cancer.
     Munster P N; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A;
ΑU
     Seidman A; Booser D; Theriault R; Norton L; Hudis C
     Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (2001 Apr 1) Vol. 19, No. 7, pp. 2002-9.
CS
SO
     Journal code: 8309333. ISSN: 0732-183X.
CY
     United States
      (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE I)
DT
     Journal; Article; (JOURNAL ARTICLE)
      (MULTICENTER STUDY)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
LA
FS
     Priority Journals
     200105
EM
     Entered STN: 17 May 2001
     Last Updated on STN: 17 May 2001
     Entered Medline: 3 May 2001
     ANSWER 73 OF 93
                           MEDLINE on STN
L9
Full
     Text
AN
     2001220436
                      MEDLINE
     PubMed ID: 11309635.
DN
ΤI
     Cognitive function in postmenopausal women treated with raloxifene.
     Yaffe K; Krueger K; Sarkar S; Grady D; Barrett-Connor E; Cox D A;
AII
     Department of Psychiatry, University of California at San Francisco,
CS
     94121, USA. (Multiple Outcomes of Raloxifene Evaluation Investigators). K23-AG00888 (NIA)
NC
SO
     The New England journal of medicine, (2001 Apr 19) Vol. 344, No. 16, pp.
     1207-13.
     Journal code: 0255562. ISSN: 0028-4793.
CY
     United States
      (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
      (MULTICENTER STUDY)
      (RANDOMIZED CONTROLLED TRIAL)
```

```
(RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     English
T.A
FS
     Abridged Index Medicus Journals; Priority Journals
EΜ
     200105
ED
     Entered STN: 17 May 2001
     Last Updated on STN: 17 May 2001
     Entered Medline: 3 May 2001
L9
     ANSWER 74 OF 93
                         MEDLINE on STN
<u>Full</u>
    Text
AN
     2001084172
                    MEDLINE
     PubMed ID: 10948439
DN
ΤI
     Managing menopausal problems.
ΑU
     Cobleigh M A
CS
     Rush-Presbyterian-St. Luke's Medical Center, USA.
     Cancer treatment and research, (2000) Vol. 103, pp. 1-23. Ref: 111
SO
     Journal code: 8008541. ISSN: 0927-3042.
CY
     Netherlands
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     200101
ED
     Entered STN: 22 Mar 2001
     Last Updated on STN: 22 Mar 2001
     Entered Medline: 18 Jan 2001
     ANSWER 75 OF 93
                         MEDLINE on STN
L9
Full Text
     2001078370
                    MEDLINE
AN
     PubMed ID: 11112238
DN
     Long-term effects of raloxifene on bone mineral density, bone turnover,
ΤI
     and serum lipid levels in early postmenopausal women: three-year data from
     2 double-blind, randomized, placebo-controlled trials.
     Johnston C C Jr; Bjarnason N H; Cohen F J; Shah A; Lindsay R; Mitlak B H;
AU
     Huster W; Draper M W; Harper K D; Heath H 3rd; Gennari C; Christiansen C;
     Arnaud C D; Delmas P D
     Indiana University School of Medicine, Emerson Hall Room 421, 545 Barnhill
CS
     Dr, Indianapolis, IN 46202, USA.
     Archives of internal medicine, (Dec 11-25 2000) Vol. 160, No. 22, pp.
SO
     3444-50.
     Journal code: 0372440. ISSN: 0003-9926.
     United States
CY
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EΜ
     200101
ED
     Entered STN: 22 Mar 2001
     Last Updated on STN: 22 Mar 2001
     Entered Medline: 11 Jan 2001
     ANSWER 76 OF 93
                         MEDLINE on STN
L9
Full
     Text
AN
     2001038660
                    MEDLINE
     PubMed ID: 11075748
DN
     Soy isoflavones: are they useful in menopause?.
ΤI
     Vincent A; Fitzpatrick L A
ΑIJ
     Division of Endocrinology, Metabolism, Nutrition and Internal Medicine,
CS
     Mayo Clinic, Rochester, Minn 55905, USA.
SO
     Mayo Clinic proceedings. Mayo Clinic, (2000 Nov) Vol. 75, No. 11, pp.
     1174-84. Ref: 91
     Journal code: 0405543. ISSN: 0025-6196.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EΜ
     200011
```

```
Entered STN: 22 Mar 2001
ED
     Last Updated on STN: 22 Mar 2001
     Entered Medline: 30 Nov 2000
                          MEDLINE on STN
L9
     ANSWER 77 OF 93
Full
    Text
ΑN
     2000452135
                     MEDLINE
     PubMed ID: 11006795
DN
TI
     Raloxifene hydrochloride.
     Snyder K R; Sparano N; Malinowski J M
ΑU
     Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA
CS
     18766, USA.. snyder@wilkes.edu
     American journal of health-system pharmacy : AJHP : official journal of
SO
     the American Society of Health-System Pharmacists, (2000 Sep 15) Vol. 57,
     No. 18, pp. 1669-75; quiz 1676-8. Ref: 27
     Journal code: 9503023. ISSN: 1079-2082.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EM
     200101
ED
     Entered STN: 22 Mar 2001
     Last Updated on STN: 22 Mar 2001
     Entered Medline: 5 Jan 2001
L9
     ANSWER 78 OF 93
                          MEDLINE on STN
Full Text
     2000196877
AN
                     MEDLINE
DN
     PubMed ID: 10732328
     Selective estrogen receptor modulators (SERMs) in clinical practice.
ΤI
UΑ
     Plouffe L Jr
     Eli Lilly and Co., US Medical Endocrine Division, Indianapolis, Indiana,
CS
     USA.
     Journal of the Society for Gynecologic Investigation, (2000 Jan-Feb) Vol.
     7, No. 1 Suppl, pp. S38-46. Ref: 103
     Journal code: 9433806. ISSN: 1071-5576.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DТ
     General Review; (REVIEW)
LA
     English
     Priority Journals
FS
EΜ
     200004
     Entered STN: 5 May 2000
ED
     Last Updated on STN: 5 May 2000
     Entered Medline: 26 Apr 2000
L9
     ANSWER 79 OF 93
                          MEDLINE on STN
Full
    <u>Text</u>
AN
     2000150592
                     MEDLINE
     PubMed ID: 10687884
DN
ΤI
     Characterization of hot flashes reported by healthy postmenopausal
     women receiving raloxifene or placebo during osteoporosis prevention
     trials.
     Cohen F J; Lu Y
AU
     Lilly Research Laboratories, Indianapolis, IN 46285, USA..
CS
     fjcohen@lilly.com
     Maturitas, (2000 Jan 15) Vol. 34, No. 1, pp. 65-73.
SQ
     Journal code: 7807333. ISSN: 0378-5122.
     Ireland
CY
     (COMPARATIVE STUDY)
DT
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Priority Journals
EM
     200005
     Entered STN: 12 May 2000
Last Updated on STN: 12 May 2000
ED
     Entered Medline: 4 May 2000
L9
     ANSWER 80 OF 93
                          MEDLINE on STN
```

Full Text

```
AN
     2000144327
                     MEDLINE
     PubMed ID: 10680075
DN
TI
     Chemoprevention of breast cancer in the older patient.
ΑU
     Minton S E
     Department of Medicine, H. Lee Moffitt Cancer Center and Research
CS
     Institute, University of South Florida, Tampa, USA.
Hematology/oncology clinics of North America, (2000 Feb) Vol. 14, No. 1,
SO
     pp. 113-30. Ref: 99
     Journal code: 8709473. ISSN: 0889-8588.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
T.A
FS
     Priority Journals
     200003
EM
ED
     Entered STN: 27 Mar 2000
     Last Updated on STN: 27 Mar 2000
     Entered Medline: 10 Mar 2000
     ANSWER 81 OF 93
L9
                          MEDLINE on STN
Full Text
AN
     2000127246
                     MEDLINE
DN
     PubMed ID: 10665480
ΤI
     Antiestrogens -- tamoxifen, SERMs and beyond.
ΑU
     Dhingra K
CS
     Hoffman-La Roche Inc., Nutley, NJ 07110, USA.
SO
     Investigational new drugs, (1999) Vol. 17, No. 3, pp. 285-311. Ref: 247
     Journal code: 8309330. ISSN: 0167-6997.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LΑ
     English
FS
     Priority Journals
EM
     200002
     Entered STN: 29 Feb 2000
ED
     Last Updated on STN: 29 Feb 2000
     Entered Medline: 17 Feb 2000
L9
     ANSWER 82 OF 93
                           MEDLINE on STN
Full Text
     2000000052
AN
                     MEDLINE
     PubMed ID: 10532252
DN
ΤI
     Tolerability profile of SERMs.
AU 😉
     Agnusdei D; Iori N
     Skeletal Diseases, Eli Lilly & Co., Eli Lilly Italy, Firenze, Italy.
CS
     Journal of endocrinological investigation, (1999 Sep) Vol. 22, No. 8, pp.
     641-5. Ref: 27
     Journal code: 7806594. ISSN: 0391-4097.
CY
     Italy
דת
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LA
     Priority Journals
FS
EM
     199911
     Entered STN: 11 Jan 2000
ED
     Last Updated on STN: 11 Jan 2000
     Entered Medline: 17 Nov 1999
L9
     ANSWER 83 OF 93
                          MEDLINE on STN
Full Text
AN
     1999450119
                     MEDLINE
DN
     PubMed ID: 10520416
     [Results of international clinical trials with raloxifene].
     Resultats des etudes cliniques internationales du raloxifene.
     Agnusdei D; Liu-Leage S; Augendre-Ferrante B
ΑU
     Eli Lilly & Co., Florence, Italie.. <u>agnusdeidonato@lilly.com</u>
Annales d'endocrinologie, (1999 Sep) Vol. 60, No. 3, pp. 242-6. Ref: 18
CS
SO
     Journal code: 0116744. ISSN: 0003-4266.
CY
     France
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
```

```
French
LΑ
     Priority Journals
FS
EM
     199911
ED
     Entered STN: 11 Jan 2000
     Last Updated on STN: 11 Jan 2000
     Entered Medline: 23 Nov 1999
                         MEDLINE on STN
     ANSWER 84 OF 93
L9
Full Text
AN
     1999256919
                    MEDLINE
     PubMed ID: 10326987
DN
     Selective estrogen receptor modulators: a controversial approach
     for managing postmenopausal health.
ΑU
     Curtis M G
     Department of Obstetrics, Gynecology, and Reproductive Medicine,
CS
     University of Texas at Houston, 77026, USA.
     Journal of women's health / the official publication of the Society for
     the Advancement of Women's Health Research, (1999 Apr) Vol. 8, No. 3, pp.
     321-33. Ref: 151
     Journal code: 9208978. ISSN: 1059-7115.
     United States
CY
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LA
FS
     Priority Journals
EΜ
     199907
     Entered STN: 14 Jul 1999
     Last Updated on STN: 14 Jul 1999
     Entered Medline: 1 Jul 1999
                         MEDLINE on STN
     ANSWER 85 OF 93
L9
Full Text
                    MEDLINE
AN
     1999156327
     PubMed ID: 10068418
DN
     Clinical effects of raloxifene hydrochloride in women.
ΤI
ΑU
     Khovidhunkit W; Shoback D M
     University of California, San Francisco, and Veterans Affairs Medical
     Center, 94121, USA.
     DK 43400 (NIDDK).
NC
     Annals of internal medicine, (1999 Mar 2) Vol. 130, No. 5, pp. 431-9.
SO
     Ref: 86
     Journal code: 0372351. ISSN: 0003-4819.
CY
     United States
     (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     General Review; (REVIEW)
     English
FS
     Abridged Index Medicus Journals; Priority Journals
     199903
     Entered STN: 16 Mar 1999
     Last Updated on STN: 3 Mar 2000
     Entered Medline: 4 Mar 1999
     ANSWER 86 OF 93
                         MEDLINE on STN
L9
Full Text
     1999098006
ΑN
                    MEDLINE
     PubMed ID: 9881331
DN
     The effect of estrogens and antiestrogens in a rat model for hot flush.
TI
     Merchenthaler I; Funkhouser J M; Carver J M; Lundeen S G; Ghosh K;
     Winneker R C
     Functional Morphology Division, Women's Health Research Institute,
     Wyeth-Ayerst Research, Radnor, PA 19087, USA.. Merchel@war.wyeth.com
     Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 307-16.
     Journal code: 7807333. ISSN: 0378-5122.
CY
     Ireland
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
EM
     199903
```

```
ED
     Entered STN: 13 Apr 1999
     Last Updated on STN: 13 Apr 1999
     Entered Medline: 26 Mar 1999
L9
     ANSWER 87 OF 93
                          MEDLINE on STN
Full Text
AN
     1999097998
                    MEDLINE
DN
     PubMed ID: 9881323
     Post-menopausal women and osteoporosis: available choices for maintenance
ΤI
     of skeletal health.
     Termine J D; Wong M
AU
     Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
CS
     46285, USA.
     Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 241-5. Ref: 42
SO
     Journal code: 7807333. ISSN: 0378-5122.
CY
     Ireland
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EΜ
     199903
     Entered STN: 13 Apr 1999
ED
     Last Updated on STN: 13 Apr 1999
     Entered Medline: 26 Mar 1999
     ANSWER 88 OF 93
                          MEDLINE on STN
L9
Full Text
AN
     1999078785
                    MEDLINE
     PubMed ID: 9861792
DN
     Hormone replacement therapy and breast cancer: revisiting the issues.
ТT
ΑU
     DeGregorio M W; Taras T L
     Department of Internal Medicine, University of California, Sacramento
CS
     95817, USA.. <u>mwdegregorio@ucdavis.edu</u>
5T32ES07059 (NIEHS)
NC
     Journal of the American Pharmaceutical Association (Washington, D.C.
SO
     1996), (1998 Nov-Dec) Vol. 38, No. 6, pp. 738-44; quiz 744-6. Ref: 51
     Journal code: 9601004. ISSN: 1086-5802.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
DT
     General Review; (REVIEW)
LΑ
     English
     Priority Journals
FS
EΜ
     199901
ED
     Entered STN: 15 Jan 1999
     Last Updated on STN: 15 Jan 1999
     Entered Medline: 6 Jan 1999
     ANSWER 89 OF 93
L9
                          MEDLINE on STN
Full Text
AN
     1998001916
                    MEDLINE
DN
     PubMed ID: 9342556
ΤI
     Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
ΑU
     Maenpaa J U; Ala-Fossi S L
     Department of Obstetrics and Gynecology, University Hospital, Tampere,
CS
     Finland.
     Drugs & aging, (1997 Oct) Vol. 11, No. 4, pp. 261-70. Ref: 53
SO
     Journal code: 9102074. ISSN: 1170-229X.
CY
     New Zealand
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LA
FS
     Priority Journals
EΜ
     199712
     Entered STN: 9 Jan 1998
     Last Updated on STN: 9 Jan 1998
     Entered Medline: 3 Dec 1997
L9
     ANSWER 90 OF 93
                          MEDLINE on STN
Full Text
AN
     94108991
                  MEDLINE
     PubMed ID: 8281625
```

DN

```
Phase I trial of droloxifene in patients with metastatic breast cancer.
     Buzdar A U; Kau S; Hortobagyi G N; Theriault R L; Booser D; Holmes F A;
ΑU
     Walters R; Krakoff I H
     Department of Medical Oncology/Medical Breast Service, University of Texas
CS
     M.D. Anderson Cancer Center, Houston 77030.
     Cancer chemotherapy and pharmacology, (1994) Vol. 33, No. 4, pp. 313-6.
SO
     Journal code: 7806519. ISSN: 0344-5704.
     GERMANY: Germany, Federal Republic of
CY
     (CLINICAL TRIAL)
DΤ
     (CLINICAL TRIAL, PHASE I)
     (CONTROLLED CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
     Priority Journals
FS
EM
     199402
     Entered STN: 28 Feb 1994
ED
     Last Updated on STN: 29 Jan 1999
     Entered Medline: 17 Feb 1994
L9
     ANSWER 91 OF 93
                           MEDLINE on STN
<u>Full</u>
     Text
ΑN
     93205190
                   MEDLINE
     PubMed ID: 8384328
DN
     Clinical and radiographic response in a minority of patients with
TI
     recurrent malignant gliomas treated with high-dose tamoxifen.
     Couldwell W T; Weiss M H; DeGiorgio C M; Weiner L P; Hinton D R; Ehresmann
ΑU
     G R; Conti P S; Apuzzo M L
     Department of Neurological Surgery, University of Southern California, Los
     Angeles.
     Neurosurgery, (1993 Mar) Vol. 32, No. 3, pp. 485-9; discussion 489-90. Journal code: 7802914. ISSN: 0148-396X.
SO
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
     Priority Journals
FS
EΜ
     199304
     Entered STN: 7 May 1993
Last Updated on STN: 7 May 1993
ED
     Entered Medline: 20 Apr 1993
                           MEDLINE on STN
     ANSWER 92 OF 93
L9
Full Text
ΑN
     92044719
                   MEDLINE
     PubMed ID: 1834808
DN
     Phase I study of toremifene in patients with advanced cancer.
ΤI
     Hamm J T; Tormey D C; Kohler P C; Haller D; Green M; Shemano I Department of Medicine, University of Louisville, KY 40292.
ΑU
CS
     Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (1991 Nov) Vol. 9, No. 11, pp. 2036-41.
SO
     Journal code: 8309333. ISSN: 0732-183X.
CY
     United States
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Priority Journals
EΜ
     199112
     Entered STN: 24 Jan 1992
     Last Updated on STN: 24 Jan 1992
     Entered Medline: 6 Dec 1991
L9
     ANSWER 93 OF 93
                            MEDLINE on STN
Full Text
AN
     86079062
                   MEDLINE
DN
     PubMed ID: 3940620
     Trioxifene mesylate in the treatment of advanced breast cancer.
TI
     Lee R W; Buzdar A U; Blumenschein G R; Hortobagyi G N
ΑU
     Cancer, (1986 Jan 1) Vol. 57, No. 1, pp. 40-3.
SO
     Journal code: 0374236. ISSN: 0008-543X.
```

CY United States
DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)

LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198602
ED Entered STN: 21 Mar 1990
 Last Updated on STN: 6 Feb 1995
 Entered Medline: 12 Feb 1986

=> d 19 an ti au so ab kwic 69 70 77 78 79 81 82 84 85 86 87 88

L9 ANSWER 69 OF 93 MEDLINE on STN Full Text

AN 2001441220 MEDLINE

TI Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.

AU Dhingra K

SO Cancer investigation, (2001) Vol. 19, No. 6, pp. 649-59. Ref: 67 Journal code: 8307154. ISSN: 0735-7907.

Female hormones, especially estrogens, play an important role in the pathogenesis of breast neoplasms and are a principal determinant of their ·AB biological behavior. Endocrine manipulation through medical or surgical means can often lead to objective shrinkage of breast tumors. Tamoxifen, a triphenylethylene estrogen receptor modulator, is currently the most widely used hormonal treatment for breast cancer. It has been conclusively demonstrated to reduce the risk of relapse following definitive local therapy (and systemic chemotherapy, when indicated) of invasive or noninvasive breast cancer. Recently, it has also been shown to reduce the incidence of breast cancer in healthy women who are at high risk of developing the disease. In addition, it can prevent osteoporosis and reduce the risk of fractures in postmenopausal women. However, its use is also complicated by an increased incidence of endometrial hyperplasia/carcinoma, venous thromboembolism, cataracts, and in some cases, emergence of tamoxifen-dependent clones of breast cancer. These side effects (except cataracts) are believed to be related to estrogen-agonist effects of tamoxifen. Newer drugs, which are "pure antiestrogens" or inhibitors of estrogen biosynthesis, are devoid of such estrogen-agonist activity and may not have the liability of many of these side effects. However, these agents would also be expected to lack the potentially beneficial effects of tamoxifen on lipids and skeletal system. The ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of selective estrogen-receptor modulation. Selective estrogen receptor modulators (SERMs), which are devoid of estrogen-agonist effects on the uterus or breast cancer cells but retain potentially beneficial effects on bones and lipids, have been described as "ideal" SERMs. A number of such compounds are currently being tested. Raloxifene is already approved for prevention of osteoporosis and has potential efficacy for prevention and treatment of breast cancer. An analogue of raloxifene, LY353381, is currently in Phase II clinical trials for treatment of breast cancer, with promising early results. EM800 and CP336156 are other promising ideal SERMs in clinical trials. These compounds may provide better treatment and chemoprevention alternatives for breast cancer as compared to tamoxifen, aromatase inhibitors, and pure antiestrogens. In addition, they may also prove to be useful for the treatment and prevention of prostate cancer as well as for treating benign gynecological diseases such as fibroids and endometriosis. Future laboratory efforts should focus on further broadening the efficacy profile of SERMs (e.g., prevention of Alzheimer's disease and elevation of high-density lipoproteins to improve the likelihood of cardiovascular benefit) and narrowing their side-effect profile (e.g., risk of thromboembolism and hot flashes).

TI Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.

AB . . . ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of selective estrogen-receptor modulation. Selective estrogen receptor modulators (SERMs), which are devoid of estrogen-agonist effects on the uterus or breast cancer cells but retain potentially

beneficial effects on. . . of high-density lipoproteins to improve the likelihood of cardiovascular benefit) and narrowing their side-effect profile (e.g., risk of thromboembolism and hot flashes).

1.9 ANSWER 70 OF 93 MEDLINE on STN

Full Text

2001334440 MEDLINE AN

Tamoxifen to raloxifene and beyond. ΤI

O'Regan R M; Jordan V C ΑU

Seminars in oncology, (2001 Jun) Vol. 28, No. 3, pp. 260-73. Ref: 119 Journal code: 0420432. ISSN: 0093-7754. SO

Tamoxifen, a selective estrogen receptor modulator (SERM), is AB the treatment of choice for all stages of hormone-responsive breast cancer and has been shown to prevent breast cancer in high-risk women. Despite acting as an antiestrogen on the breast, tamoxifen has partial estrogenic effects on other target tissues. These partial estrogen agonistic actions produce beneficial effects on bones and the lipid profile in postmenopausal women. However, tamoxifen is associated with an increase in endometrial cancer. Additionally, its antiestrogenic effects in the central nervous system result in hot flashes in postmenopausal women. Raloxifene is another SERM approved for the prevention of osteoporosis in postmenopausal women. Like tamoxifen, raloxifene appears to prevent breast cancer in high-risk women and has not, to date, been noted to increase the incidence of endometrial cancer. The Study of Tamoxifen and Raloxifene will compare the effects of the two agents on breast cancer prevention and endometrial cancer risk. A number of new agents are being developed for breast cancer treatment and prevention and osteoporosis prevention. These include other SERMs, selective estrogen receptor downregulators (SERDs), and aromatase inhibitors. It is hoped that one of these new agents will be the ideal agent, acting as an antiestrogen on breast and endometrium while having estrogenic effects on bones, the lipid profile, and the central nervous system. Semin Oncol 28:260-273.

Copyright 2001 by W.B. Saunders Company.

Tamoxifen, a selective estrogen receptor modulator (SERM), is the treatment of choice for all stages of hormone-responsive breast cancer and has been shown to prevent breast cancer in high-risk women. Despite acting as an antiestrogen on the breast, tamoxifen has partial estrogenic effects on other target tissues. These partial estrogen agonistic actions produce beneficial effects. . . tamoxifen is associated with an increase in endometrial cancer. Additionally, its antiestrogenic effects in the central nervous system result in hot flashes in postmenopausal women. Raloxifene is another SERM approved for the prevention of osteoporosis in postmenopausal women. Like tamoxifen, raloxifene appears to prevent breast cancer in high-risk women. and aromatase inhibitors. It is hoped that one of these new agents will be the ideal agent, acting as an antiestrogen on breast and endometrium while having estrogenic effects on bones, the lipid profile, and the central nervous system. Semin Oncol.

Hormone-Dependent: DT, drug therapy

Neoplasms, Hormone-Dependent: PC, prevention & control

Raloxifene: CH, chemistry
Raloxifene: PD, pharmacology
*Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators: TU, therapeutic use

Tamoxifen: AA, analogs & derivatives Tamoxifen: CH, chemistry Tamoxifen: PD, pharmacology *Tamoxifen: TU, therapeutic.

0 (Aromatase Inhibitors); 0 (Estrogen Antagonists); 0 (Selective CN Estrogen Receptor Modulators)

L9 ANSWER 77 OF 93 MEDLINE on STN

Full Text

2000452135 ANMEDLINE

ΤI Raloxifene hydrochloride.

ΑU Snyder K R; Sparano N; Malinowski J M

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, (2000 Sep 15) Vol. 57, No. 18, pp. 1669-75; quiz 1676-8. Ref: 27 Journal code: 9503023. ISSN: 1079-2082.

```
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects,
AB
      and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene
      is a selective estrogen-receptor modulator (SERM) that has been
      approved for use in the prevention and treatment of osteoporosis in
      postmenopausal women. A SERM interacts with estrogen receptors,
      functioning as an agonist in some tissues and an antagonist in other
      tissues. Because of their unique pharmacologic properties, these agents
      can achieve the desired effects of estrogen without the possible stimulatory effects on the breasts or uterus. Raloxifene is rapidly
      absorbed from the gastrointestinal tract and undergoes extensive
      first-pass glucuronidation. Approximately 60% of a dose is absorbed;
      however, absolute bioavailability is only 2%. The volume of distribution is 2348 L/kg for a single oral dose of 30-150 mg, and the elimination
      half-life averages 32.5 hours. In clinical trials in postmenopausal
      women, raloxifene had an estrogen-like effect on bone turnover and
      increased bone mineral density. It reduced the risk of fractures in women with osteoporosis. Raloxifene also seemed to reduce the risk of breast
      cancer and positively influenced blood lipid markers of cardiovascular disease. Raloxifene is generally well tolerated; the most common adverse
      effects are hot flashes and leg cramps. A serious adverse effect is venous thromboembolism. The recommended dosage is 60 mg/day orally
      without regard to meals. Ultimately, it will be information on
      cardiovascular or breast cancer benefits that will determine the future
      role of raloxifene. Raloxifene is an alternative to traditional hormone
      replacement therapy for the prevention and treatment of osteoporosis in
      selected postmenopausal women. More study is needed to verify possible
      benefits related to heart disease and breast cancer.
      The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene
AB
      is a selective estrogen-receptor modulator (SERM) that has been
      approved for use in the prevention and treatment of osteoporosis in
```

postmenopausal women. A SERM interacts with estrogen receptors, functioning as an agonist in some tissues and an antagonist in other tissues. Because of their. . . and positively influenced blood lipid markers of cardiovascular disease. Raloxifene is generally well tolerated; the most common adverse effects are hot flashes and leg cramps. A serious adverse effect is venous thromboembolism. The recommended dosage is 60 mg/day orally without regard to.

Postmenopausal: PC, prevention & control

*Raloxifene

Raloxifene: AE, adverse effects

Raloxifene: ME, metabolism Raloxifene: PK, pharmacokinetics Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators: AE, adverse effects

Selective Estrogen Receptor Modulators: ME, metabolism

Selective Estrogen Receptor Modulators: PK, pharmacokinetics Selective Estrogen Receptor Modulators: TU, therapeutic use

Tissue Distribution

CN 0 (Selective Estrogen Receptor Modulators)

MEDLINE on STN L9 ANSWER 78 OF 93

Full Text

AN 2000196877 MEDLINE

Selective estrogen receptor modulators (SERMs) in clinical practice. ΤI

ΑU Plouffe L Jr

Journal of the Society for Gynecologic Investigation, (2000 Jan-Feb) Vol. 7, No. 1 Suppl, pp. S38-46. Ref: 103 Journal code: 9433806. ISSN: 1071-5576.

The objective of this literature review is to familiarize the reader with AB the clinical data on selective estrogen receptor modulators (SERMs) and antiestrogens currently in use in the US, excluding data on breast effects. Four compounds in the SERM and antiestrogen families are presently in clinical use in the US: clomiphene (CC), tamoxifen (TAM), toremifene (TOR), and raloxifene (RLX). The clinical database on these compounds is among the largest available. Each compound demonstrates a specific profile for its target tissue effects, and this may differ between premenopausal and postmenopausal women. CC is the most widely used agent for ovulation induction. TAM is indicated in the management of breast cancer and for prevention in women at high risk. TAM may have

additional effects on the cardiovascular and skeletal systems. TOR also is used for its effects on breast tissue and may have positive cardiovascular effects. RLX is approved in the management of osteoporosis with data supporting favorable effects on the cardiovascular system and breast tissue. TAM and TOR appear to have stimulatory effects on the uterus and endometrium, whereas RLX is neutral. Few adverse events have been attributed to these agents, with hot flashes being the most common one. There appears to be an increased risk of thromboembolic events with continuous use of TAM, TOR, and RLX. SERMs and antiestrogens continue to be studied extensively. Their evolving profiles support key roles for these agents in modern day medicine, particularly in the management of postmenopausal women's health.

Selective estrogen receptor modulators (SERMs) in clinical practice.

The objective of this literature review is to familiarize the reader with the clinical data on selective estrogen receptor modulators (SERMs) and antiestrogens currently in use in the US, excluding data on breast effects. Four compounds in the SERM and antiestrogen families are presently in clinical use in the US: clomiphene (CC), tamoxifen (TAM), toremifene (TOR), and raloxifene (RLX). The clinical. . . effects on the uterus and endometrium, whereas RLX is neutral. Few adverse events have been attributed to these agents, with hot flashes being the most common one. There appears to be an increased risk of thromboembolic events with continuous use of TAM, . .

therapeutic use

Estrogen Antagonists: TU, therapeutic use

Humans

Osteoporosis, Postmenopausal: PC, prevention & control

Ovulation Induction

Raloxifene: TU, therapeutic use

*Selective Estrogen Receptor Modulators: TU, therapeutic use Tamoxifen: TU, therapeutic use Toremifene: TU, therapeutic use

0 (Estrogen Antagonists); 0 (Selective Estrogen Receptor Modulators)

L9 ANSWER 79 OF 93 MEDLINE on STN

Full Text

AN 2000150592 MEDLINE

TI Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

AU Cohen F J; Lu Y

SO Maturitas, (2000 Jan 15) Vol. 34, No. 1, pp. 65-73. Journal code: 7807333. ISSN: 0378-5122.

OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, is AB estrogen-like in the skeleton and cardiovascular system and antiestrogenic in reproductive tissues. In contrast to estrogens, raloxifene is not indicated for the treatment of hot flashes. This study was designed to examine the characteristics of hot flashes among healthy postmenopausal women participating in osteoporosis prevention trials who were receiving raloxifene or placebo. METHODS: Adverse event data from three randomized, double-blind trials (N = 876) comparing raloxifene 60 mg/day with placebo for 30 months were integrated and analyzed. Two of the three trials (one European, two North American) were identically designed and were open to healthy postmenopausal women ages 45 through 60 without regard to prior hysterectomy. The third trial was multinational, was open to women ages 40 through 60, and all enrollees had prior hysterectomy at baseline. Women were questioned in general terms about the occurrence of adverse events at 3-6-month intervals. Treatment-emergent adverse events pertaining to hot flashes were included in the current study. RESULTS: At baseline, 12% of women randomly assigned to placebo and 13% assigned to raloxifene reported prevalent hot flashes. After 30 months, the cumulative incidence of hot flashes was 21% for placebo and 28% for raloxifene (P = 0.022), with the difference in incidence rate confined to the first 6 months of There was no difference between placebo and raloxifene in reported maximum severity of or early discontinuations as a result of hot flashes (< or = 3% per group for both outcomes). Among women whose hot flashes had stopped completely during the 30-month study period, the median total duration of the event prior to becoming symptom-free was 246 days for placebo and 205 days for raloxifene. all women reporting a hot flash, the extrapolated total duration of

hot flashes was the same for women treated with either raloxifene or placebo. No subgroup-by-therapy interactions were detected. Multivariable regression analysis revealed several factors that were independently weakly predictive of hot flashes. CONCLUSIONS: Raloxifene slightly affects the incidence but not the natural history of hot flashes in healthy postmenopausal women seeking prevention therapy. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. OBJECTIVE: Raloxifene, a selective estrogen receptor modulator, is AB estrogen-like in the skeleton and cardiovascular system and antiestrogenic in reproductive tissues. In contrast to estrogens, raloxifene is not indicated for the treatment of hot flashes. This study was designed to examine the characteristics of hot flashes among healthy postmenopausal women participating in osteoporosis prevention trials who were receiving raloxifene or placebo. METHODS: Adverse event data from. Women were questioned in general terms about the occurrence of adverse events at 3-6-month intervals. Treatment-emergent adverse events pertaining to hot flashes were included in the current study. RESULTS: At baseline, 12% of women randomly assigned to placebo and 13% assigned to raloxifene reported prevalent hot flashes. After 30 months, the cumulative incidence of hot flashes was 21% for placebo and 28% for raloxifene (P = 0.022), with the difference in incidence rate There was no difference between placebo and confined to the. raloxifene in reported maximum severity of or early discontinuations as a result of hot flashes (< or = 3% per group for both outcomes). Among women whose hot flashes had stopped completely during the 30-month study period, the median total duration of the event prior to becoming symptom-free was 246 days for placebo and 205 days for raloxifene. Among all women reporting a hot flash, the extrapolated total duration of hot flashes was the same for women treated with either raloxifene or placebo. No subgroup-by-therapy interactions were detected. Multivariable regression analysis revealed several factors that were independently weakly predictive of hot flashes. CONCLUSIONS: Raloxifene slightly affects the incidence but not the natural history of hot flashes in healthy postmenopausal women seeking prevention therapy. CTCheck Tags: Female Adult Double-Blind Method Estrogen Antagonists: AE, adverse effects *Estrogen Antagonists: TU, therapeutic use Hot Flashes: CI, chemically induced *Hot Flashes: EP, epidemiology Humans Incidence Middle Aged *Osteoporosis, Postmenopausal: PC, prevention & control Raloxifene: AE, adverse effects *Raloxifene: TU, therapeutic use Randomized Controlled Trials Risk Factors Selective Estrogen Receptor Modulators: AE, adverse effects *Selective Estrogen Receptor Modulators: TU, therapeutic use Severity of Illness Index Time Factors 0 (Estrogen Antagonists); 0 (Selective Estrogen Receptor Modulators) CN ANSWER 81 OF 93 MEDLINE on STN L9 <u>Full</u> 2000127246 MEDLINE Antiestrogens -- tamoxifen, SERMs and beyond. ΤI ΑU Dhingra K Investigational new drugs, (1999) Vol. 17, No. 3, pp. 285-311. Ref: 247 SO Journal code: 8309330. ISSN: 0167-6997. Estrogens play a central role in reproductive physiology. The cellular effects of estrogens are mediated by binding to nuclear receptors (ER) which activate transcription of genes involved in cellular growth control. At least two such receptors, designated ERalpha and ERbeta, mediate these effects in conjunction with a number of coactivators. These receptors can directly interact with other members of the steroid receptor superfamily. A complex cross-talk exists between the estrogen-signaling pathways and

the downstream signaling events initiated by growth factors, such as

epidermal growth factor and insulin-like growth factors. Estrogens are also a causative factor in the pathogenesis of a variety of neoplastic and non-neoplastic diseases, including breast cancer, endometrial cancer, endometriosis, and uterine fibroids, among others. Antiestrogens, such as tamoxifen, are widely used for the treatment of breast cancer. Tamoxifen produces objective tumor shrinkage in advanced breast cancer, reduces the risk of relapse in women treated for invasive breast cancer, and prevents breast cancer in high-risk women. Although, initially developed as an antiestrogen, tamoxifen can also prevent postmenopausal osteoporosis as well as reduce cholesterol, due to its estrogen-agonist effects. Its estrogen-agonist activity, however, can lead to significant side-effects such as endometrial cancer and thromboembolic phenomena. This has led to the concept of "ideal" selective estrogen receptor modulators (SERMs), drugs that would have the desired, tissue selective, estrogen-agonist or -antagonist effects. Raloxifene is a SERM which has the desirable mixed agonist/antagonist effects of tamoxifen but does not cause uterine stimulation. "Pure" antiestrogens may provide very potent estrogen-antagonist drugs, but are likely to be devoid of beneficial effects on bone and lipids. Future drug development efforts should focus on developing superior SERMs that have a greater efficacy against ER-positive tumors and do not cause hot flashes or thromboembolism, and explore combination strategies to simultaneously target hormone-dependent as well as hormone-independent breast cancer. . relapse in women treated for invasive breast cancer, and prevents breast cancer in high-risk women. Although, initially developed as an antiestrogen, tamoxifen can also prevent postmenopausal osteoporosis as well as reduce cholesterol, due to its estrogen-agonist effects. Its estrogen-agonist activity, however, . . . can lead to significant side-effects such as endometrial cancer and thromboembolic phenomena. This has led to the concept of "ideal" selective estrogen receptor modulators (SERMs), drugs that would have the desired, tissue selective, estrogen-agonist or -antagonist effects. Raloxifene is a SERM which has the desirable mixed agonist/antagonist effects of tamoxifen but does not cause uterine stimulation. "Pure" antiestrogens may provide very. development efforts should focus on developing superior SERMs that have a greater efficacy against ER-positive tumors and do not cause hot flashes or thromboembolism, and explore combination strategies to simultaneously target hormone-dependent as well as hormone-independent breast cancer. ANSWER 82 OF 93 MEDLINE on STN Full Text 2000000052 MEDLINE Tolerability profile of SERMs. Agnusdei D; Iori N Journal of endocrinological investigation, (1999 Sep) Vol. 22, No. 8, pp. 641-5. Ref: 27 Journal code: 7806594. ISSN: 0391-4097. Check Tags: Female Estrogen Replacement Therapy: AE, adverse effects Hot Flashes: CI, chemically induced Osteoporosis, Postmenopausal: PC, prevention & control Raloxifene: AE, adverse effects Raloxifene: TU, therapeutic use *Selective Estrogen Receptor Modulators: AE, adverse effects *Selective Estrogen Receptor Modulators: TU, therapeutic use Tamoxifen: AE, adverse effects Tamoxifen: TU, therapeutic use Venous Thrombosis: CI, chemically induced 0 (Selective Estrogen Receptor Modulators) ANSWER 84 OF 93 MEDLINE on STN Full Text 1999256919 MEDLINE

Selective estrogen receptor modulators: a controversial approach

Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research, (1999 Apr) Vol. 8, No. 3, pp.

for managing postmenopausal health.

AB

L9

AN

ΤI

ΑU SO

CT

CN

L9

AN TI

AU

Curtis M G

· **3**21-33. Ref: 151

41

- Journal code: 9208978. ISSN: 1059-7115.
- AB Hormone replacement therapy (HRT) is considered the standard of care for managing the acute (e.g., hot flashes, vaginal dryness) and long-term (e.g., increased risk of cardiovascular disease, osteoporosis) sequelae of menopause. A group of synthetic nonsteroidal compounds, which act on the estrogen receptor, have been promoted for use as an alternative to hormonal therapy for postmenopausal women. Originally called antiestrogens because of their ability to antagonize the action of estrogen, these compounds possess both agonist and antagonist properties of estrogen action. They are now referred to as selective estrogen receptor modulators (SERMs). This article reviews the mechanism of action and the efficacy and safety data for SERMs currently used for clinical purposes. These data may indicate why the use of SERMs is a controversial alternative to HRT.
- TI Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health.
- AB Hormone replacement therapy (HRT) is considered the standard of care for managing the acute (e.g., hot flashes, vaginal dryness) and long-term (e.g., increased risk of cardiovascular disease, osteoporosis) sequelae of menopause. A group of synthetic nonsteroidal compounds, . . . action of estrogen, these compounds possess both agonist and antagonist properties of estrogen action. They are now referred to as selective estrogen receptor modulators (SERMs). This article reviews the mechanism of action and the efficacy and safety data for SERMs currently used for clinical.
- L9 ANSWER 85 OF 93 MEDLINE on STN
- Full Text
- **AN 1**999156327 MEDLINE
- TI Clinical effects of raloxifene hydrochloride in women.
- AU Khovidhunkit W; Shoback D M
- SO Annals of internal medicine, (1999 Mar 2) Vol. 130, No. 5, pp. 431-9.
 Ref: 86
 - Journal code: 0372351. ISSN: 0003-4819.
- PURPOSE: To review clinical data on raloxifene hydrochloride, a AB selective estrogen receptor modulator that was recently approved for the prevention of osteoporosis in postmenopausal women. DATA SOURCES: English-language articles published from 1980 to May 1998 were identified through MEDLINE searches. Bibliographies, book chapters, and meeting abstracts were reviewed for additional relevant publications. STUDY SELECTION: Publications that contained information on the background of development, structure, mechanism of action, tissue-selective effects, and adverse effects of raloxifene hydrochloride were included. DATA EXTRACTION: Data in selected articles were reviewed, and relevant clinical information was extracted. DATA SYNTHESIS: Raloxifene hydrochloride was developed in an effort to find a treatment for breast cancer and osteoporosis. It binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen receptor subtypes in various tissues, and intracellular events after ligand binding. Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. An increase in bone mineral density at the spine, total hip, and total body has been reported with raloxifene but seems to be less than that seen with estrogen or alendronate therapy. Raloxifene has been shown to produce a reduction in total and low-density lipoprotein cholesterol concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholesterol and triglyceride concentrations do not increase during raloxifene therapy. In the uterus, raloxifene does not stimulate the endometrium. Long-term data on the effects of raloxifene in reduction of risk for fracture; prevention of cardiovascular events; cognitive function; and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is hot flashes. CONCLUSIONS: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug of choice for hormonal therapy in most postmenopausal women, raloxifene may be an alternative in certain groups of women at risk for osteoporosis.
- AB PURPOSE: To review clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was recently approved

for the prevention of osteoporosis in postmenopausal women. DATA SOURCES: English-language articles published from 1980 to. . . binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators. Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure, interaction of the ligand with different estrogen. . . and the incidence of breast, ovarian, and uterine cancer are not available. The most common adverse effect of raloxifene is hot flashes. CONCLUSIONS: Raloxifene has been shown to have beneficial effects in selected organs in postmenopausal women. Although estrogen remains the drug.

ANSWER 86 OF 93 MEDLINE on STN L9

Full Text

1999098006 MEDLINE AN

- The effect of estrogens and antiestrogens in a rat model for hot flush. TΙ
- Merchenthaler I; Funkhouser J M; Carver J M; Lundeen S G; Ghosh K; ΑU Winneker R C
- Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 307-16. Journal code: 7807333. ISSN: 0378-5122.
- The present studies evaluated the effect of estrogens and the selective AB estrogen receptor modulator (SERM) tamoxifen and raloxifene in a rat model for hot flush. In this model, ovariectomized rats were treated for 8 or 9 days either sc or po. Rats were dependent to morphine by implanting a morphine pellet (75 mg each) sc on days 3 and 5 of treatment. On the last day of treatment, a thermistor, connected to a data acquisition system, was placed on the tail of each animal and morphine addiction was withdrawn by naloxone injection (1.0 mg/kg, sc).

 Temperature measurements were taken for 1 h under ketamine (80 mg/kg, im) anesthesia. In general, vehicle treated rats showed a 5-6 degrees C elevation of their tail skin temperature with the peak occurring about 15 min after naloxone injection. 17 alpha-Ethinyl estradiol (EE) was evaluated both sc and po using a broad range of doses. The IC50 for inhibition of tail skin temperature rise was approximately 0.1 mg/kg, sc and 0.2 mg/kg, po. 17 beta-Estradiol and 17 alpha-estradiol were also active in this model whereas non-estrogenic steroids were inactive. Raloxifene and tamoxifen were tested for estrogen agonist and antagonist activity administered sc and po. Raloxifene did not demonstrate reproducible estrogen agonist activity at doses up to 10 mg/kg, whereas it demonstrated significant antagonistic activity at the 10 mg/kg dose regardless of the route of administration. Tamoxifen exhibited significant estrogen agonist activity at all doses tested (0.1-10.0 mg/kg) and was a significant antagonist of EE at the 1.0 mg/kg dose. Our results demonstrate the potential utility of this model to evaluate and discriminate among classes of compounds with varying degrees of estrogen agonist and antagonist activity.

The present studies evaluated the effect of estrogens and the selective AΒ estrogen receptor modulator (SERM) tamoxifen and raloxifene in a rat model for hot flush. In this model, ovariectomized rats were treated for 8 or.

*Body Temperature: DE, drug effects

Disease Models, Animal

- *Estrogen Antagonists: TU, therapeutic use
- *Estrogens: AG, agonists
- *Estrogens: TU, therapeutic use
- *Hot Flashes: DT, drug therapy Hot Flashes: ME, metabolism

Random Allocation

Rats

Rats, Sprague-Dawley

ANSWER 87 OF 93 MEDLINE on STN L9

Full Text

AN 1999097998 MEDLINE

- Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health.
- AII Termine J D; Wong M
- Maturitas, (1998 Nov 16) Vol. 30, No. 3, pp. 241-5. Ref: 42 Journal code: 7807333. ISSN: 0378-5122. SO
- AΒ OBJECTIVE: To briefly summarize the therapeutic choices for osteoporosis prevention which are currently available to post-menopausal women.

METHODS: Results of randomized clinical trials and epidemiological studies in postmenopausal women, and pre-clinical studies in ovariectomized rats were summarized. RESULTS: Estrogen combined with progestogen in hormone replacement therapy (HRT) is effective in relieving perimenopausal symptoms and maintaining bone mineral density. However, the increased breast cancer risk associated with long-term HRT use makes it a less desirable option for many women. Selective estrogen receptor modulators (SERMs), such as raloxifene, are also effective in maintaining bone density, without stimulating the breast or uterus. However, SERMs do not relieve perimenopausal hot flashes. CONCLUSION: HRT is effective for acute relief of perimenopausal symptoms, but for women who are unwilling or unable to take HRT long-term, SERMs such as raloxifene are a useful therapy for the prevention of osteoporosis.

. . . . However, the increased breast cancer risk associated with

AB . . . However, the increased breast cancer risk associated with long-term HRT use makes it a less desirable option for many women.

Selective estrogen receptor modulators (SERMs), such as raloxifene, are also effective in maintaining bone density, without stimulating the breast or uterus. However, SERMs do not relieve perimenopausal hot flashes. CONCLUSION: HRT is effective for acute relief of perimenopausal symptoms, but for women who are unwilling or unable to take. . .

L9 ANSWER 88 OF 93 MEDLINE on STN

Full Text

AN 1999078785 MEDLINE

TI Hormone replacement therapy and breast cancer: revisiting the issues.

AU DeGregorio M W; Taras T L

- SO Journal of the American Pharmaceutical Association (Washington, D.C.: 1996), (1998 Nov-Dec) Vol. 38, No. 6, pp. 738-44; quiz 744-6. Ref: 51 Journal code: 9601004. ISSN: 1086-5802.
- AΒ OBJECTIVE: To assess current ideas about the benefits and risks of estrogen and hormone replacement therapy (ERT/HRT) in postmenopausal women. DATA SOURCES: MEDLINE searches, supplemented by various texts, of the literature on HRT, ERT, and selective estrogen receptor modulators (SERMs): tamoxifen, toremifene, and raloxifene. DATA SYNTHESIS: HRT is primarily used for improving quality of life in women suffering from vasomotor symptoms associated with menopause. HRT is beneficial in postmenopausal women for preventing cardiovascular disease, osteoporosis, and Alzheimer's disease. Review of meta-analyses of clinical trials showed that ERT/HRT ever-users (patients who have ever used ERT/HRT) did not have an increased risk of breast cancer, but current users did have an increased risk, with some studies reporting increasing risk with duration of ERT. No relationship was found between dose or the addition of progestin to ERT and increased breast cancer risk. Overall breast cancer mortality rates associated with HRT were decreased in current users. In general, HRT does not increase the risk of breast cancer in women with a family history of the disease, compared with those without a family history. New HRT strategies that could potentially prevent breast cancer are now being developed. The SERMs tamoxifen and toremifene appear to have positive clinical effects on bone and serum lipids; they are currently being investigated for use as breast cancer chemopreventive agents. Raloxifene, a new SERM used for the prevention of osteoporosis, is an alternative for women who cannot tolerate HRT. Unfortunately, these SERMS have anti-estrogenic effects and thus cause vasomotor adverse effects such as hot flashes and vaginal dryness. addition, SERMs do not protect against heart disease or prevent osteoporosis as well as does HRT. CONCLUSION: Presently, SERMs will not become first-line HRT, as the positive effects of ERT/HRT may outweigh any potentially increased risk of breast cancer. The development of new agents with pharmacodynamic profiles similar to that of ERT/HRT but lacking its adverse effects would be greatly beneficial for postmenopausal women.
- AB . . . therapy (ERT/HRT) in postmenopausal women. DATA SOURCES: MEDLINE searches, supplemented by various texts, of the literature on HRT, ERT, and selective estrogen receptor modulators (SERMs): tamoxifen, toremifene, and raloxifene. DATA SYNTHESIS: HRT is primarily used for improving quality of life in women suffering from. . . on bone and serum lipids; they are currently being investigated for use as breast cancer chemopreventive agents. Raloxifene, a new SERM used for the prevention of osteoporosis, is an alternative for women who cannot tolerate HRT. Unfortunately, these SERMS have anti-estrogenic effects and thus cause vasomotor adverse effects such as hot flashes and vaginal

dryness. In addition, SERMs do not protect against heart disease or prevent osteoporosis as well as does HRT.. . .

=> d his (FILE 'HOME' ENTERED AT 22:46:46 ON 30 MAR 2007). FILE 'REGISTRY' ENTERED AT 22:46:57 ON 30 MAR 2007 E TAMOXIFEN/CN 1 S E3 L1E RALOXIFENE/CN 1 S E3 1.2 E TOREMIFENE/CN 1 S E3 L3E TRIPHENYLETHYLENE/CN 1 S E3 T.4 FILE 'MEDLINE' ENTERED AT 22:48:34 ON 30 MAR 2007 5161 S (ANTIESTROGEN OR SELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM) L5 L6 12869 S L1 OR L2 OR L3 OR L4 16501 S (TAMOXIFEN OR RALOXIFENE OR TOREMIFENE OR TRIPHENYLETHYLENE) L7 1538 S (HOT FLASH?) L8 93 S L5 AND L8 L9 16501 S L6 OR L7 L10 182 S L8 AND L10 L11=> d 1-182 **L11 A**NSWER **1** OF 182 MEDLINE on STN Full Text AN 2007090333 MEDLINE PubMed ID: 17200148 DN Five years of letrozole compared with tamoxifen as initial adjuvant TI therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates Alan S; Keshaviah Aparna; Thurlimann Beat; Mouridsen Henning; ΑU Mauriac Louis; Forbes John F; Paridaens Robert; Castiglione-Gertsch Monica; Gelber Richard D; Colleoni Marco; Lang Istvan; Del Mastro Lucia; Smith Ian; Chirgwin Jacquie; Nogaret Jean-Marie; Pienkowski Tadeusz; Wardley Andrew; Jakobsen Erik H; Price Karen N; Goldhirsch Aron International Breast Cancer Study Group (IBCSG), IBCSG Coordinating CS Center, Bern, Switzerland. alan.coates@ibcsg.org NC CA-75362 (NCI) Journal of clinical oncology : official journal of the American Society of SO Clinical Oncology, (2007 Feb 10) Vol. 25, No. 5, pp. 486-92. Electronic Publication: 2007-01-02. Journal code: 8309333. E-ISSN: 1527-7755. CY United States דת Journal; Article; (JOURNAL ARTICLE) (MULTICENTER STUDY) (RANDOMIZED CONTROLLED TRIAL) (RESEARCH SUPPORT, N.I.H., EXTRAMURAL) (RESEARCH SUPPORT, NON-U.S. GOV'T) (CLINICAL TRIAL) English LA Priority Journals FS EM 200703 ED Entered STN: 10 Feb 2007 Last Updated on STN: 16 Mar 2007 Entered Medline: 15 Mar 2007 L11 ANSWER 2 OF 182 MEDLINE on STN Full Text 2007028979 MEDLINE AN DN PubMed ID: 17225620 Psychological well-being improves in women with breast cancer after ΤI treatment with applied relaxation or electro-acupuncture for vasomotor symptom. Nedstrand Elizabeth; Wyon Yvonne; Hammar Mats; Wijma Klaas ΑU Division of Obstetrics and Gynecology, Faculty of Health Sciences, CS

Linkoping University Hospital, Linkoping, Sweden...

```
elizabeth.nedstrand@lio.se
     Journal of psychosomatic obstetrics and gynaecology, (2006 Dec) Vol. 27,
SO
     No. 4, pp. 193-9.
     Journal code: 8308648. ISSN: 0167-482X.
     England: United Kingdom
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (CLINICAL TRIAL)
     English
T.A
FS
     Priority Journals
     200703
EΜ
     Entered STN: 18 Jan 2007
     Last Updated on STN: 2 Mar 2007
     Entered Medline: 1 Mar 2007
L11 ANSWER 3 OF 182
                          MEDLINE on STN
Full Text
     2007013928
AN
                    MEDLINE
     PubMed ID: 17211091
     Therapeutic agents for disorders of bone and calcium metabolism:
TI
     Bazedoxifene.
ΑU
     Chaki Osamu
CS
     Yokohama City University Medical Center, Section of Gynecology.
     Clinical calcium, (2007 Jan) Vol. 17, No. 1, pp. 30-5. Ref: 8
SO
     Journal code: 9433326. ISSN: 0917-5857.
CY
     Japan
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Japanese
FS
     Priority Journals
EΜ
     200703
     Entered STN: 10 Jan 2007
ED
     Last Updated on STN: 24 Mar 2007
     Entered Medline: 23 Mar 2007
L11 ANSWER 4 OF 182
                          MEDLINE on STN
Full Text
ΑN
     2006719192
                     MEDLINE
DN
     PubMed ID: 17162554
     Long-term administration of mifepristone (RU486): clinical tolerance
     during extended treatment of meningioma.
ΑU
     Grunberg Steven M; Weiss Martin H; Russell Christy A; Spitz Irving M;
     Ahmadi Jamshid; Sadun Alfredo; Sitruk-Ware Regine
     Division of Hematology/Oncology, University of Vermont College of
CS
     Medicine, Burlington, Vermont, USA. steven.grunberg@uvm.edu
NC
     2P30 CA14089 (NCI)
SO
     Cancer investigation, (2006 Dec) Vol. 24, No. 8, pp. 727-33.
     Journal code: 8307154. ISSN: 0735-7907.
     United States
CY
DT
     (CLINICAL TRIAL, PHASE II)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (CLINICAL TRIAL)
LA
     English
FS
     Priority Journals
     200703
EΜ
ED
     Entered STN: 13 Dec 2006
     Last Updated on STN: 6 Mar 2007
     Entered Medline: 5 Mar 2007
L11 ANSWER 5 OF 182
                          MEDLINE on STN
Full Text
AN
     2006715159
                     MEDLINE
DN
     PubMed ID: 16936184
ΤI
     Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole
     after 5 years of tamoxifen in postmenopausal women with early stage
     breast cancer.
     Moy B; Tu D; Pater J L; Ingle J N; Shepherd L E; Whelan T J; Goss P E Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114,
ΑU
CS
```

```
USA. . bmoy@partners.org
     Annals of oncology : official journal of the European Society for Medical
SO
     Oncology / ESMO, (2006 Nov) Vol. 17, No. 11, pp. 1637-43. Electronic
     Publication: 2006-08-25.
     Journal code: 9007735. ISSN: 0923-7534.
CY
     England: United Kingdom
     Journal; Article; (JOURNAL ARTICLE)
DT
     (RANDOMIZED CONTROLLED TRIAL)
     (CLINICAL TRIAL)
LA
     English
FS
     Priority Journals
EΜ
     200702
     Entered STN: 13 Dec 2006
ED
     Last Updated on STN: 2 Feb 2007
     Entered Medline: 1 Feb 2007
L11 ANSWER 6 OF 182
                         MEDLINE on STN
Full Text
ΑN
     2006713123
                    MEDLINE
     PubMed ID: 16971671
DN
     Menopausal-type symptoms in young breast cancer survivors.
     Leining M G; Gelber S; Rosenberg R; Przypyszny M; Winer E P; Partridge A H
ΑU
     Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA,
CS
     Annals of oncology : official journal of the European Society for Medical
SO
     Oncology / ESMO, (2006 Dec) Vol. 17, No. 12, pp. 1777-82. Electronic Publication: 2006-09-13.
     Journal code: 9007735. ISSN: 0923-7534.
CY
     England: United Kingdom
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
EΜ
     200703
ED
     Entered STN: 12 Dec 2006
     Last Updated on STN: 2 Mar 2007
     Entered Medline: 1 Mar 2007
L11 ANSWER 7 OF 182
                         MEDLINE on STN
Full Text
AN
     2006552765
                    MEDLINE
     PubMed ID: 16978958
DN
     Side effects of aromatase inhibitors versus tamoxifen: the patients'
     perspective.
ΑU
     Garreau Jennifer R; Delamelena Tammy; Walts Deb; Karamlou Kasra; Johnson
     Nathalie
     OHSU Department of Surgery, Portland, OR 97210, USA.. garreauj@ohsu.edu
CS
     American journal of surgery, (2006 Oct) Vol. 192, No. 4, pp. 496-8. Journal code: 0370473. ISSN: 0002-9610.
SO
CY
     United States
     (COMPARATIVE STUDY)
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Abridged Index Medicus Journals; Priority Journals
EM
     200611
     Entered STN: 19 Sep 2006
ED
     Last Updated on STN: 7 Nov 2006
     Entered Medline: 6 Nov 2006
L11 ANSWER 8 OF 182
                         MEDLINE on STN
Full Text
AN
     2006534953
                    MEDLINE
     PubMed ID: 16958819
DN
     Effectiveness of raloxifene on bone mineral density and serum lipid
     levels in post-menopausal women with low BMD after discontinuation of
     hormone replacement therapy.
     Song E K; Yeom J-H; Shin H T; Kim S H; Shin W G; Oh J M
ΑU
     Department of Pharmacy, Sejong General Hospital, Seoul, Korea.
CS
     Journal of clinical pharmacy and therapeutics, (2006 Oct) Vol. 31, No. 5,
     pp. 421-7.
     Journal code: 8704308. ISSN: 0269-4727.
CY
     England: United Kingdom
     Journal; Article; (JOURNAL ARTICLE)
```

```
LA
     English
FS
     Priority Journals
EΜ
     200612
     Entered STN: 9 Sep 2006
ED
     Last Updated on STN: 19 Dec 2006
     Entered Medline: 15 Dec 2006
L11 ANSWER 9 OF 182
                          MEDLINE on STN
Full Text
AN
     2006495512
                     MEDLINE
DN
     PubMed ID: 16921052
     Influence of hormone replacement therapy on tamoxifen-induced vasomotor
     symptoms.
     Sestak Ivana; Kealy Roseann; Edwards Robert; Forbes John; Cuzick Jack
ΑU
     Cancer Research UK, Centre for Epidemiology, Mathematics and Statistics,
CS
     Wolfson Institute of Preventive Medicine, London, United Kingdom.
     Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (2006 Aug 20) Vol. 24, No. 24, pp. 3991-6.
SO
     Journal code: 8309333. E-ISSN: 1527-7755.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
LA
     English
FS
     Priority Journals
EΜ
     200609
ED
     Entered STN: 22 Aug 2006
     Last Updated on STN: 13 Sep 2006
     Entered Medline: 12 Sep 2006
                           MEDLINE on STN
L11 ANSWER 10 OF 182
Full Text
                     MEDLINE
AN
     2006492805
     PubMed ID: 16916481
DN
     A Canadian observational study of the optimal method of transition from
TΤ
     postmenopausal hormone therapy to raloxifene.
ΑU
     Lorraine Joanne; Lee Bobbie
CS
     Eli Lilly Canada, Toronto ON.
     Journal of obstetrics and gynaecology Canada : JOGC = Journal
     d'obstetrique et gynecologie du Canada : JOGC, (2006 Jul) Vol. 28, No. 7,
     pp. 583-94.
     Journal code: 101126664. ISSN: 1701-2163.
CY
     Canada
DT
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (CLINICAL TRIAL)
     English
LA
FS
     Priority Journals
EΜ
     200609
     Entered STN: 19 Aug 2006
     Last Updated on STN: 19 Sep 2006
     Entered Medline: 18 Sep 2006
L11 AMSWER 11 OF 182
                           MEDLINE on STN
Full Text
     2006453370
                     MEDLINE
AN
DN
     PubMed ID: 16877740
     Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences
     clinical effect but not hot flashes: data from the Italian Tamoxifen
     Bonanni Bernardo; Macis Debora; Maisonneuve Patrick; Johansson Harriet A;
ΑU
     Gucciardo Giacomo; Oliviero Pasquale; Travaqlini Roberto; Muraca Maria G;
     Rotmensz Nicole; Veronesi Umberto; Decensi Andrea U
     Journal of clinical oncology: official journal of the American Society of
SO
     Clinical Oncology, (2006 Aug 1) Vol. 24, No. 22, pp. 3708-9; author reply
     Journal code: 8309333. E-ISSN: 1527-7755.
CY
     U ited States
     Commentary
     Letter
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
```

```
Priority Journals
FS
EM
     2,0608
ED
     Entered STN: 1 Aug 2006
     Last Updated on STN: 15 Aug 2006
     Entered Medline: 14 Aug 2006
L11 ANSWER 12 OF 182
                            MEDLINE on STN
Full Text
AN
     2006414662
                     MEDLINE
     PubMed ID: 16735939
DN
     Dietary factors and vasomotor symptoms in breast cancer survivors: the
     WHEL Study.
     Gold Ellen B; Flatt Shirley W; Pierce John P; Bardwell Wayne A; Hajek
AIJ
     Richard A; Newman Vicky A; Rock Cheryl L; Stefanick Marcia L
Division of Epidemiology, Department of Public Health Sciences, University
CS
     of California, Davis, Davis, CA 95616, USA.
NC
     CA69375 (NCI)
     M01-RR00070 (NCRR)
     M01-RR00079 (NCRR)
     M01-RR00827 (NCRR)
SO
     Menopause (New York, N.Y.), (2006 May-Jun) Vol. 13, No. 3, pp. 423-33.
     Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
DT
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
FS
     Priority Journals
EΜ
     200608
     Entered STN: 14 Jul 2006
ED
     Last Updated on STN: 3 Aug 2006
     Entered Medline: 2 Aug 2006
L11 ANSWER 13 OF 182
                            MEDLINE on STN
Full Text
AN
     2006355459
                     MEDLINE
     PubMed ID: 16770112
DN
     Introduction of new drug: letrozole, a new non-steroidal aromatase
     inhibitor for the treatment of postmenopausal women with breast cancer.
ΑU
     Tsukaqoshi Shiqeru
CS
     The Tokyo Cooperative Oncology Group.
     Gan to kagaku ryoho. Cancer & chemotherapy, (2006 Jun) Vol. 33, No. 6, pp.
SO
     839-63. Ref: 11
Journal code: 7810034. ISSN: 0385-0684.
CY
     Japan
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Japanese
FS
     Priority Journals
     200607
     Entered STN: 14 Jun 2006
     Last Updated on STN: 6 Jul 2006
     Entered Medline: 5 Jul 2006
L11 AFSWER 14 OF 182
                            MEDLINE on STN
Full Text
AN
     2006343989
                     MEDLINE
     PubMed ID: 16757696
DN
ΤI
     Raloxifene prevails in STAR trial, may face easier road to acceptance
     than previous drugs.
ΑU
     Vastag Brian
     Journal of the National Cancer Institute, (2006 Jun 7) Vol. 98, No. 11,
SO
     pp. 733-5.
     Journal code: 7503089. E-ISSN: 1460-2105.
CY
     United States
DT
     News Announcement
LA
     English
FS
     P iority Journals
EΜ
     2 0606
ED
     Entered STN: 8 Jun 2006
```

Last Updated on STN: 24 Jun 2006

Entered Medline: 23 Jun 2006 L11 AMSWER 15 OF 182 MEDLINE on STN Full Text ΑN 2006251095 MEDLINE DN PubMed ID: 16675918 Inherited gene affects tamoxifen's benefit in some breast cancers. TI ΑU Mayo Clinic women's healthsource, (2006 Jun) Vol. 10, No. 6, pp. 3. SO Journal code: 9891120. ISSN: 1091-0220. CY United States News Announcement DT LΑ English FS Consumer Health 200606 ΕM ΕD Entered STN: 6 May 2006 Last Updated on STN: 28 Jun 2006 Entered Medline: 27 Jun 2006 L11 ANSWER 16 OF 182 MEDLINE on STN Full Text IN-PROCESS 2006154614 AN PubMed ID: 16542048 DN Serotonergic agents as an alternative to hormonal therapy for the ΤI treatment of menopausal vasomotor symptoms. Stearns Vered AU Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of CS Medicine, Baltimore, Maryland, USA. Treatments in endocrinology, (2006) Vol. 5, No. 2, pp. 83-7. SO Journal code: 101132977. ISSN: 1175-6349. CY New Zealand Journal; Article; (JOURNAL ARTICLE) DT LA English NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals FS ED Entered STN: 18 Mar 2006 Last Updated on STN: 12 Dec 2006 L11 ANSWER 17 OF 182 MEDLINE on STN Full Text 2)06123472 MEDLINE AN PibMed ID: 16509835 Rindomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Kimmick Gretchen G; Lovato James; McQuellon Richard; Robinson Emily; Muss ΑU CS Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina, USA.. <u>gretchen.kimmick@duke.edu</u> SO The breast journal, (2006 Mar-Apr) Vol. 12, No. 2, pp. 114-22. Journal code: 9505539. ISSN: 1075-122X. United States CYJournal; Article; (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL) (CLINICAL TRIAL) English LA FS Priority Journals 2)0604 EΜ ED Entered STN: 3 Mar 2006 Last Updated on STN: 5 Apr 2006 Entered Medline: 4 Apr 2006 L11 ANSWER 18 OF 182 MEDLINE on STN Full Text AN 2706039179 MEDLINE DN PubMed ID: 16428125 Monopausal symptoms in women treated for breast cancer: the prevalence and

s verity of symptoms and their perceived effects on quality of life.

Gipta P; Sturdee D W; Palin S L; Majumder K; Fear R; Marshall T; Paterson

W men's Unit, Solihull Hospital, Heart of England NHS Foundation Trust,

AU

CS .

Solihull.

50

```
Climacteric: the journal of the International Menopause Society, (2006
· so
      Feb) Vol. 9, No. 1, pp. 49-58.
      Journal code: 9810959. ISSN: 1369-7137.
 CY
      United States
      Journal; Article; (JOURNAL ARTICLE)
DT
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LA
      English
 FS
      Priority Journals
 EM
      200604
      Entered STN: 24 Jan 2006
ED
      Last Updated on STN: 21 Apr 2006
      Entered Medline: 20 Apr 2006
L11 ANSWER 19 OF 182
                             MEDLINE on STN
Full Text
AN
      2006034876
                      MEDLINE
      P. bMed ID: 16422310
DN
      Identifying methodologies in the assessment of treatment effects on the
      repeated occurrences of hot flashes in postmenopausal women.
 ΑU
      He Weili; Deng Weiping
 CS
      Clinical Biostatistics, Merck Research Laboratories, RY34-A316, 126
      Lincoln Avenue, Rahway, NJ 07065, USA.. weili_he@merck.com
      Clinical trials (London, England), (2005) Vol. 2, No. 6, pp. 497-508. 
Journal code: 101197451. ISSN: 1740-7745.
 SO
      England: United Kingdom
 CY
      (COMPARATIVE STUDY)
DT
     Journal; Article; (JOURNAL ARTICLE)
      English
 T.A
 FS
      Priority Journals
      200603
 EΜ
      Entered STN: 21 Jan 2006
      Last Updated on STN: 18 Mar 2006
      Entered Medline: 17 Mar 2006
L11 ANSWER 20 OF 182
                             MEDLINE on STN
 Full Text
      2006034298
 AN
                      MEDLINE
 DN
      PubMed ID: 16329712
      Therapy for menopausal symptoms during and after treatment for breast
 TI
      cancer: safety considerations.
      Baber Rodney; Hickey Martha; Kwik Michelle
 AU
      D vision of Women's and Children's Health, Royal North Shore Hospital of
 CS
      Sudney, Sydney, New South Wales, Australia.
      D ug safety: an international journal of medical toxicology and drug
 SO
      experience, (2005) Vol. 28, No. 12, pp. 1085-100. Ref: 124 Journal code: 9002928. ISSN: 0114-5916.
      New Zealand
 CY
      Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
      General Review; (REVIEW)
 LA
      English
 FS
      Priority Journals
 ΕM
      200703
 ED
      Entered STN: 21 Jan 2006
      Last Updated on STN: 12 Dec 2006
      Entered Medline: 14 Mar 2007
 L11 A SWER 21 OF 182
                             MEDLINE on STN
 Full Text
 AN
      2006009528
                      MEDLINE
 DN
      PubMed ID: 16390756
      Vasomotor symptoms decrease in women with breast cancer randomized to
 TΤ
      treatment with applied relaxation or electro-acupuncture: a preliminary
      study.
 AU
      Nedstrand E; Wijma K; Wyon Y; Hammar M
      Division of Obstetrics and Gynecology and Unit of Medical Psychology,
 CS
      Department of Molecular and Clinical Medicine, Faculty of Health Sciences,
      Linkoping, Sweden.
Climacteric: the journal of the International Menopause Society, (2005 S.p) Vol. 8, No. 3, pp. 243-50.
 SO
      Jurnal code: 9810959. ISSN: 1369-7137.
 CY
      United States
```

```
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (CLINICAL TRIAL)
     English
LA
FS
     Priority Journals
     200602
EM
ED
     Entered STN: 7 Jan 2006
     Last Updated on STN: 1 Mar 2006
     Entered Medline: 28 Feb 2006
L11 ANSWER 22 OF 182
                           MEDLINE on STN
Full Text
AN
     2005676831
                     MEDLINE
     PubMed ID: 16343926
DN
ΤI
     Hot flushes in breast cancer patients.
     Mom Constantijne H; Buijs Ciska; Willemse Pax H B; Mourits Marian J E; de
ΑU
     Vries Elisabeth G E
     Department of Medical Oncology, University Medical Center, P.O. Box 30001,
CS
     9700 RB Groningen, The Netherlands.
     Critical reviews in oncology/hematology, (2006 Jan) Vol. 57, No. 1, pp.
     63-77. Ref: 94
     Journal ccde: 8916049. ISSN: 1040-8428.
CY
     Ireland
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
T.A
     En.qlish
FS
     Priority Journals
EΜ
     200603
     Entered STN: 22 Dec 2005
ED
     Last Updated on STN: 30 Mar 2006
     Entered Medline: 29 Mar 2006
L11 ANSWER 23 OF 182
                           MEDLINE on STN
Full Text
                     MEDLINE
AN
     2005673349
DN
     PubMed ID: 16361630
     Pharmacogenetics of tamoxifen biotransformation is associated with
TI
     clinical outcomes of efficacy and hot flashes.
     Goetz Matthew P; Rae James M; Suman Vera J; Safgren Stephanie L; Ames
ΑU
     Matthew M; Visscher Daniel W; Reynolds Carol; Couch Fergus J; Lingle Wilma
     L: Flockhart David A; Desta Zeruesenay; Perez Edith A; Ingle James N
     Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN
CS
     55905, USA.. goetz.matthew@mayo.edu
     CA 90628-03 (NCI)
NC
     U-01 GM61373 (NIGMS)
     Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (2005 Dec 20) Vol. 23, No. 36, pp. 9312-8.
SO
     Journal code: 8309333. ISSN: 0732-183X.
CY
     United States
     Journal; Etticle; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
     English
LΑ
     P iority Journals
FS
     2 0602
EΜ
     Entered STN: 21 Dec 2005
     Last Updated on STN: 3 Feb 2006
     Entered Mcdline: 3 Feb 2006
                            MEDLINE on STN
L11 ANSWER 24 OF 182
Full Text
     2005664555
AN
                     MEDLINE
DN
     PubMed ID: 16352931
     Assessment of goserelin treatment in adjuvant therapy for premenopausal
     patients with breast cancer in Japan-zoladex breast cancer study group
     trial-B.
     Mitsuyama Shosyu; Nomura Yasuo; Ohno Shinji; Miyauchi Mitsuru; Yamamoto
AU
     Neoto; Kimura Tsunehito; Saku Motonori; Miura Shigeto; Yoshikawa Nobuteru;
     Tsujinaka Toshimasa; Koh Junichi; Ishida Tsunehiro; Abe Osahiko; Ohashi
     Yasuo
```

Dept. of Surgery, Kitakyushu Municipal Medical Center.

CS

```
Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Dec) Vol. 32, No. 13,
SO
     pp. 2071-7.
     Journal code: 7810034. ISSN: 0385-0684.
CY
     Japan
     (ENGLISH ABSTRACT)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (CLINICAL TRIAL)
     Japanese
LA
     Priority Journals
FS
     200601
EΜ
ED
     Entered STN: 18 Dec 2005
     Last Updated on STN: 7 Jan 2006
     Entered Medline: 6 Jan 2006
L11 ANSWER 25 OF 182
                          MEDLINE on STN
Full Text
     2005616357
                    MEDLINE
AN
DN
     PubMed ID: 16297087
     Quality of life in Brazilian breast cancer survivors age 45-65 years:
ΤI
     associated factors.
     Conde Delio Marques; Pinto-Neto Aarao Mendes; Cabello Cesar; Santos-Sa
ΑU
     Danielle; Costa-Paiva Lucia; Martinez Edson Zangiacomi
     Department of Gynecology and Obstetrics, Universidade Estadual de
CS
     Campinas, Campinas, Brazil.. condedelio@uol.com.br
     The breast journal, (2005 Nov-Dec) Vol. 11, No. 6, pp. 425-32.
SO
     Journal code: 9505539. ISSN: 1075-122X.
     United States
CY
DT
     Journal; Article; (JOURNAL ARTICLE)
     English
LA
FS
     Priority Journals
EM
     200512
     Entered STN: 22 Nov 2005
ED
     Last Updated on STN: 18 Dec 2005
     Entered Medline: 13 Dec 2005
L11 ANSWER 26 OF 182
                          MEDLINE on STN
Full Text
AN
     2005550268
                    MEDLINE
     PubMed ID: 16227740
DN
ТT
     Experience of high-dose toremifene treatment for postmenopausal women
     with metastatic breast cancer.
     Yamamoto Yutaka; Kawazoe Teru; Iwase Hirotaka
ΑU
     Dept. of Breast & Endocrine Surgery, Faculty of Medical and Pharmaceutical
CS
     Sciences, Kumamoto University.
     Gan to kagaku ryoho. Cancer & chemotherapy, (2005 Oct) Vol. 32, No. 10,
     pp. 1415-9.
     Journal code: 7810034. ISSN: 0385-0684.
CY
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
LA
     Japanese
     Priority Journals
FS
EM
     200511
     Entered STN: 18 Oct 2005
ED
     Last Updated on STN: 9 Nov 2005
     Entered Madline: 8 Nov 2005
L11 ANSWER 27 OF 182
                          MEDLINE on STN
Full Text
AN
     2005506720
                    MEDLINE
     PubMed ID: 16088965
DN
     New aromatase inhibitors as second-line endocrine therapy in
     postmenopausal patients with metastatic breast carcinoma: a pooled
     analysis of the randomized trials.
     Carlini Faolo; Bria Emilio; Giannarelli Diana; Ferretti Gianluigi; Felici
ΑU
     Alessandra; Papaldo Paola; Fabi Alessandra; Nistico Cecilia; Di Cosimo
     Serena; Puggeri Enzo Maria; Milella Michele; Mottolese Marcella; Terzoli
     Edmondo; Cognetti Francesco
CS
     Department of Medical Oncology, Regina Elena Cancer Institute, Rome,
```

Italy. pcarlini@iol.it. pcarlini@yahoo.it

```
Cancer, (2005 Oct 1) Vol. 104, No. 7, pp. 1335-42. Ref: 31 Journal code: 0374236. ISSN: 0008-543X.
SO
CY
     United States
     (COMPARATIVE STUDY)
DT
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
     General Review; (REVIEW)
     English
LA
FS
     Abridged Index Medicus Journals; Priority Journals
EM
     Entered STN: 24 Sep 2005
ED
     Last Updated on STN: 15 Dec 2005
     Entered Medline: 1 Dec 2005
L11 ANSWER 28 OF 182
                            MEDLINE on STN
Full Text
AN
     2005503730
                     MEDLINE
     PubMed ID: 16175702
DN
     Opinions of research participants about study paperwork.
ΤI
     Walker Gay; de Valois Beverly; Davies Raten; Young Teresa; Maher Jane
ΑU
     Lynda Jackson Macmillan Centre, Mount Vernon Cancer Centre, Northwood,
CS
     Middlesex HA6 2RN, UK.. <u>GayW@mvh-ljmc.org</u>
Bulletin of medical ethics, (2005 Feb) No. 205, pp. 21-4.
SO
     Journal code: 9103287. ISSN: 0962-9564.
     Report No.: KIE-122340.
CY
     England: United Kingdom
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Bioethics
EΜ
     200512
     Entered STN: 23 Sep 2005
ED
     Last Updated on STN: 18 Dec 2005
     Entered Medline: 13 Dec 2005
L11 ANSWER 29 OF 182
                            MEDLINE on STN
Full Text
     2005474704
AN
                     MEDLINE
     PubMed ID: 16143229
DN
     Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot
ΤI
     flushes in breast cancer survivors.
     Biglia N; Torta Riccardo; Roagna R; Maggiorotto F; Cacciari F; Ponzone R;
ΑU
     Kubatzki F; Sismondi P
CS
     Academic Gynaecological Oncology Department, University of Turin, IRCC
     (Institute for Cancer Research and Treatment) of Candiolo, Turin and
     Mauriziano Umberto I Hospital, Largo Turati 62, Torino 10128, Italy..
     nbiglia@mauriziano.it
     Maturitas, (2005 Sep 16) Vol. 52, No. 1, pp. 78-85. Journal code: 7807333. ISSN: 0378-5122.
so
CY
     Ireland
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (CLINICAL TRIAL)
LA
     English
FS
     Priority Journals
ΕM
     200512
ED
     Entered STN: 7 Sep 2005
     Last Updated on STN: 18 Dec 2005
     Entered Medline: 9 Dec 2005
L11 ANSWER 30 OF 182
                            MEDLINE on STN
Full Text
     2005393435
                     MEDLINE
AN
     PubMed IF: 16037759
DN
     Menopause symptoms and quality of life in women aged 45 to 65 years with
ΤI
     and without breast cancer.
ΑU
     Conde Delio M; Pinto-Neto Aarao M; Cabello Cesar; Sa Danielle S;
     Costa-Paiva Lucia; Martinez Edson Z
     Department of Gynecology and Obstetrics, Universidade Estadual de
CS
     Campinas, Campinas, Brazil.
     Menopause (New York, N.Y.), (2005 Jul-Aug) Vol. 12, No. 4, pp. 436-43.
SO
     Electronic Publication: 2005-07-21.
     Journal code: 9433353. ISSN: 1072-3714.
```

```
CY
      United States
      (COMPARATIVE STUDY)
ידת
      Journal; Article; (JOURNAL ARTICLE)
LA
      English
      Priority Journals
FS
ΕM
      200512
      Entered STN: 31 Jul 2005
      Last Updated on STN: 18 Dec 2005
      Entered Medline: 13 Dec 2005
L11 ANSWER 31 OF 182
                             MEDLINE on STN
Full Text
AN
      2005390217
                      MEDLINE
      PubMed ID: 16048357
DN
      Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
ΤI
      Cranney Ann; Adachi Jonathan D
ΑU
      Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
CS
      Drug safety: an international journal of medical toxicology and drug experience, (2005) Vol. 28, No. 8, pp. 721-30. Ref: 74
SO
      Journal code: 9002928. ISSN: 0114-5916.
     New Zealand
CY
     Journal; Article; (JOURNAL ARTICLE)
DT
      General Review; (REVIEW)
A.T
      English .
FS
      Priority Journals
      200510
EM
     Entered STN: 29 Jul 2005
Last Updated on STN: 1 Nov 2005
      Entered Medline: 31 Oct 2005
L11 ANSWER 32 OF 182
                             MEDLINE on STN
Full Text
                      MEDLINE
AN
      2005236210
DN
      PubMed ID: 15772568
TI
      Effects of ospemifene and raloxifene on hormonal status, lipids, genital
      tract, and tolerability in postmenopausal women.
     Komi Janne; Lankinen Kari S; Harkonen Pirkko; DeGregorio Michael W; Voipio Sari; Kivinen Seppo; Tuimala Risto; Vihtamaki Tarja; Vihko Kimmo;
AU
     Ylikorkala Olavi; Erkkola Risto
CS
      Hormos Medical Corporation, Turku, Finland.
     Menopause (New York, N.Y.), (2005 Mar) Vol. 12, No. 2, pp. 202-9. Journal code: 9433353. ISSN: 1072-3714.
SO
     United States
CY
      (CLINICAL TRIAL)
DT
      Journal; Article; (JOURNAL ARTICLE)
      (RANDOMIZED CONTROLLED TRIAL)
      (RESEARCH SUPPORT, NON-U.S. GOV'T)
T.A
      English
FS
      Priority Journals
EM
     200507
      Entered STN: 6 May 2005
      Last Updated on STN: 22 Jul 2005
      Entered Medline: 21 Jul 2005
L11 ANSWER 33 OF 182
                             MEDLINE on STN
Full Text
ΑN
     2005138116
                      MEDLINE
DN
     PubMed ID: 15770000
TI
      Tamoxifen pharmacogenetics moves closer to reality.
ΑU
     Garber Ken
     Journal of the National Cancer Institute, (2005 Mar 16) Vol. 97, No. 6,
     pp. 412-3.
     Journal code: 7503089. E-ISSN: 1460-2105.
CY
     United States
DT
     News Announcement
LA
     English
FS
     Priority Journals
ΕM
     200503
ED
     Entered STN: 17 Mar 2005
     Last Updated on STN: 23 Mar 2005
     Entered Medline: 22 Mar 2005
```

```
L11 ANSWER 34 OF 182
                            MEDLINE on STN
Full Text
AN
     2005118744
                     MEDLINE
     PubMed ID: 15750360
DN
     Homeopathy for menopausal symptoms in breast cancer survivors: a
TI
     preliminary randomized controlled trial.
     Jacobs Jennifer; Herman Patricia; Heron Krista; Olsen Steven; Vaughters
AU
     Department of Epidemiology, University of Washington School of Public
     Health and Community Medicine, Seattle, WA, USA. jjacobs@igc.org
     Journal of alternative and complementary medicine (New York, N.Y.), (2005
     Feb) Vol. 11, No. 1, pp. 21-7.

Journal code: 9508124. ISSN: 1075-5535.
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA
     English
FS
     Priority Journals
ΕM
     200505
     Entered STN: 8 Mar 2005
ED
     Last Updated on STN: 25 May 2005
     Entered Medline: 24 May 2005
L11 ANSWER 35 OF 182
                            MEDLINE on STN
Full Text
     2005115366
AN
                     MEDLINE
     PubMed ID: 15746052
DN
     Endocrine effects of tamoxifen plus exemestane in postmenopausal women
ΤI
     with breast cancer.
     Love Richard R; Hutson Paul R; Havighurst Thomas C; Cleary James F
ΑU
     Department of Medicine, University of Wisconsin, 610 Walnut Street, 256 Warf Office Building, Madison, WI 53726, USA.. <a href="mailto:rrlove@facstaff.wisc.edu">rrlove@facstaff.wisc.edu</a>
CS
     Clinical cancer research : an official journal of the American Association
SO
     for Cancer Research, (2005 Feb 15) Vol. 11, No. 4, pp. 1500-3.
     Journal code: 9502500. ISSN: 1078-0432.
    United States
CY
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LΑ
     English
FS
     Priority Journals
EΜ
     200507
ED
     Entered STN: 5 Mar 2005
     Last Updated on STN: 29 Jul 2005
     Entered Medline: 28 Jul 2005
L11 ANSWER 36 OF 182
                            MEDLINE on STN
Full Text
AN
     2005072224
                     MEDLINE
DN
     PubMed ID: 15701885
     TAS-108: a novel steroidal antiestrogen.
TI
ΑU
     Buzdar Aman U
     University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030,
CS
     USA.. abuzdar@mdanderson.org
SO
     Clinical cancer research : an official journal of the American Association
     for Cancer Research, (2005 Jan 15) Vol. 11, No. 2 Pt 2, pp. 906s-8s. Ref:
     Journal code: 9502500. ISSN: 1078-0432.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
FS
     Priority Journals
EM
     200505
     Entered STN: 10 Feb 2005
     Last Updated on STN: 10 May 2005
     Entered Medline: 6 May 2005
L11 ANSWER 37 OF 182
                            MEDLINE on STN
Full Text
```

```
AN
     2005036327
     PubMed ID: 15663589
DN
ΤI
     The effect of tibolone in postmenopausal women receiving tamoxifen after
     surgery for breast cancer: a randomised, double-blind, placebo-controlled
     trial.
     Kroiss R; Fentiman I S; Helmond F A; Rymer J; Foidart J M; Bundred N;
AU
     Mol-Arts M; Kubista E
     Medical University of Vienna, Ludwig Boltzmann Institute for Clinical
     Experimental Oncology, Austria.
     BJOG: an international journal of obstetrics and gynaecology, (2005 Feb)
SO
     Vol. 112, No. 2, pp. 228-33.
     Journal code: 100935741. ISSN: 1470-0328.
CY
     England: United Kingdom
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
LΑ
     English
     Abridged Index Medicus Journals; Priority Journals
FS
ΕM
     200502
ED
     Entered STN: 25 Jan 2005
     Last Updated on STN: 18 Feb 2005
     Entered Medline: 17 Feb 2005
L11 ANSWER 38 OF 182
                            MEDLINE on STN
Full Text
     2005006638
AN
                     MEDLINE
DN
     PubMed ID: 15632378
TI
     CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during
     adjuvant breast cancer treatment.
     Jin Yan; Desta Zeruesenay; Stearns Vered; Ward Bryan; Ho Herbert; Lee
     Kyung-Hoon; Skaar Todd; Storniolo Anna Maria; Li Lang; Araba Adjei;
Blanchard Rebecca; Nguyen Anne; Ullmer Lynda; Hayden Jill; Lemler Suzanne;
Weinshilboum Richard M; Rae James M; Hayes Daniel F; Flockhart David A
CŚ
     Division of Clinical Pharmacology, Department of Medicine, Indiana
     University School of Medicine, Indianapolis, IN 46202, USA.
NC
     5T32-GM-08425 (NIGMS)
     R-01 GM56898 (NIGMS)
     U-01 GM61373 (NIGMS)
SO
     Journal of the National Cancer Institute, (2005 Jan 5) Vol. 97, No. 1, pp.
     Journal code: 7503089. E-ISSN: 1460-2105.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     English
LA
     Priority Journals
EΜ
     200501
     Entered STN: 6 Jan 2005
     Last Updated on STN: 22 Jan 2005
     Entered Medline: 21 Jan 2005
L11
     ANSWER 39 OF 182
                           MEDLINE on STN
Full
    Text
     2004615625
ΑN
                     MEDLINE
DN
     PubMed ID: 15592280
TI
     Predictors of hot flushes in postmenopausal women who receive raloxifene
     Aldrighi Jose M; Quail Deborah C; Levy-Frebault Jacques; Aguas Fernanda;
     Kosian Kurt, Garrido Lurdes, Bosio-Le Goux Brigitte, Sarachaga Max; Graebe
     Alice; Nino Antonio J; Nickelsen Thomas
CS
     Faculdade De Saude Publica Da Universidade De Sao Paulo, Brazil.
     American journal of obstetrics and gynecology, (2004 Dec) Vol. 191, No. 6,
SO
     pp. 1979-£3.
     Journal code: 0370476. ISSN: 0002-9378.
CY
     United States
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICEMER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
```

MEDLINE

```
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
     200501
EM
     Entered STN: 20 Dec 2004
     Last Updated on STN: 28 Jan 2005
     Entered Medline: 27 Jan 2005
L11 ANSWER 40 OF 182
                           MEDLINE on STN
Full Text
     2004603075
ΑN
                    MEDLINE
     PubMed ID: 15577140
DN
     Which is the better choice, estrogen or SERMs in postmenopausal women?.
     Shintani Masafumi
ΑU
     Department of Obstetrics and Gynecology, Nara Prefectural Mimuro Hospital.
CS
     Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 105-10. Ref: 17
SO
     Journal code: 9433326. ISSN: 0917-5857.
CY
     (COMPARATIVE STUDY)
DT
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     Japanese
     Priority Journals
FS
EM
     200502
ED
     Entered STN: 4 Dec 2004
     Last Updated on STN: 1 Mar 2005
     Entered Medline: 25 Feb 2005
L11 ANSWER 41 OF 182 MEDLINE on STN Full Text
     2004603074
                    MEDLINE
     PubMed ID: 15577139
     Safety profile of raloxifene.
ΤI
     Morii Hirotoshi
ΑU
     Osaka City University.
CS
     Clinical calcium, (2004 Oct) Vol. 14, No. 10, pp. 100-4. Ref: 22
     Journal code: 9433326. ISSN: 0917-5857.
CY
     Japan
     (ENGLISH ABSTRACT)
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     Japanese
LA
     Priority Journals
FS
EM
     200502
     Entered STN: 4 Dec 2004
ED
     Last Updated on STN: 1 Mar 2005
     Entered Medline: 25 Feb 2005
L11 ANSWER 42 OF 182
                           MEDLINE on STN
Full Text
AN
     2004597013
                     MEDLINE
     PubMed ID: 15501350
DN
     [Menopause in 2004: "hormone replacement therapy" is not what it used to
     be anymore].
     Menopause en 2004: le "traitement hormonal substitutif" n'est plus ce
     qu'il etait.
ΑU
     Azoulay C
     Service de gynecologie, hopital intercommunal, 40, avenue de Verdun, 94010
     Creteil cedex, France. catherine.azoulay@chicreteil.fr.
     <catherine.azoulay@chicreteil.fr>
     La Revue de medecine interne / fondee ... par la Societe nationale française de medecine interne, (2004 Nov) Vol. 25, No. 11, pp. 806-15.
so
     Ref: 62
     Journal code: 8101383. ISSN: 0248-8663.
CY
     France
     (ENGLISH ABSTRACT)
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     French
FS
     Friority Journals
     200502
EΜ
     Entered STN: 2 Dec 2004
```

Last Updated on STN: 16 Feb 2005 Entered Medline: 15 Feb 2005 L11 ANSWER 43 OF 182 MEDLINE on STN Full Text 2004592433 AN PubMed ID: 15565808 DN Pilot evaluation of black cohosh for the treatment of hot flashes in TI women. Pockaj Barbara A; Loprinzi Charles L; Sloan Jeff A; Novotny Paul J; Barton AU Debra L; Hagenmaier Andrea; Zhang Huayan; Lambert George H; Reeser Kristine A; Wisbey Joyce A Department of Surgery, Mayo Clinic, Scottsdale, Arizona 85259, USA.. CS pockaj.barbara@mayo.edu Cancer investigation, (2004) Vol. 22, No. 4, pp. 515-21. SO Journal code: 8307154. ISSN: 0735-7907. CY United States DT (CLINICAL TRIAL) English LAFS Priority Journals 200412 ED Entered STN: 30 Nov 2004 Last Updated on STN: 20 Dec 2004 Entered Medline: 7 Dec 2004 L11 ANSWER 44 OF 182 MEDLINE on STN Full Text AN 2004526546 MEDLINE PubMed ID: 15494636 DN Acute effects of tamoxifen and third-generation aromatase inhibitors on TΤ menopausal symptoms of breast cancer patients. Morales Leilani; Neven Patrick; Timmerman Dirk; Christiaens Marie-Rose; ITA Vergote Ignace; Van Limbergen Erik; Carbonez An; Van Huffel Sabine; Ameye Lieveke; Paridaens Robert CS Department of Medical Oncology, University Hospitals, Leuven, Belgium. SO Anti-cancer drugs, (2004 Sep) Vol. 15, No. 8, pp. 753-60. Journal code: 9100823. ISSN: 0959-4973. CY England: United Kingdom (CLINICAL TRIAL) DТ (COMPARATIVE STUDY) Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) English LA Friority Journals FS EΜ 200412 Entered STN: 23 Oct 2004 ED Last Updated on STN: 20 Dec 2004 Entered Medline: 16 Dec 2004 **L11** ANSWER 45 OF 182 MEDLINE on STN Full Text ΑN 2004511174 MEDLINE PubMed ID: 15356404 DN TΙ Association of breast cancer and its therapy with menopause-related symptoms. ΑU Crandall Carolyn; Petersen Laura; Ganz Patricia A; Greendale Gail A CS Division of General Internal Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 90095-7023, USA.. ccrandallemednet.ucla.edu P30 CA16042 (NCI) SO Menopause (New York, N.Y.), (2004 Sep-Oct) Vol. 11, No. 5, pp. 519-30. Journal code: 9433353. ISSN: 1072-3714. CY United States (COMPARATIVE STUDY) דת Journal; Frticle; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.) LA English Priority ocurnals FS EΜ 200501

Entered ST: 15 Oct 2004

Last Updated on STN: 19 Jan 2005 Entered Medline: 18 Jan 2005 MEDLINE on STN L11 ANSWER 46 OF 182 Full Text 2004422164 ΑN MEDLINE PubMed ID: 15328180 DN A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Blakely L Johnetta; Buzdar Aman; Chang Hsiu-Yin; Frye Debra; Theriault AU Richard; Valero Vicente; Rivera Edgardo; Booser Daniel; Kuritani Jun; Tsuda Masuhiro CS Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Aug 15) Vol. 10, No. 16, pp. 5425-31. Journal code: 9502500. ISSN: 1078-0432. CYUnited States DΤ (CLINICAL TRIAL) (CLINICAL TRIAL, PHASE I) Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) LA English FS Priority Cournals EM 200502 Entered STN: 26 Aug 2004 Last Updated on STN: 18 Feb 2005 Entered Medline: 17 Feb 2005 L11 ANSWER 47 OF 182 MEDLINE on STN Full Text AN2004417648 MEDLINE PubMed ID: 15243274 DΝ TТ Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Carpenter Janet S; Gilchrist Janet M; Chen Kong; Gautam Shiva; Freedman ΑU Robert R Indiana University School of Nursing, 1111 Middle Drive NU 340D, CS Indianapolis, IN 46202-5107, USA.. carpenti@iupui.edu RR 00095 (NCRR) NC Menopause (New York, N.Y.), (2004 Jul-Aug) Vol. 11, No. 4, pp. 375-81. SO Journal code: 9433353. ISSN: 1072-3714. CY United States DTJournal; Futicle; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.) LΑ English Friority Cournals FS EΜ 200409 ED Entered SWI: 25 Aug 2004 Last Updated on STN: 29 Sep 2004 Entered Mcdline: 28 Sep 2004 L11 ANSWER 48 OF 182 MEDLINE on STN Full Text ANMEDLINE 2004390355 PubMed ID: 15295352 DN TΤ Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. Palacios Santiago; Farias Maria Lucia F; Luebbert Horst; Gomez Gustavo;

flushes in postmenopausal women for whom therapy is appropriate.

AU Palacios Santiago; Farias Maria Lucia F; Luebbert Horst; Gomez Gustavo; Yabur Juan A; Quail Deborah C; Turbi Carmen; Kayath Marcia J; Almeida Maria J; Monnig Elisabeth; Nickelsen Thomas

CS Instituto Palacios, Madrid, Spain.

SO American Cournal of obstetrics and gynecology, (2004 Jul) Vol. 191, No. 1, pp. 121-37.

Journal code: 0370476. ISSN: 0002-9378.

CY United States

DT (CLINICAL TRIAL)

Journal; Trticle; (JOURNAL ARTICLE)

(MULTICENTER STUDY)

```
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     English
     Abridged Index Medicus Journals; Priority Journals
FS
EΜ
     200409
ED
     Entered STN: 6 Aug 2004
     Last Updated on STN: 15 Sep 2004
     Entered Modline: 14 Sep 2004
L11 ANSWER 49 OF 182
                            MEDLINE on STN
Full Text
     2004390192
                     MEDLINE
AN
     FubMed ID: 15293890
DN
     Veralipride administered in combination with raloxifene decreases hot
ΤI
     flushes and improves bone density in early postmenopausal women.
     Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
     Department of Pediatrics, Obstetrics and Reproductive Medicine, University
CS
     of Siena, Siena, Italy.
     Gynecological endocrinology: the official journal of the International
SO
     Society of Gynecological Endocrinology, (2004 Apr) Vol. 18, No. 4, pp.
     Journal code: 8807913. ISSN: 0951-3590.
CY
     England: United Kingdom
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
      'RANDOMIZED CONTROLLED TRIAL)
LA
     English
FS
     Friority Journals
EΜ
     200408
     Entered STN: 6 Aug 2004 .
ED
     Last Updated on STN: 20 Aug 2004
     Entered Midline: 19 Aug 2004
L11
     ANSWER 50 OF 182
                            MEDLINE on STN
Full Text
     2004171210
DN
     PubMed ID: 15021446
     Transition from estrogen therapy to raloxifene in postmenopausal women:
ΤI
     effects on treatment satisfaction and the endometrium-a pilot study.
     Pavis Susan R; O'Neill Sheila M; Eden John; Baber Rodney; Ekangaki Abie;
ΑIJ
     Stocks Jodie M; Thiebaud Daniel
CS
     Jean Hailes Foundation, Melbourne, Australia...
     <u>susan.davis@jeanhailes.org.au</u>
Menopause (New York, N.Y.), (2004 Mar-Apr) Vol. 11, No. 2, pp. 167-75.
SO
     Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
     (CLINICAL TRIAL)
DT
     (COMPARATIVE STUDY)
     Journal; Article; (JOURNAL ARTICLE)
     (MULTICENTER STUDY)
     (RANDOMIZED CONTROLLED TRIAL)
     RESEARCH SUPPORT, NON-U.S. GOV'T)
LA
     Fnglish
FS
     Friority Journals
EΜ
     200405
     Entered S T: 7 Apr 2004
ED
     Last Updated on STN: 10 May 2004
     Fitered Milline: 7 May 2004
L11 ANSWER 51 )F 182
                           MEDLINE on STN
Full Text
     200415707
                     MEDLINE
ΑN
     PubMed ID: 15050912
Selective strogen receptor modulation: concept and consequences in
DΝ
ΤI
     cancer.
     Cordan V Caig
AU
     Northwest in University, Chicago, IL, USA.. vcjordan@northwestern.edu
CS
     F50 CA083 18-04S1 (NCI)
Cancer ce'l, (2004 Mar) Vol. 5, No. 3, pp. 207-13. Ref: 56
SO
     Cournal cade: 101130617. ISSN: 1535-6108.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
RESEARCH SUPPORT, NON-U.S. GOV'T)
DΤ
```

```
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     General Review; (REVIEW)
LA
     English
FS
     Priority Cournals
EΜ
     200405
ED
     Entered S'N: 31 Mar 2004
     Last Upda ed on STN: 18 May 2004
     Intered M Aline: 17 May 2004
L11 ANSWER 52 OF 182
                           MEDLINE on STN
Full Text
                    MEDLINE
ΑN
     200414600
DN
     PubMed ID: 15039600
     Association of tamoxifen (TAM) and TAM metabolite concentrations with
TI
     self-reported side effects of TAM in women with breast cancer.
     Gallicchi, Lisa; Lord Gwyn; Tkaczuk Katherine; Danton Malcolm; Lewis Lynn
     M; Lim Chang K; Flaws Jodi A
CS
     Department of Epidemiology and Preventive Medicine, University of Maryland
     School of Medicine, Baltimore, MD 21201, USA.
     Freast camer research and treatment, (2004 May) Vol. 85, No. 1, pp.
SO
     Journal code: 8111104. ISSN: 0167-6806.
     Petherlands
CY
     Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
DT
     (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA
     English
FS
     Priority Journals
\mathbf{E}\mathbf{M}
     200406
     Entered S' II: 25 Mar 2004
ED
     Last Updated on STN: 2 Jun 2004
     Entered Madline: 1 Jun 2004
L11 ANSWER 53 OF 182
                           MEDLINE on STN
Full Taxt
     200413249
ΑN
                    MEDLINE
     FubMed ID: 15025087
DN
     Hormone a ternative doesn't worsen vasomotor symptoms or impact urinary
     incontine de in post-menopausal women.
AU
     Rollins Gina
     Report on medical guidelines & outcomes research, (2004 Mar 5) Vol. 15,
SO
     No. 5, pp. 7-9.
     Journal code: 9106372. ISSN: 1050-5636.
CY
     United States
     (COMPARATIVE STUDY)
DT
     News Announcement
LA
     English
FS
     Health Technology
EΜ
     200404
     Entered S'N: 18 Mar 2004
ED
     Last Updated on STN: 10 Apr 2004
     Entered Medline: 9 Apr 2004
     ANSWER 54 OF 182
                           MEDLINE on STN
L11
Full Text
ΑN
     200410534€
                    MEDLINE
DN
     PubMed ID: 14997058
     Pilot stu'v using gabapentin for tamoxifen-induced hot flashes in
ΤI
     women wit breast cancer.
     Fandya Kithan J; Thummala Anuradha R; Griggs Jennifer J; Rosenblatt Joseph
AU
     D; Sahasr budhe Deepak M; Guttuso Thomas J; Morrow Gary R; Roscoe Joseph A
     James P. ilmot Cancer Center, University of Rochester, Rochester, NY
CS
     14642 USA . kishan pandya@urmc.rochester.edu
     Breast ca per research and treatment, (2004 Jan) Vol. 83, No. 1, pp. 87-9.
SO
     Journal o de: 8111104. ISSN: 0167-6806.
     Netherlan s
CY
     (CLINICAI TRIAL)
DT
     Journal; Inticle; (JOURNAL ARTICLE)
LA
     Frglish
FS
     Friority ournals
EΜ
     2 0405
     Entered S I: 4 Mar 2004
```

Last Updated on STN: 14 May 2004 Entered Medline: 13 May 2004 ANSWER 55 OF 182 MEDLINE on STN L11Full Text AN 2004076419 MEDLINE PubMed ID. 14965585 Exemestanes: a review of its clinical efficacy and safety. ΤI ΑU Lonning P E Department of Therapeutic Oncology and Radiophysics, Haukeland University CS Hospital, Bergen, Norway.. plon@haukeland.no Breast (Edinburgh, Scotland), (2001 Jun) Vol. 10, No. 3, pp. 198-208. Journal c de: 9213011. ISSN: 0960-9776. so Scotland: United Kingdom Journal; "ticle; (JOURNAL ARTICLE) CY DT LA English NONMEDLIN'; PUBMED-NOT-MEDLINE FS 200402 EMED Entered STN: 18 Feb 2004 Last Upda.ed on STN: 2 Mar 2004 Entered Mcdline: 26 Feb 2004 MEDLINE on STN L11 ANSWER 56 OF 182 Full Text AN2004054125 MEDLINE PubMed ID: 14754694 DN Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Gordon Staphen; Walsh Brian W; Ciaccia Angelina V; Siddhanti Suresh; Rosen AU Amy S; Plouffe Leo Jr CS Women's Health and Internal Medicine, Comprehensive NeuroScience, Inc, 6065 Roswell, Suite 820, Atlanta, GA 30328, USA.. flashmd 4919@msn.com Obstetrics and gynecology, (2004 Feb) Vol. 103, No. 2, pp. 267-73. SO Journal code: 0401101. ISSN: 0029-7844. CY United States (CLINICAL TRIAL) DΤ (COMPARATIVE STUDY) Journal; Article; (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL)
(RESTARCE SUPPORT, NON-U.S. GOV'T) LA English FS Alridged Index Medicus Journals; Priority Journals EΜ 200403 ED Estered S N: 3 Feb 2004 Last Upda ed on STN: 9 Mar 2004 Entered Mcdline: 8 Mar 2004 L11 ANSWER 57 OF 182 MEDLINE on STN Full Text 2004040541 MEDLINE ANPubMed ID: 14740790 Nonhormonal alternatives for the treatment of hot flashes. ΤI Sicat Brigitte L; Brokaw Deborah K ΑU Dipartment of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, USA. CS Pharmacotherapy, (2004 Jan) Vol. 24, No. 1, pp. 79-93. Ref: 55 Journal ccde: 8111305. ISSN: 0277-0008. United States CY DT (EVALUATION STUDIES) Journal; Article; (JOURNAL ARTICLE) General Review; (REVIEW) LA English FS Priority Curnals 2:10406 EΜ Entered S N: 27 Jan 2004 ED List Updated on STN: 18 Jun 2004 Fritared Viline: 17 Jun 2004 L11 F SWIT 58 F 182 MEDLINE on STN Full T xt. AN 210358853 MEDLINE

I. bMcd .I

14669536

DN

```
ΤI
     [The effects of tamoxifen on the female genital tract].
     Tamoxifen en gynaecologische bijwerkingen.
     Mourits M J; van der Zee A G; Willemse P H; Hollema H; de Vries E G Afd. Gynascologische Oncologie, Academisch Ziekenhuis Groningen,
ΑU
CS
     Hanzeplein 1, 9711 EZ Groningen.. m.j.e.mourits@og.azg.nl
     Nederlands tijdschrift voor geneeskunde, (2003 Nov 22) Vol. 147, No. 47,
SO
     pp. 2315-20. Ref: 31
Journal code: 0400770. ISSN: 0028-2162.
CY
     Netherlands
     (ENGLISH ABSTRACT)
DT
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
LA
     Dutch
FS
     Priority Journals
EM
     2 10401
     Entered STM: 16 Dec 2003
ED
     Last Updated on STN: 9 Jan 2004
     Entered Midline: 8 Jan 2004
L11 ANSWER 59 OF 182
                          MEDLINE on STN
Full Text
     2 0356913
AN
                    MEDLINE
     PubMed ID: 14652237
DN
TΤ
     Active tamoxifen metabolite plasma concentrations after coadministration
     of tamoxi en and the selective serotonin reuptake inhibitor paroxetine.
     Stearns Vered; Johnson Michael D; Rae James M; Morocho Alan; Novielli
AII
     Amtonella; Bhargava Pankaj; Hayes Daniel F; Desta Zeruesenay; Flockhart
     David A
     The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center,
CS
     Georgetown University Medical Center, Washington, DC, USA.
     5732-GM-08425 (NIGMS)
NC
     R 01 GM56298 (NIGMS)
     U-01 GM61373 (NIGMS)
    Journal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
     pp. 1758-64.
     Journal code: 7503089. E-ISSN: 1460-2105.
     United States
CY
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
(LESFARCH SUPPORT, U.S. GOV'T, P.H.S.)
LΑ
     English
     Friority Journals
FS
     2:0401
EΜ
     Entered S.M: 16 Dec 2003
     List Upda and on STN: 3 Jan 2004
     Entered Midline: 5 Jan 2004
L11 AUSWER 60 OF 182
                         MEDLINE on STN
Full 1 xt
AN 2 0356913
                    MEDLINI
     PubMed II. 14652227
DN
     A hot flath on tamoxifen metabolism.
ΤI
     Gretz Matthew P; Loprinzi Charles L
ΑU
     Cournal of the National Cancer Institute, (2003 Dec 3) Vol. 95, No. 23,
     pp. 1734-5. Ref: 23
     Journal code: 7503089. E-ISSN: 1460-2105.
     United States
CY
     Commentar
     Fditoria?
     General kuriew; (REVIEW)
     Frglish
LA
     Priority Journals
FS
     2 0401
EΜ
     Entered STN: 16 Dec 2003
     Last Updated on STN: 6 Jan 2004
     Entered Modline: 5 Jan 2004
L11 FISWER 67 OF 182
                          MEDLINE on STN
Full Terr
AN
     2001 2523
                    MEDLINE
     PubMod II · 14551341
DN
```

```
A randomized trial of letrozole in postmenopausal women after five years
     of tamoxiden therapy for early-stage breast cancer.
     Goss Paul \Sigma; Ingle James N; Martino Silvana; Robert Nicholas J; Muss Hyman
ΑU
     B; Miccart Martine J; Castiglione Monica; Tu Dongsheng; Shepherd Lois E;
      Pritchard Kathleen I; Livingston Robert B; Davidson Nancy E; Norton Larry;
      Perez Edith A; Abrams Jeffrey S; Therasse Patrick; Palmer Michael J; Pater
     Joseph L
     Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, ON,
CS
     Canada...<u>egoss@interlog.com</u>
CA21115 (PCI)
NC
     CA25224 (MCI)
     CA31946 (MCI)
     CA32102 (WCI)
     CA38926 (NCI)
     The New England journal of medicine, (2003 Nov 6) Vol. 349, No. 19, pp.
SO
     1793-802. Electronic Publication: 2003-10-09.
     Cournal code: 0255562. E-ISSN: 1533-4406.
CY
     United States
      (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE III)
DT
     Journal; Article; (JOURNAL ARTICLE)
      (PANDOMIZED CONTROLLED TRIAL)
     (LESEARCH SUPPORT, NON-U.S. GOV'T)
(TESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
     Figlish
LA
     Abridged Index Medicus Journals; Priority Journals
     2 0311
EΜ
     Fitered ["N: 7 Nov 2003
     List Updated on STN: 11 Nov 2003
     Entered Medline: 10 Nov 2003
                             MEDLINE on STN
L11 ANSWER 62 OF 182
Full Text
     2003507728
AN
                      MEDLINE
DN
     PubMed ID: 14584060
ΤI
     Anastrozole alone or in combination with tamoxifen versus tamoxifen
     alone for adjuvant treatment of postmenopausal women with early-stage
     rreast career: results of the ATAC (Arimidex, Tamoxifen Alone or in Combinati n) trial efficacy and safety update analyses.
     Baum M; Bazdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T
ΑU
     Universit College London, London, United Kingdom. (The ATAC (Arimidex,
CS
     Tamoxifer Alone or in Combination) Trialists' Group).
     Cancer, (2003 Nov 1) Vol. 98, No. 9, pp. 1802-10. Journal code: 0374236. ISSN: 0008-543X.
SO
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (PANDOMIZED CONTROLLED TRIAL)
LA
     English
FS
     Abridged Undex Medicus Journals; Priority Journals
     210311
EM
     Fitered Firm: 31 Oct 2003
     Lest Updated on STN: 5 Nov 2003
     Entered Midline: 5 Nov 2003
L11 ANSWER 6' OF 182
                            MEDLINE on STN
Full Text
     2007 764
                     MEDLINE
AN
     Public II: 14555500
Fulvistrest in postmenopausal women with advanced breast cancer.
DN
ΤI
ΑU
     Bross Pet : F; Baird Amy; Chen Gang; Jee Josephine M; Lostritto Richard T;
     Morse David E; Rosario Liliam A; Williams Gene M; Yang Peiling; Rahman Atique; Filliams Grant; Pazdur Richard
     Division of Oncology Drug Products, Center for Drug Evaluation and
CS
     R search Good and Drug Administration, Rockville, Maryland 20852, USA.
     Cinical anner research: an official journal of the American Association for Cance Research, (2003 Oct 1) Vol. 9, No. 12, pp. 4309-17. Ref: 22
SO
     Journal orce: 9502500. ISSN: 1078-0432.
CY
     United Stores
     Journal; "rticle; (JOURNAL ARTICLE)
DT
     General Naview; (REVIEW)
LA
     Erg sh
```

```
FS
     Priority Cournals
     200405
EΜ
     Entered STN: 14 Oct 2003
Last Updated on STN: 21 May 2004
ED
     Entered Midline: 20 May 2004
L11 ANSWER 6: OF 182
                            MEDLINE on STN
Full Tel
     2003441489
AN
                     MEDLINE
     PubMed II: 14501605
DN
     Effects of ospemifene, a novel SERM, on hormones, genital tract,
     climacteric symptoms, and quality of life in postmenopausal women: a
     double-blind, randomized trial.
     Rutanen Deva-Marja; Heikkinen Jorma; Halonen Kaija; Komi Janne;
ΑU
     Lammintausta Risto; Ylikorkala Olavi
ĊS
     Department of Obstetrics and Gynecology, Helsinki University Central
     Hospital, Helsinki, Finland.. <u>eeva-marja.rutanen@hus.fi</u>
     Menopause (New York, N.Y.), (2003 Sep-Oct) Vol. 10, No. 5, pp. 433-9. Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
     (CLINICAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE)
     (RANDOMIZED CONTROLLED TRIAL)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
     English
LA
FS
     Priority Journals
ΕM
     200313
     Entered FTM: 23 Sep 2003
     Last Updated on STN: 18 Dec 2003
     Entered Medline: 8 Dec 2003
L11 ANSWER 65 OF 182
                            MEDLINE on STN
Full Text
     2003428812
AN
                     MEDLINE
DN
     Publish ID: 12968972
ΤI
     Hot flashes in breast cancer survivors.
     Hoda Daamish; Perez Domingo G; Loprinzi Charles L Mayo Climic, Rochester, Minnesota 55905, USA.
ΑU
CS
     The preast journal, (2003 Sep-Oct) Vol. 9, No. 5, pp. 431-8. Ref: 93
SO
     Journal code: 9505539. ISSN: 1075-122X.
CY
     Unlited States
     Journal; Article; (JOURNAL ARTICLE)
DT
     General Review; (REVIEW)
LA
     English
FS
     Priority Journals
EM
     200401
     Entered STN: 13 Sep 2003
     Last Updated on STN: 17 Jan 2004
     Entered Medline: 16 Jan 2004
L11 ANSWER 66 OF 182
                            MEDLINE on STN
Full Text
ΑN
     2003381095
                     MEDLINE
     PubMed ID: 12916292
DN
     Selective estrogen-receptor modulators.
TI
ΑU
     Cosman Felicia
     Helen Hayes Hospital, Route 9W, West Haverstraw, NY 10993, USA..
     ccsmunfg genhaveshosm.org
SO
     Clinics in geriatric medicine, (2003 May) Vol. 19, No. 2, pp. 371-9. Ref:
     Journal code: 8603766. ISSN: 0749-0690.
     set & Jrinu
CY
     Journal; write; (JCURNAL ARTICLE)
General: Triew; (REVIEW)
DT
     Er~
LA
     Priority Journals
FS
     200-16
EΜ
     Entered 1 M: 15 Aug 2003
Land Updated on STN: 3 Oct 2003
ED
     Entertl Micline: 2 Oct 2003
L11 AMSWER 67 OF 182
```

MEDLINE on STN

```
Full Text
     2003373456
                     MEDLINE
MΔ
DN
     PubMed ID: 12851517
     Prevention of osteoporosis and uterine effects in postmenopausal women
TI
     taking raloxifene for 5 years.
     Jolly Elrine E; Bjarnason Nina H; Neven Patrick; Plouffe Leo Jr; Johnston
ΑU
     C Contad Jr; Watts Steven D; Arnaud Claude D; Mason Timothy M; Crans
     Gerali: Aters Robin; Draper Michael W
     Depar me. t. of Obstetrics and Gynecology, Ottawa General Hospital, Ottawa,
CS
     Meninause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 337-44.
so
     Journal code: 9433353. ISSN: 1072-3714.
CY
     United States
DT
     (CLINICAL TRIAL)
     Journal; Article; (JOURNAL ARTICLE)
     (RAMDOMI; HD CONTROLLED TRIAL)
     (RESTARCH SUPPORT, NON-U.S. GOV'T)
LΑ
     Englush
     Priority Journals
FS
EM
     200310
     Entered STN: 12 Aug 2003
ED
     Last Updated on STN: 8 Oct 2003
     Enternal Madline: 7 Oct 2003
L11 ANSTER 65 OF 182
                           MEDLINE on STN
Full Text
     2003367824
ΔN
                     MEDLINE
DN
     PubMed ID: 12902876
TI
     Examining quality of life issues in relation to endocrine therapy for
     breast cancer.
ΑU
     Thomas Robert
     Addenbrocke's Hospital, Cambridge, United Kingdom.
CS
SO
     American journal of clinical oncology, (2003 Aug) Vol. 26, No. 4, pp.
     Journal dode: 8207754. E-ISSN: 1537-453X.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     Erc ish
     Priority Journals
FS
     20040
\mathbf{E}\mathbf{M}
ED
     Entered ofN: 7 Aug 2003
     Last Updated on STN: 29 Jan 2004
     Entropel Lucline: 28 Jan 2004
L11 ANSWER 6 OF 182
                           MEDLINE on STN
Full Taxt
AN
     2003.1522.8
                     MEDLINE
     PubMed II: 12884894
DN
     The homeopathic approach to the treatment of symptoms of oestrogen
TΤ
     withdrawal in breast cancer patients. A prospective observational study.
ΑU
     Thompson E A; Reilly D
     Glissjow Fomeopathic Hospital, 1053 Great Western Road, Glasgow, Scotland, Gl2 0KO, UK. elizabeth.thompson@ubht.swest.nhs.uk
CS
     Homoopathy: the journal of the Faculty of Homoopathy, (2003 Jul) Vol. 92,
SO
     No. 3, pp. 131-4.
     Journal code: 101140517. ISSN: 1475-4916.
CY
     Scot and: United Kingdom
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
     200312
EM
     Entered TM: 30 Jul 2003
Last Tmd red on STN: 20 Dec 2003
     Ente codline: 19 Dac 2003
          7. CF 182
L11 K
                            4EDLINE on STN
Full T K
     200: 63 NEDL
AN
                     MEDLINE
DN
     Futrous replacement therapy in breast cancer survivors: a materials a trailed series.
TI
              id A; Tettinga Jane E; VanderVelde Nancy; Huang Raywin R; Kestin
AU
```

```
Larry; Burdakin John H
      Department of Medicine, William Beaumont Hospital, Royal Oak-Troy, MI
CS
      48073, USA.. <u>ddecker@beaumont.edu</u>
Menopause (New York, N.Y.), (2003 Jul-Aug) Vol. 10, No. 4, pp. 277-85.
Journal code: 9433353. ISSN: 1072-3714.
SO
      United States
CY
DT
      Journal; Article; (JOURNAL ARTICLE)
LA
      English
FS
       Priority Journals
       200310
EΜ
      Entered STN: 10 Jul 2003
      Lan: Updated on STN: 8 Oct 2003
      Endered Wedline: 7 Oct 2003
L11 ANSWER 7% OF 182
                                 MEDLINE on STN
Full Text
      2003 [44] 0
AN
                         MEDLINE
DN
      PubMed T : 12843154
      Efficiery and safety of raloxifene 60 milligrams/day in postmenopausal
      Asiar woren.
ΑU
      Kung Ann a W C; Chao Hsiang-Tai; Huang Ko-En; Need Allan G;
      Taechakraichana Pimit; Loh Foo-Hoe; Gonzaga Florante; Sriram Usha; Ismail
      Nik Mohd Nasri; Farooqi Abid; Rachman Ichramsjah Azim; Crans Gerald G;
      Wong Mayme; Thiebaud Daniel
      Department of Medicine, The University of Hong Kong, Division of
CS
      Enterinology, Queen Mary Hospital, Hong Kong, People's Republic of China. The Journal of clinical endocrinology and metabolism, (2003 Jul) Vol. 88,
SO
      No. 7, pp. 3130-6.
Journal code: 0375362. ISSN: 0021-972X.
CY
      United States
      (CLTTICAT TRIAL)
DT
      Journal; Article; (JOURNAL ARTICLE)
       (RANDOMIZED CONTROLLED TRIAL)
       (RESEARCH SUPPORT, NON-U.S. GOV'T)
T.A
      English
      Abridged Index Medicus Journals; Priority Journals
FS
EΜ
      200308
ED
      Entered STN: 8 Jul 2003
      Last Updated on STN: 9 Aug 2003
      Entered Medline: 8 Aug 2003
L11 AMSWFR 7: OF 182
                                MEDLINE on STN
Full 7: xt
AN 2:00:1107:2 MEDLI
DN F: bb = 10: 17:839141
                         MEDLINE
      Counseling patients who elect to discontinue hormone therapy.
TI
ΑU
      Simon James A; Mack Carol J
CS
      Department of Obstetrics and Gynecology, George Washington University,
      School of Medicine, Washington, D.C., USA.

Incorrectional journal of fertility and women's medicine, (2003 May-Jun)
      Vol. 45, No. 3, pp. ill-6; discussion 137-8. Ref: 13
      Journal code: 9706779. ISSN: 1534-892X.
CY
      United States
      Journal; Article; (JCURNAL ARTICLE)
DT
      (RESPARCE SUPPORT, NON-U.S. GOV'T)
      Coneval Meview; (REVIEW)
English
LA
      Pricrity Journals
FS
      200910
EΜ
      Entered STN: 4 Jul 2003
      List Updated on STN: 11 Oct 2003
      Entered . edline: 10 Cct 2003
L11 AMSWER 73 OF 182
                                MEDLINE on STN
Full Tax*: AN 2000221602
                        MEDLITE
DN
      F bled II: 12753941
      Monchans after preast cancer: a survey on breast cancer survivors.

Fig. a Modelta: Commarella Marilena; Cacciari Franca; Ponzone Riccardo;

Flagra Modelta: Campo; Magriorotto Furio; Sismondi Piero
TΙ
      Fraction Department of Gynecological Oncology, University of Turin,

Note to Department of Gynecological Oncology, University of Turin,

Note to Department of Gynecological Oncology, University of Turin,
CS
```

```
and Treatment of Candiolo, Turin, Italy.. <a href="mailto:nbiglia@mauriziano.it">nbiglia@mauriziano.it</a> Maturitas, (2303 May 30) Vol. 45, No. 1, pp. 29-38.
SO
     Journal code: 7807333. ISSN: 0378-5122.
CY
     Ireland
     Journal; Article; (JOURNAL ARTICLE)
DT
     English
LΑ
     Priority Journals
FS
     200309
EM
     Entered STN: 20 May 2003
ED
     Last Undated on STN: 30 Sep 2003
     Entered Medline: 29 Sep 2003
L11
     ANSWER 74 OF 182
                              MEDLINE on STN
Full Text
AN
     2003175723
                       MEDLINE
DN
     PubMed ID: 12693307
ΤI
      [Hormone replacement therapy after breast cancer. Yes...or no?].
      Traitement hormonal apres cancer du sein. Oui ... ou non?.
     Foidart & M; Desreux J; Lifrange E; Colin C
ΑU
     Departement de Gynecologie-Obstetrique-Senologie, CHU de Liege.
     Revue medicale de Liege, (2003 Feb) Vol. 58, No. 2, pp. 77-82. Ref: 61
SO
     Journal code: 0404317. ISSN: 0370-629X.
CY
     Belgium
דת
     (ENGLISH ABSTLACT)
     Journal; Article; (JOURNAL ARTICLE) -
     General Review; (REVIEW)
     French
I.A
     Prioricy Journals 200305
FS
EM
ED
     Entered STN: 17 Apr 2003
     Last Updated on STN: 22 May 2003
     Entered Medline: 21 May 2003
L11 ANSWER 75 OF 182
                             MEDLINE on STN
Full Text
     2003134335
ΑN
                      MEDLINE
DΝ
     PribMed ID: 12648026
ΤI
     Pharmacokinetics of selective estrogen receptor modulators.
ΑU
     Morello Karla C; Wurz Gregory T; DeGregorio Michael W
     Department of Internal Medicine, University of California, Davis,
     Sacramento, California 95817, USA.
SO
     Clinical pharmacokinetics, (2003) Vol. 42, No. 4, pp. 361-72. Ref: 73
     Journal code: 7606849. ISSN: 0312-5963.
CY
     New Zealand
     Journal; Article; (JOURNAL ARTICLE)
     General Review; (REVIEW)
     English
LA
     Friority Journals
FS
     2 2305
EΜ
     Foremed STN: 02 Mar 2003
     Last Updated on STN: 12 Jun 2003
     Fittered Medline: 11 Jun 2003
L11 ALSWER 70 OF 182
                             MEDLINE on STN
Full Text
     2003197715
ΑN
                      MEDLINE
     FubMed IV: 12609560
DN
     C^4 \mathfrak{m} \{\pi^4 \} \mathfrak{m}_{\mathfrak{p} \mathfrak{q}} rademosa for the treatment of hot flushes in women surviving
     bross strander.
     Francies Munoz Gerando; Pluchino Salvatore
     Contro Cinico de Maternidad Leopoldo Aguerrevere, Av. Rio Manapire,
CS
     Pargus Humboldt, Pragos del Este, Caracas, Venezuela.. drgeher@cantv.net Nuturitas, (2003 Mar 14) Vol. 44 Suppl 1, pp. S59-65. Guarul 1008: 7807333. ISSN: 0378-5122.
SO
CY
     Imelan:
     A LINUCAL TRIAL)
DT
     Journal; Article; (JOURNAL ARTICLE) (RANDOWIZED CONTROLLED TRIAL)
     English
LA
     Priority Journals
FS
EΜ
     Entered CTM: 2 Mar 2003
ED
```

```
That Updated on STN: 18 Jul 2003
Entered Recline: 17 Jul 2003
L11 FISHER 77 OF 182
                                                         MEDLINE on STN
Full 5em
AN 2.05 373 2
                                           MEDLI!'E
           Fiblind In: L7198849
DN
           [ffeeds of tamoxife and estrogen replacement therapy on lipid
ΤI
           notabelism and some ther cardiovascular risk factors. A prospective study
           is hysterectomised women].
           Effetti del tamoxifene e della terapia estrogenica sostitutiva sul
           metabolismo lipidico e su altri fattori di rischio cardiovascolare. Studio
           prospettice in donne isterectomizzate.
             Inperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
AU
           Dipartimento di Scienze Ginecologiche, Perinatologia e Puericultura, II
           Facolta di Medicina e Chirurgia, Universita degli Studi di Roma La
           Spienza, Roma, Italy.. <u>fabioimp.ginecol@tin.it</u>
Linerva ginecologica, (2003 Feb) Vol. 55, No. 1, pp. 87-93.
Lournal code: 0400731. ISSN: 0026-4784.
SO
           I al…
CY
            (COMPARA LIVE STUDY)
DT
            (ENGLISH ABSTRACT)
           Journal; Article; (JOURNAL ARTICLE)
LA
           I a ian
           Friority Journals
           2103111
EM
          1 3.2d TN: 25 Feb 2003
1 3. Obd ted on STN: 30 Aug 2003
Enterod redline: 29 Mug 2003
L11 FUNDO 70 CF 182 Full f 2
                                                         MEDLINE on STN
           <u>/</u>
// 23 33047
// 70:
                                           MEDLINE
\Lambda\Lambda
           Park 13 FD: 12594939
DΝ
           The tolk of aromatase inhibitors in early breast cancer.
           Chung Cathie I; Carlson Robert W
           Envision of Checology, Stanford University, 300 Pasteur Drive, H0274, Stanford CA 94305, USA. <u>ochung@stanford.edu</u>
           Current treatment options in oncology, (2003 Apr) Vol. 4, No. 2, pp.
SO
           10-10. Ref: 30 cmal code: 100900046. ISSN: 1527-2729.
           United Scates
CY
           Cournal, Armidle, (GOURNAL ARTICLE)
GRESHARCH SUPPORT, NON-U.S. GOV'T)
DT
           Ceneral Deview; (REVIEW)
           Fuglish
LA
           Priority Journals
           200307
EΜ
           Ertered STN: 22 Feb 2003
ED
           Last Updated on STN: 8 Jul 2003
           Fitored Medline: 7 Jul 2003
L11 / SWYR 70 OF 182
                                                         MEDLINE on STN
Full :
           Publication MEDIATE

Fublication of the analyternative therapy for menopause?

Figure 10 of the analyternative therapy for menopause?

Figure 20 of the Fabricant Daniel; Chadwick Lucas R; Dietz Birgit

Figure 20 of the American Dietary Supplements Research, Programments Rese
ΑN
DN
TI
ΑU
           The star for L tanical Dietary Supplements Research, Program for
                     or time Research in the Pharmaceutical Sciences, University of
           I. O.E. Chicago, I linois, USA. Pro 477 (1564)4 (NCC/M)
NC
           hammion in clinical care : an official publication of Tufts University,
SO
           Cura code: $80967. ISSN: 1096-6781.
CY
           Tit difiata
           Control of the Cournal Article)

( action of Surgart, U.S. GOV'T, P.H.S.)

Gang of action; (REVIEW)
DT
T.A
           F .a
                      Townsls
           F 1
2 2
FS
EИ
```

```
ED
           Entered STN: 3 Feb 2003
           Last Difference STN: 23 Apr 2003
           Entres ledline: 22 Apr 2003
L11 ANSTI C & OF 182
                                                          MEDLINE on STN
Full Tout 70.6
          Public In: 13:144676
If france of raloxifene on the efficacy of an estradiol-releasing ring for treating raginal atrophy in postmenopausal women.

The results of the Company of the Compa
DN
            P ni rton Chain V; Shifren Jan L; La Valleur June; Rosen Amy; Roesinger
ΑU
           North Siddle thi Sureth
           Unitarity of Virginia Health System, Charlottesville, VA, USA.
Mencaus: (Man York, N.Y.), (2003 Jan-Feb) Vol. 10, No. 1, pp. 45-52.
CS
SO
            Journal dodg: 9433354. ISSN: 1072-3714.
CY
           Unit . 1 Status
            (CLINICAL TRIAL)
DT
           Journal; Article; (JOURNAL ARTICLE)
(MUTTICESTER STUDY)
(RATIONISED CONTROLLED TRIAL)
            (PERSONARCE SUPPORT, MON-U.S. GOV'T)
            Engl: sh
            Pricrity Journals
FS
            200004
EM
ED
           Entered STN: 25 Jan 2003
           Last Updated on STN: 29 Apr 2003
            Entered Medline: 28 Apr 2003
L11 ANSWIR 81 OF 182
                                                          MEDLINE on STN
Full Text
            2002 79709
MΑ
                                             MEDLINE
            PubMed ID: 12:56626
            Effectiveness of combined GnRH analogue plus raloxifene administration
TΙ
            in the stant of aterine leiomyomas: a prospective, randomized,
            su parb ind, placero-controlled clinical trial.
Purba Stefano; Rucso Tiziana; Orio Francesco Jr; Tauchmanova Libuse;
ΑU
            Zupi Errice: Panici Dier Luigi Benedetti; Nappi Carmine; Colao Annamaria;
           Lomi rdi Gardano; Zu lo Fulvio
Dipo imment se Obstatics Gynecology, University 'Magna Graecia' of
Catomara, disanzene stefanopalomba@tin.it
           Huma: represention Exford, England), (2002 Dec) Vol. 17, No. 12, pp.
SO
            321. 4.
            Journal code: 8701100. ISSN: 0268-1161.
           England: United Kingiom (CLTTCAN TRUEL)
CY
DT
            Journal; Article; (COURNAL ARTICLE)
            (RATIOMINED CONTROLIED TRIAL)
            En oah
LA
            Priority Journals
FS
            2:0:55
EM
            Entered STM: 31 Dec 3002
            Last Updated on STM: 5 Jun 2003
            Ente ad Medline: 4 Jun 2003
L11 ANSWER 82 OF 182
                                                           MEDLINE on STN
Full Text
            2002 38637
AN
                                          MEDLINE
            PubM d ID: 12490735
DM
           FDA daug approval summaries: fulvestrant.

Boss Peler Cohen Martin H; Williams Grant A; Pazdur Richard
TI
ΑU
CS
            D:- '
                     tion of thecology Drug Products, Center for Drug Evaluation and
                     rch. For and Drug Administration, HFD-
ill, 2085 USA. b:pssp@cder.fda.gov
rcopic, (Clip) Vol. 7, No. 6, pp. 477-80.
rd. pp. 477-80.
                                                           nd Drug Administration, HFD-150, 5600 Fishers Lane,
            R .
            R
SO
            T'1€
            Ju
           Uni
CY
                                          'le; . 'URNAL ARTICLE)
DT
            มี วน
                       īl; A
                                                     3. GOV'T, P.H.S.) ·
                                          ORT.
            (RE
                        .RC
LA
            Eng
                        :h
                      ity J :: rals
FS
            Prin
El-i
            200
                        ED
            En-
```

```
Last Updated on STN: 7 Feb 2003
      Entered Medline: 6 Feb 2003
L11 ANSWIR 83 OF 182
                               MEDLINE on STN
Full Text
AΝ
      2002 333049
                       MEDLINE
      PubNid ID: 12:43837
DN
      Effects of pamemifers (FC-1271a) on uterine endometrium, vaginal
      maturation index, and hormonal status in healthy postmenopausal women.
      Voi: 5 S K; Tomi J; Kangas L; Halonen K; DeGregorio M W; Erkkola R U
ΔIJ
     Der tment of Obsternics and Gynecology, Turku University Central Hos tal Fin-20520 Turku, Finland.
Mat: ita:, (2002 Now 20) Vol. 43, No. 3, pp. 207-14.
Jou al od:: 7807333. ISSN: 0378-5122.
CS
SO
      Ire: nd
CY
      (CLI TCAY, TW FAL)
(CLI TCAL TRATA, PHASE I)
DT'
      Jour hal; Article; (COURNAL ARTICLE)
      (RAI DMINED CONTROLLED TRIAL)
T.A
      Engl. sh
      Pric ity Journals
FS
      2003 3
EΜ
     Entered (TN: 12 Nev-2002
Las: Updates in STM: 31 Mar 2003
Entered Section: 23 Mar 2003
ED
L11 ANS***IR 84 C) 82
                              MEDLINE on STN
Full Text
      2002 34715
AN
                       MEDLINE
DN
      Publy d III: 17394205
      Tamo ifer as an ergogenic agent in women body builders.
      Seeh sen Dear A; Glorioso John E
ΑU
      Department of Family Practice and Emergency Medical Services, Tripler Army Medical Center, Hawaii 96859, USA.
SO
      Clinical journal of sport medicine : official journal of the Canadian
      Acad my of Sport Medicine, (2002 Sep) Vol. 12, No. 5, pp. 313-4.
      Jou al coca: 9103300. ISSN: 1050-642X.
      United States
(CA.: REMOFT
CY
DΤ
      Jour al; Article; (COURNAL ARTICLE)
LA
      Eng sh
      Pric ity Journals
FS
      2002
EH
     Ente ed \delta T h: 4 Oct 1002
Last Update on STM: 13 Dec 2002
ED
      Ente ed Medifile: 12 Nov 2002
     ANST 12 85 C 1 182
L11
                               MEDLINE on STN
Full Ter
MΑ
                       MEDIA: IE
      Pult of ID: 02.87278
DN
ΤI
      ACC Practice Bulletin: Clinical Management Guidelines for
           rriciant-typecologists: Number 39, October 2002. Selective estrogen
      reductor modulators.
      Anor mous
ΑU
      Amer can Collage of Obstetricians and Gynecologists.
C.3
SO
      Obst tries at Egymecology, (2002 Oct) Vol. 100, No. 4, pp. 835-43.
      Journal coda: 0401161. ISSN: 0029-7844.
      Unit d States
CY
      (GUT ELINE)
      Journal; Archile; GJOURNAL ARTICLE) (PF. TICE GJOELINE
LA
      Ena
          ged Inda: Medicus Journals; Priority Journals
FS
     Ahr
EM.
      200
            nd JTY: 2 Out 2002
      Ent
ED
            "pd tc. n STM: 13 Dec 2002
ed lec. e: 7 "v 2002
      Las
      Ent
Lll ANS:
            : 8 (
                      82
                               MEDLINE on STN
Full Tex
A:1
      200.
             46:0
                       ME":
```

```
PubM .d II.: 02 71450
       Home pathic Weatment of hot flushes: a pilot study.
TΙ
. AU
       Clovin A: Estatey D
       Tunk ridge Vells Kome sopathic Hospital, UK.. anne clover@lineone.net
CS
       Home pathy: the journal of the Faculty of Homeopathy, (2002 Apr) Vol. 91,
SO
       No. . pr. 75 9.
       Jour al coc. 101147517. ISSN: 1475-4916.
Scot and: United Kingdom
(CLIVICAL TWAL)
Journal; Article; (JOURNAL ARTICLE)
CY
DT
       Engl sh
LA
FS
       Priority Journals
EΜ
       2003)1
ED
       Entered STM: IO Oct. 2002
       Last Updated on STN: 2 Feb 2003
Entered Mediane: 31 Jan 2003
L11 ANSWIR 87 OF 182
                                 MEDLINE on STN
Full Text
       2002 137 2
                          ME_I IE
AN
       Publ : III: 102437
DN
       Meta analysis of the apies for postmenopausal osteoporosis. IV. Meta analysis of rabbailene for the prevention and treatment of
TI
                       of rabxifene for the prevention and treatment of osle porosis.
       post no au.
       Crangey Lnn.; Tugwell Peter; Zytaruk Nicole; Robinson Vivian; Weaver Bruce; Adac I Jana Han; Me 's George; Shea Beverley; Guyatt Gordon
ΑU
       Oste por sile than pogy Group and The Osteoporosis Research Advisory
CS
       Endo rine retrews. 2002 Aug) Vol. 23, No. 4, pp. 524-8. Ref: 19
SO
       Journal model 8000033. ISSN: 0163-769X.
       United Shat we
CY
       Journal; Arthole; .JOURNAL ARTICLE)
DT
       (MET -ANALYS -)
       (RES LARCH SUPPORT, MON-U.S. GOV'T)
       General Review; (REVIEW)
       Enql sh
LA
       Prichity Journals
FS
EM
       200311
       Entered STN: 11 Aug 2002
Last Updated on STN: 3 Apr 2003
ED
       Entered Mediine: 7 Feb 2003
L11 ANSWTR 88 CF 7.82
                                   MEDLINE on STN
Full Text
       2002 40786
                          WE IT ME
I \cap A
DN
       Publ d ID: / 19780
       Public 10: 1978 Trea ment for hot finishes in women receiving tamoxifen.

Bydd of Sear 1: Sp., ligel A

Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands,

WA . siyd light 11.com

The dical curnical Australia, (2002 Sep 2) Vol. 177, No. 5, pp. 266.

Jour 1 code 040 The ISSN: 0025-729X.

Aust this

Jour 1: Article; IN URNAL ARTICLE)
TΙ
ΑU
CS
SO
CY
DT
       Engl sh
LA
       Pric ty Jon als
FS
       2002
E \cdot I
       ED
L11 ANSV 1 8: CF 182
                                   MEDLINE on STN
Full Text
             76"1
                          MF . TE
\mathbf{A}\mathcal{A}
       2002
       Publ | ID: 1 23333
DN
       Inti musculin depot medroxyprogesterone versus oral megestrol for the
TI
       cont of a stmenophusal hot flashes in breast cancer patients: a
       rand mizid stidy.

Bert ili G; Vinturini M; Del Mastro L; Bergaglio M; Sismondi P; Biglia N;
ΑU
       Venturini S: Porcile G; Pronzato P; Costantini M; Rosso R
       Medical (nc) egy, f. Croce General Hospital, Cuneo, Italy.. giar ili pc. mtell tiscalinet.it
 СЗ
```

```
Annals of the logar official journal of the European Society for Medical Oncology / 1800, 70 2 Jun) Vol. 13, No. 6, pp. 883-8. Journal code: 90077 5. ISSN: 0923-7534.
SO
      England: Un ad Katadom (CLI HCA Term)
CY
DT
      (COMPARATIVE STUDY
      Journal; Article; [DURNAL ARTICLE]
(RAN OMIMEL CONTROL OF TRIAL)
(RES DARCH SUPPORT, 'N-U.S. GOV'T)
      Engl sh
      Prichity Journals
FS
EΜ
      2003 /1
      Enternd STN: 9 Jul 1002
Last 'pdated in SlJ: 10 Jan 2003
ED
      Entered Medline: 9 . nn 2003
L11 ANSWER 90 OF 82
                              MEDLINE on STN
Full_Text
      2002354979
AN
                      MEDL. NE
      PubMed ID: 12198608
ΤI
      SERM: curror states and future trends.
      More to Mark C; White Gregory T; DeGregorio Michael W
ΑU
      Department o Interal Medicine, Division of Hematology/Oncology, Cancer
      Centur, University of California, Davis, 4501 X Street Room 3016, Sacremento, to 9581 / USA.
      Crit al ref ws to oncology/hematology, (2002 Jul) Vol. 43, No. 1, pp.
SO
          . Ref.
      63-
      Journal cog: 8915 - 1. ISSN: 1040-8428.
CY
      Irel u.d
      Journal; Aminie; DURNAL ARTICLE)
      General Review; (Prolew)
      English
LA
FS
      Pricedty Johnals
      2003 17
EΜ
      Entered STIT: 1 Jul 2002
      Last Updated in STD: 11 Dec 2002
      Entered Medrine: 1: Jul 2003
     ANSV 12 91 C7 182
                              MEDLINE on STN
L11
Full Text
      2002 1503118
                      MEC! INE
AN
DN
      PubNed In: 11 93250
      Chemoprevention of breast cancer: a summary of the evidence for the U.S.
TI
      Preventive Schwider Task Force.
      Kinsinger Litda S; Harris Russell; Woolf Steven H; Sox Harold C; Lohr
      Kathleen N
     Cecil G. Shaye Center for Health Services Research, Program on Prevention,
      CB# 7508, Ming D, Room 383, University of North Carolina School of
      Meditine Chirel Hill, NC 27599-7508, USA.
NC
      11: 7-0 י-290
      Anna s of its graat medicine, (2002 Jul 2) Vol. 137, No. 1, pp. 59-69.
SO
      Ref: "3
      Journal sodu: 0372 . E-ISSN: 1539-3704.
     United States

Journal; All Te; COURNAL ARTICLE)

(RES URC S MORT, L.S. GOV'T, P.H.S.)

General merch ; (C.M. EW)
CY
     Englich
Abriged In . Medians Journals; Priority Journals
LΑ
FS
      200. ...
      Ent: "..d "T
                             0.2
                     Jυ
      Last Todate
                      n S % : 18 Jul 2002
           d e
                   , d: .
                             ul 2002
      Ent.
L11 ANS" T 91 ( 32
                              MEDLINE on STN
Full Tex
                      MF: TE
            03.0
KA
      2002
      Publ : ID:
DN
      Tamo difer ...
                      sts
                           ... subjective and psychosexual well-being, in a
      ranchis d 🕖
                      ast ricer study comparing high-dose and standard-dose
      cher he a;
ĽA
                      ock wann I; de Vries E G; van der Zee A G; ten Hoor K A;
```

```
van Ger Greaf W T; Sluiter W J; Willemse P H
      Department of Gynerhology, University Hospital Groningen, Hanzeplein 1,
CS
      971: 7Z frow genome Netherlands. m.j.e.mourits@og.azg.nl
Britush jours 1 o. uncer, (2002 May 20) Vol. 86, No. 10, pp. 1546-50.
Journal dorns (377 %. ISSN: 0007-0920.
SO
      Scot and the Ed and and (COL-2.RAY.I) TUDY
CY
      (COL P.RA'.I' TUD':
Jour 171; Art: 'e; URNAL ARTICLE)
DT
      Eng h
LA
      Prichity Jour als
FS
      200271
EM
      Entroed STM: 7 Jun 2002
Last Jpdated on SUN 3 Aug 2002
Entered Medice: 2 Aug 2002
ED
L11 ANSV 37 9 CF 82
                                 MEDLINE on STN
Full Text
ΑN
      200 1:8058
                        MELL ME
      Publicd ID: 1 805
DN
      The phology urso' role in educating patients on endocrine therapy for
TI
      metastatic preast dancer--focus on fulvestrant.
UΑ
      Lyn: Jean
      George Washington University Medical Center, Breast Care Center, 901 23rd St 1.4, Washington, DC 20037, USA.
CS
      Cancer nursing, (2002 Apr) Vol. 25 Suppl 2, pp. 125-175.
SO
      Journal code: 7805358. ISSN: 0162-220X.
CY
      United Shates
      Doublet; Archile; (JOURNAL ARTICLE)
English
Princity Jo: Jals; Marsing Journals
2001
DT
LA
FS
EM
      Entered STM: 6 Jim 1002
ED
      Las: `pdat .
Ent and Med ...
                       n STM: 7 Aug 2002
e: 6 T g 2002
L11 ANS: 32 94 ( 3 82
                                 MEDLINE on STN
Full Tex
            :49332
                        MEDI ME
MA
      2001
      Pub' 10: 10: 98177
DN
      Rale differe to ass moted with less side effects than tamoxifen in women with an ely broast cancer: a questionnaire study from one physician's
TI
      pra ce.
      Robertine Black Robbin; Lower Elyse E

Department of Intuit al Medicine, Division of Hematology/Oncology,
Unit asi y a Cint dati College of Medicine, Cincinnati, Ohio 45267-0562,
ΑIJ
CS
      Journal of we ren's ealth & gender-based medicine, (2002 Apr) Vol. 11, No.
SO
      3, 30. 291 33. .
Journal cods: 100683719. ISSN: 1524-6094.
      United States
CY
      (CONTARATIVE STUDY)
DΓ
      Journal; Artirle; (JOURNAL ARTICLE)
LA
      Eng ish
      Pricity Journals
FS
      200115
EM
      Entrad STF: Mar 2002
EЭ
      Last Update
                       n ST
                                20 Jun 2002
      Entraid Her
                                Jun 2002
                       Æ:
            9
L11 ANS
                        ٠2
                                 MEDLINE on STN
Full Tex
             0073
                        MF.
VA
      200
                                 JE.
D.1
      Pub"
                        563
             rean. --
TI
      A 6
                                trying to discontinue hormone replacement therapy.
                        T. OT
ΔU
             Deiro
      Gra
                        Cal
             rsi∶y .
C3
      Un :
                                mia, San Francisco, 74 New Montgomery St, Suite 600,
                              05, US: dgrady@itsa.ucsf.edu
      Sai
             ur i .
                        \mathbb{C}\mathbb{Z}
SD
      J.i.
              t e
                                  the Augrican Medical Association, (2002 Apr 24) Vol.
                        ' 'n -
      287
              ). 1.
                        D.
                               • , - 7 .
                        75
                                 . TSSN: 0098-7484.
             . `_ . `_
      Jou
             S.a'
CY
      Uni
DT
      (CI:
              RE 107
```

```
Journal; Article; GOURNAL ARTICLE) (REGRARCH STRONT, DN-U.S. GOV'T)
      English
Abrilled Inst: Medicus Journals; Priority Journals
LA
FS
EM
      Entered AT: 3 And 2002
Last Update 1 in SCM 14 Dec 2002
Entered Mesic c: 2004 2002
ED
      ANSV 12 96 0 4 82
L11
                                 MEDLINE on STN
Full Text
AN
      2007
            195 4
                        WI ...E
                        21: 1
            1 IL: 1
DN
      Pul:
      [No one relaces we therapy in peri- and postmenopause. Routine use is
TΙ
      not odia.....
      Hor Mersa der Peri- und Postmenopause. Ein routinemassiger
                       ch' iziert.
      Eir. z s
      Emo: G; W hal : 3
ĽA
      Klir k fur - make or ie und Geburtshilfe, Georg-August-Universitat
CS
      SO
CY
DT
      (ENG. SH AT 31' ACT
      Journal; And le; OURNAL ARTICLE)
LA
      Garran
      Priculty John als 2001 4
FS
EM
      Entered STF. - Apr. 102
Last Update Fon STM. 30 Apr 2002
      Entered Medicine: 29 Apr 2002
L11 AMSTER 97 CF 32
                                 MEDLINE on STN
Full Text
      2002 78476 MECANE
PubNed ID: 1 36000
Effect of the physic strogens on hot flashes in postmenopausal women
VA
DN
TI
      with preast and a randomized, controlled clinical trial.
      Van Atten d. ri . Clivotto Ivo A; Chambers G Keith; Gelmon Karen A;
AU
      His of T G on try: I apleton Edith; Wattie Angela; Prior Jerilynn C
Bri th Color ia a ter Agency, Vancouver Cancer Centre, Vancouver
Kos al and Mal Sciences Centre, and University of British Columbia,
CS
      Variable, the slumbia, Canada. cvpatten@bccancer.bc.ca

Jone all for micro encology: official journal of the American Society of
SO
      Clim cal Orac ogy, 2002 Mar 15) Vol. 20, No. 6, pp. 1449-55.
Command dorne 836 7 3. ISSN: 0732-183X.
Unit d Starty
CY
      (CLI TCAL T-F-L)
      Jour al; Armile,
(RAN OMIVE, ...)TF
(RES ARCH STUDEN
                            CURNAL ARTICLE)
TED TRIAL
                              ^N-U.S. GOV'T)
      English
Frienty Johnsla
LA
FS
EM
      200.
      Ent red ST: 3 Nor 3002
Las: "post of an ENT 18 Apr 2002
Fnt: ed Herling: 17 Apr 2002
L11 FTST 4R 98 GF 82
                                 MEDLINE on STN
Full "
      2007
                         METTE
\mathbf{Y}, \mathbf{1}
             16603
                        ^ 7 <u>5</u>
             l ID:
D.1
      E.ipt
             ນນຸສະ
ພັດເ
TT
      A cc
                         0
                                 mone replacement therapy given to women previously
      time
                         ٦.
ΑU
      Desir
             - 3 - ε. -
                         Br
                                 E; Magarey C; Schwartz P; Crea P; Wren B
             r Te
CS
      V. ".
                         Ţ:
                                 ute, Reval Hospital for Women, Barker Street,
      F 11.
              27.
                         G.
                                 ustrali..
      CTi
                             rnal of the International Menopause Society, (1998
SO
            ·· . . · · j
                        ¹h.
            ຳວີ. .
      ů.,
                                p. 137-72.
               .∵ວ
                         - 2
                                 . ISSN: 1369-7137.
      Ţ*..:
             `Star
CY
```

```
Journal; Art le; (JOURNAL ARTICLE)
              Eng. 3h
 LA
 FS
              Princity Journals
EM
              2001.4
             Enterned STM: 14 Mar 2002
Last Updates in STM: 10 Apr 2002
Enterned New York: 9 For 2002
ED
L11 ANSW 93 7 32 MEDLINE on STN
Full Text
              2002 1/2423
                                                    MFDI E
             Publication 06600.
Cheruprered in for high-risk women: tamoxifen and beyond.
Fabrua C J: K mlc F
Unit using of Karma Medical Center, Kansas City, Kansas 66160, USA..
DN
 TΙ
 ΔU
CS
              cfa mily
The reast
             Cfa | Tribur : du
The react | mns | (2001 Sep-Oct) Vol. 7, No. 5, pp. 311-20. Ref: 117
Jeu : A co : 95: 73.7. ISSN: 1075-122X.
Unit | State a
Jou : Th; A : | let : FUJRNAL ARTICLE)
Grap : Table a : Tribur : EW)
 SO
 CY
DT
LA
             Ena
              Priority Johnson
FS
              2 " : '
ЕM
             E. A. and OTTLE 1 1.42 .002
I st Update n 5 W: 19 Apr 2002:
ED
              Ente ed Merafre: 18 Apr 2002
L11 ANSTER 100 OF 182 MEDLINE on STN
Full Ter
                                                   MEDITIE
              200. 13280
             Publied ID: 11:93300
Time difen-introdec Not flashes.
Lop: nzi C To Cahasiy K M; Sloan J A; Novotny P J; Quella S K
DN
TI
ΑU
             Mayo Clinica "Ayo Foundation, Rochester, MN, USA.. cloprinzi@mayo.edu
CS
             Clin Gal branch conter, (2000 Apr) Vol. 1, No. 1, pp. 52-6.
             Journal code: 100393731. ISSN: 1526-8209.
             Urited Shahaa
             Journal; Ambielle: ( DURNAL ARTICLE)
DT
             Figlish
Priority Journals
FS
              200
\mathbf{E}\mathbf{M}
             Ent. 19d ST : 12 Nar 2002
Life Upd A. 2005 5 Apr 2002
For and General 2002
ED
L11 A'S U. 1.1
                                                   8.
                                                                     MEDLINE on STN
Full T X AN 2
                                                     MI
                            odi
SES
             F
                                                    5
DN
                                                    ai.
             F. .
                                                                     of fluoxetine for treatment of hot flashes.
TI
                            π<sup>3</sup> **
                           in the Standard Months of the Standard Months of the Standard Months of the Standard Months of the Standard Michele Y; Pruthi Sandhya; Novotny Standard Months of the Standard Months o
υA
                                                                     James A; Halyard Michele Y; Pruthi Sandhya; Novotny
              Ιŧu
             CS
 SO
             John Flord
Udia Islana
CY
                         CATA ( ALA, OF SE III)
DT
                                                e; OURNAL ARTICLE)
                             1; A:
                           rof T
                                                 "TI" D TRIAL
              ( 7.7
                           MILE
                            :17
             Fg
LA
                                            . wir
             ic
ES
                            t; 0
            ٠: ١٠
\mathbf{E}.1
                           ED
             Litt
             \mathbf{I}_{i} \cdot . :
```

```
L11 / WS . 1 7 . . . 87
                               MEDLINE on STN
Full Text
AΝ
      200
            736 . 3
                       MI JI IE
      Publ 5 ID: 0019937
Fost enonant horn ne-replacement therapy.
DN
TI
      Drv Suca
      The law Th . A per mal of medicine, (2002 Jan 3) Vol. 346, No. 1, pp.
SO
      Jon tol co .: .251 .3. ISSN: 0028-4793.
      Uni od State.
CY
      I. t+ ...
DT
      i igli sh
LA
FS
      April ged I at Meditus Journals; Priority Journals
EM
      2002
      Enterned STT: 15 Car 2002
Last Jpdstor on ETM: 25 Jan 2002
Enterned News Cornel Jan 2002
ED
L11 7''S R 1'3 1 187
                               MEDLINE on STN
Full Toy
AN 200
            198 ...
                       M_1 \times I = E
                    5: "(
      Fu -
           TT:
DИ
            mice
.au e
                     which the tringent preclinical selection criteria leading to an trivity (WAY-140424) for clinical evaluation.
ΤŢ
      Dc =
      a:
           3 S
      I m
ΑU
                      ε.
                      Remark Institute, Wyeth-Ayerst Research, Collegeville, 14. USA. <u>kommb@war.wyeth.com</u>
Tet k Academy of Sciences, (2001 Dec) Vol. 949, pp.
           ່ຣີ "ວ
      ∵ ome
CS
           education in
      I ≱n.
           / nn
      Jau.
      Uni d Sie
CY
           11; And the end OURNAL ARTICLE)
DT
      ∂ u
      Con
      Fig sh
FS
      Provity John Wals
      2001 2
EM
      Ert and STI. Of Cet .002
Is Tpdata + . STI: 22 Feb 2002
Fit and has form Teb 2002
L11 // USI // 104 ( * 182 )
                              MEDLINE on STN
Full Tox
           49890
                       MEDI JE
AΝ
                    1524
      lubi d ID:
DM
      I louifers, take and benefits.
TI
      For the Color E
UA
     I ment
                   Tamin and Preventive Medicine, University of California,
                   To . 32093, USA. <u>ebarrettconnor@ucsd.edu</u>
Tex : k Academy of Sciences, (2001 Dec) Vol. 949, pp.
      S 1".
            ingo,
      Arms s of
SO
            33.
            5 ... ISSN: 0077-8923.
      i
              . ". .
CY
           URNAL ARTICLE)
DT
      , ou
       212
      7...
LA
           .3 7.
F۶
E.I
            ra ···
                   003
22 Feb 2002
ED
        t
      ] t
           Thd +
            er 2002
L11 / US
Full T
                       1.3
            0.105
                               MUDLINE on STN
                       77 ' E
ΔN
                       - ;
D.1
            ....
                             perties of an ideal SERM?.
      ∷∴а
                       1.13
TI
                      ## ## ## Dunn B K

To Fedical Center, Washington, DC 20007, USA.

To Fedical Center, Washington, DC 20007, USA.
            w :;
ΑU
      int
            m<sup>2</sup>.05/16
C3
      -.:C:
     a ol
i
                              k Academy of Sciences, (2001 Dec) Vol. 949, pp.
SO
                             . ISSN: 0077-8923.
            S+
CY
      ī i
```

```
٠, ,
      UF!IAL ARTICLE)
DT
                                EN'
      : . .
LA
           sl.
           Mty.
FS
          .3
EM
      Fit ed ()
                      .
                                002
            Und:
                                22 Feb 2002
           und II
                                ຳລີ: 2002
L11 A STFR 136
                     3 '
                                MEDLINE on STN
Full Tix
      2007 359833
Publical IDE
                        MT T IE
ΑN
                    1. 551 (
DN
      Tiffize of
                     ٠. :
TI
                              estrogen receptor modulators on reproductive tissues
      oth than
                     i me ii um.
      Heta fix D., We gras G
AU
     I profiment of the Porics and Gynecology, Wayne State University/Hutzel Fishital, I oit Michigan 48201, USA.. <u>shendrix@med.wayne.edu</u>
7 in s or the West Wick Academy of Sciences, (2001 Dec) Vol. 949, pp.
CS
      Im sor:
SO
      1:3 0. L : 1
      Ger hal der : 75° 6° 8. ISSN: 0077-8923.
\mathbf{C}\mathbf{Y}
      U: ed S
      Goundal: Forticle: DURNAL ARTICLE)
Goundal ... TEW)
\mathbf{D}\mathbf{T}
      Eng ish
LA
           - - - -
FS
                      . :1:
           . 3
\mathbf{E}i
           -ad ::
ED
                                062
      Luc Upd to the 22 Feb 2002
For the 2002
L11 FTS R 1 TT
                                MEDLINE on STN
Full [
           1865.
                        i'.
                               *E
AN
       · a II.
                       . ť
DN
                    t a foy or
                               amoxifen in a breast cancer prevention trial: a
                               from the NSABP P-1 study. National Surgical Adjuvant
      s morry of
                    . - - - <u>1</u> .
      Ele stiann
                               lect.
AT!
      ***** R
                     the Month of School of Public Health, University
                     Programme School of Public Health, University Programme 15213, USA. (National Surgical Adjuvant Breast Study (NSABP-1)) day@ngabn nith
C.3
           1555
           'orro"
                     study (NSABP-1)). <a href="mailto:day@nsabp.pitt.edu">day@nsabp.pitt.edu</a>
Serial Racademy of Sciences, (2001 Dec) Vol. 949, pp.
SO
            3 01
      . . .
      . J rai run: '5.5 A. ISSN: 0077-8923.
      Tid id Sta
CY
                   TRIAL)
           ICA.
        I TIROLLEI.
      Jurual; A. Firse TOURNAL ARTICLE)
      (· JITICENT
      L.g [sh
LA
      Fi rity (
FS
E.:
       . tored of t
                      5
                            1002
ED
           びいざっと
                      . : 22 Feb 2002
      int rad
                               Tab 2002
                       1 1
                      8.
                                MEDLINE on STN
Lll
F: 11
            5-3 1.
A:1
                              - 17
DM
           .. F S
                               and risk of breast cancer during treatment with
TI
          .1.1ε
                                org Tu; Kenyon Emily; Cauley Jane A; Whitehead
ΑU
          11.518
          ). ;
        o dina
                            University of California, Suite 600, 74 New
C.:
                             Mandisco, CA 94105, USA. (Multiple Outcomes of MORE) Trial). scummings@psg.ucsf.edu
           สุดภูเล เก
                        25
                            . the American Medical Association, (2002 Jan 9) Vol.
SO
            ٠-.
                             SSN: 0098-7484.
С,.
```

```
(CITAICNI PAR 19)
DT
      Jem Mal; A (
                         ٩.
                               DUFNAL ARTICLE)
                                D TRIAL;
           AM.G.,
                               N-U.S. GOV'T)
           1.1
LA
           tite C
                               is Journals; Priority Journals
FS
EM.
      2.
                          E to Dag I
L s' Utida:
                                3 Apr 2003
      Entered Mon-
                               3b 2002
L11 EMSTER I. . . . IS.
                               MEDLINE on STN
Full Tax
AN 200 D57 38
DN Political Community
                        ∵ -+ 1E
                     . . . or adjuvant therapy on symptoms, functioning, and
      Constant Constant
ΑU
                        comprehensive revention and Control Research, Jonsson Comprehensive
CS
                        versity of California-Los Angeles, Box 956900, Rm.
      A - 15 CT
                            les, CA 90095-6900, USA.. pganz@ucla.edu
SO
      Jeunal of
                           mal Cancer Institute. Monographs, (2001) No. 30, pp.
      1 0 - 1.
      Journal comb + 0001105. ISSN: 1052-6773.
     United Sta :
United Sta :
United Sta :
United Sta :
(NEW EARCH STATE ONLY NON-U.S. GOV'T)
CY
\mathbf{L}\mathbf{A}
      Erg ish
      Primity 0
FS
          . ;
EΜ
      E 4 100 25
                    2002
                     ... 27 Jun 2002
: Jur 2002
      L. Upd T
            - 3C
L11 A.S TR 10
                       2.€
                                FEDLINE on STN
Full Tex 
AN 2 0 05118
DN Publish ID:
                        i. T NE
                      • • • • • •
      O a itur ci
                               ong-term, disease-free survivors of breast cancer: a
TT
      f = - \nu r \cdot r \gamma
      G the
IJΑ
                        ord Katherine A; Leedham Beth; Rowland Julia H;
      elin Thomas R
                               University of California, Los Angeles 90095-6900,
      īī
                        ą į
           .530: ± '
                        )
SO
                       M. Hall Cancer Institute, (2002 Jan 2) Vol. 94, No. 1, pp.
      3 -
      James 1.5 (15 (19. ISSN: 0027-8874. United State)
CY
      Journal; A. G. & DURNAL ARTICLE)
(RECEARCH CONFIDENCE ON TO NON-P.H.S.)
(FERBARCH CONFIDENCE OR CONFIDENCE ON TO NON-P.H.S.)
      ปีเนากลไ ; 🔬
      E. : isb
      P firsty to 1 121
FS
\mathbf{E}
                      2002
- 2002
- ar 2002
      Fith the time to the same
           The
Let
      Ε.
L11 1:3
                        2
                               LEDLINE on STN
Full T
           114
                        17 T 1E
ΑĽ
      2
DM
      P·.
      s ! : ...
TI
                        ecotor acdulators in 2001.
ΑU
                              .ar 😗 J
                             gy and Medical Oncology, Robert H. Lurie Comprehensive western University, Chicago, Illinois, USA.
Park, N. 111, (2001 Sep) Vol. 15, No. 9, pp. 1177-85,
C\Sigma
      C
                             11 7-4.
                              € 390-9091.
CY
```

```
Journal; And in OURNAL ARTICLE)
DΤ
     Fig ish
Pil vity
\mathbf{L}^{\mu}
FS
EΜ
      2
           3 1
     E: : Fred NULL: 0 : .001
L st. Upd .: : : 111 . 25 Jan 2002
E trond Wer I :: / .an 2002
\mathbf{E}D
L11 ANGUR 17. CONTROL MEDLING ON STN
Full To X
      200 3365E
                            NE
ΑN
      P1 2 2 ...
DN
      Sel min
                            receptor modulation and reduction in risk of breast
TΙ
      Cc 1 117.
                             , and commany heart disease.
ΑU
                             S; Morrow M
     R • 1 7
                            remensive Cancer Center, Chicago, IL 60611, USA..
\mathbf{C}\Sigma
          £1. . .
     <u>(</u>
7.
     NC.
                           nal Cancer Institute, (2001 Oct 3) Vol. 93, No. 19,
SO
      r . 44%
Juinal co
                            . 6
                            9. ISSN: 0027-8874.
      U if ad \mathcal{B} .
CY
      Journal; 5
                             OURNAL ASTICLE)
DT
                      . %
      (CT MARCA
(AR SUBCE
                    .S. GOV'T, NON-P.H.S.)

R. J.S. GOV'T, P.H.S.)

IEW)
                             ON U.S. GOV'T)
      (TTY FARCE)
      Ġ, tertaŭ lis
     End ish
Pri city J
LA.
                     - 5
\mathbf{F}\Sigma
\mathbf{E}^{\mathbb{M}}
                    . C 1001
--- 11: 22 Jan 2002
      F . ed .
Lan Upda
· ED
                   : 22 Jan
: ec 2001
      I to red No-
L11 A 3 SR SR ST 5 (8
                              MEDLINE on STN
Full T X
          1345)
3d 77.
\mathbf{A}\mathbf{N}
                             NE
DN
                     norausal sequelae in patients with breast cancer.
           1/200
TI
ΑU
                       spital, Sutton, Surrey, UK...
CS.
      T
                             ame 3.nhs.dk
oyal College of Radiologists (Great Britain)), (2001)
      ć
SO
                             174-80. Ref: 56
           . .
                             2. ISSN: 0936-6555.
                       ť.
                          dor.
     I j w: .
J i al:
CY
                           OUFNAL ARTICLE)
      G 7 - 42 - -
      E isl.
LA
           --+--
FS
      F
EΜ
      2
      ΕD
                           ec 2001
           .01
           7.
L11 F.
                              : EDLINE on STN
                      1 (
Full TAN I
                    i NE
           isell
id ISi
DN
      I
      F.7 1385
                             y for menopausal symptoms?.
                   ch ed.), (2001 Aug 18) Vol. 323, No. 7309, pp. 354-5.
TI
ΑU
     T * 5 =
           C7i-
SO
      J: mal d
I: me: me:
                              don.
\mathbf{D}\mathbf{T}
LA
FS
                             us Journals: Priority Journals
ΕI
                             20
E
                         . 1 Sep 1103
                              Set 2001
```

```
Lii Am VR II . . . . . .
                                                               FEDLINE on STN
 <u>Full 7</u> :.
                160717
                                                 i NE
 ΑN
                                                15
DN
             Fig. :t of '
                                             and raloxifene on the tail temperature of
 TΙ
                                              M Mars A H; Kloosterboer H J
             or allogen-c
                    .dsc:: :
 ΑU
                                            The life A H; Krooscerboer I Compared to the life of t
 CS
             Far rado o
                  '' aland.
             Empleation
Jon 142 co
 SO
             Nett intant.
 CY
            Jonath, Fire of
                                             COURNAL ARTICLE)
DT
\mathbf{L} \mathbb{A}
FS.
             Fil
EM
                                                      2001
                          :c :
ED
                          Up 1 2 21 Aug 2001 ec Vec 1 Aug 2001
                                                                  FEDLINE on STN
L11 I.
                        3 5
 Full '
                                                                 NE
 NA
             F
DN
                                                                ecoptor modulation: the search for an ideal hormonal
T_{a}^{a}
             S.
                        ಎಸ್ತ f
                                               . 8
             t.
                                                                anser.
                        ΔII
             L
                        annet i
                                                The Inc., Nutley, New Jersey 07110, USA..
 CS
                                                 2 com. (2001) Vol. 19, No. 6, pp. 649-59. Ref: 67
 SO
                 i na" coc
                      i distat
 CY
            Contal: As
Gural Mar
DT
                                                               'OUFNAL AFTICLE)
                                                ( FIEW)
LA
             Ţ
                        sh
FS
             £
                      it; Jo
\mathbf{E}V
             First and oil
                                                 2001
ED
             L11 / 7 7 33
                                                                 MEDLINE on STN
Full .
                          33.31.3
                                                  NE
· AN ·
                       Ĺ,
TI
                                                                cancer: symptom reporting.
                                                          C: Lees A W; Handman M D; Cumming D C; Urion C gy, University of Alberta, Edmonton, Canada. (2001 Mar-Apr) Vol. 7, No. 2, pp. 97-100.
                          t. f.
ΑU
                                                   i ·
                          tr. · · E
 CS
                       1 36 -11 D
SC
                                                        9. ISSN: 1:75-122X.
C."
                        , ÷
DT
                                                                TOURNAL ATTICLE)
                                                                CON U.S. GOV'T)
LA
             F
 FS
EΜ
                                                                 2011
                                                   . . 1. Jul 2001
: . Jul 2001
                          Jim. I
                          ec e.
                          R . 8
                                                                   'EDLIRY on STN
L11
Full
                                                                NE
 Αï
DN
 ΤI
                                                                iens and beyond.
ΑU
                                                                'gy/Oncology, Robert H. Lurie Comprehensive Cancer
 CS
                                                                Uriversity Medical School, 303 E Chicago Ave.,
                           ijC.,
                                                                t, 2001 Jun) Vol. 28, No. 3, pp. 260-73. Ref: 119
 so
                                                                '2. ISSN: 0093-7754.
 CY
```

```
C a a Time ( IET)
           For sh.
To mit J
T.A
FS
                     <sup>-</sup>7
EM
            I cad II
ED
                                                      20.1
                                                     Ju 2001
            I = Upc-to
            12 कि अ. ∃
                                                        MEDLINE on STN
L11 A W R & 0
Full Tet AN 2017/04783
            DN
TΙ
AU.
CS
            NC
            i sa no
CY
            Cartal: At the COULNAL APTICLE)
(KARAGEORY COUNTAL ARTICLE)
General Countal Co
             Fnj. sl
FS
             ri
            200 3
EM
            Ynt red [7] | 1 | 000

In. Upda | 4 Jun 2001

The red For a common May 2001
L11 /M R TO Decomposition
                                                           LEDLING on STN
Temposition to the transfer and gynecologic side effects: a review.
            Hourts M. C. Las M. G; Willemse P. H; Ten Hoor K. A; Hollema H; Van der
UA
             Ze: 1 0
            Tep. ton to 1 the arries and Gynecology, University Hospital Groningen, Tandelia , 4 to 3Z Groningen, The Netherlands.. m.j.e.mourits@og.azg.nl Obsertures to granology, (2001 May) Vol. 97, No. 5 Pt 2, pp. 855-66.
            Tef: 121
            CommaD coch 14 1 01. ISSN: 0029-7844.
CY
            That od State
            .ormal: At
                                                          JOUFNAL ARTICLE)
DT
            Central; And Course TOUFN
Central Fer (TWIEW)
            inglish
LA
            The iged Ir in the Journals; Priority Journals
FS
            Face of all of Jack Distriction
EM
                                                              20:1
ED
                                                             - 21 May 2001
              at el or
                                                             May 2001
L11 .NS' .. '
                                                               TEDLING on STN
Full w.
AN
                                                             NF
                     al III
al IIII
an II
DM
                                                             on therapies for breast cancer: how informative are
TI
               )
                                                             retiles in medical notes for 'well-tolerated'
               C
             re men':
             ,el ve. `
ΑU
                                                             ela L J; Saunders C M; Houghton J
                                                             ol gy Gram, Royal Free & University College Medical
CS
            CRC
                         \mathfrak{I}\mathbf{y}' . \mathfrak{I}
                        and treatment, (2001 Mar) Vol. 66, No. 1, pp.
             5 21
SO
               26
               3.
               ou al 😁 🐇
                                                             4. ISSN: (167-6806.
               et 1 1
CY
                                                            OUTNAL ATTICLE)
DT
               DU:
                        7.5
                                                            ON U.S. GOVIT)
                       31
LA
                       -11-
FS
EΜ
                         -3
```

```
Fint red off of following the following following the following the following the following term of the following term of the following following the following following the following fo
                                                                      100
ED
                                                                       1 Oct 2001
                                                                         Se<sup>*</sup> 2001
            7. TSTOTR 11.2 + ---
                                                                          MEDLINE on STN
 Full ? 27
               2001154:3
 NA
               Publicd 1
DN
             Rancemia was also be accessed for the treatment of not reasness among works. It is only of breast cancer.

Jack son J. A. Roman J. A. B. Evans J. Klaus L.; Vahdat L.; Kinne D.; Lo K. M.;

Noor and A. Roman J. J.; Kaufmar E. L.; Neugut A. I.; Grann V. R.

Heriert in the management of the mail of the mail of the mail of the local college, New York NV 18-30 countries of the mail of the American Society of Clinical Dr. G. (2011 May 15) Vol. 19, No. 10, pp. 2739-45.

Journal for the treatment of not reasness among the treatment of not reasness.
TΤ
               Rancimi 🔧
                                                                     blok deresh for the treatment of hot flashes
ΑU
CS
SO
CY
               "nited 3 at
                 CLI IICA
DT
                                                         JOUFNAL ARTICLE)
               Journal: And (RANDOMT E.
                (RES JARCE L
                                                         . . ION-U.S. GOV'T)
               Engl:sh
T.A
               Priority Tom
               2001 6
EM
               Entered (17) 2011

ast Upgar : : 1 Jun 2001

Ontered (17) . Tun 2001
T.11
             ANSW IR . 3 . MEDLINE on STN
Full
                "ext
                                                         . ...NF.
               2001 136 - 3
NA
               PubM d ∷ :
DN
TI
               Phas I
                                                       thi d-generation selective estrogen receptor modulator,
               LY35 387. N
Muns er 7 7
                                                                   das atic breast cancer.
                                                       A; Dhingra K; Enas N; Ni L; Major M; Melemed A; ; Teriault R; Norton L; Hudis C
ΑIJ
              Seic an Hemo ial
              CS
SO
               Unit d State
CY
               (CLI 'ICF.' F'
              (CLI IC. Jour al Architecture) (MUL ICI II (RES ARCHIE
                                                                       SE I)
                                                                      TOU! NAL ARTICLE)
                                                                     JON-U.S. GOV'T)
               Engl sh
               Priority Jc 👉 🗓
FS
EM
               2001 5
                                                                     201
ED
               Entered STI
               Last Update : 17 May 2001
Entered Led : 1 May 2001
L11 ANSW R 12: 1 .
                                                                         MEDLINE on STN
Full
             Text
                                                                  INF
               2001 20
AN
TΙ
               Cogn ti
                                                                  n patma opausal women treated with raloxifene.
               Yaff K
Nick ls
ΑU
                                                                        Sa car B: Grady D; Barrett-Connor E; Cox D A;
               Depa tm
CS
                                                e stdoses of Raloxifene Evaluation Investigators).
                                                                       at 7, University of California at San Francisco,
               9412 ,
NC
               K23- 7C
              The Gw 1207 13
SO
                                                                       ma of markicine, (2001 Apr 19) Vol. 344, No. 16, pp.
               Jour al
                                                                      42. ISSM: 0028-4793.
               Unit n
CY
               (CTI L.C.
DT
               Jour i. (MUL (
                                                                     TOUT VAL AFFICLE)
```

```
(RAN DMICTO : THE TRIAL'
(RESMARCH: PRINCE NON-U.S. GOV'T)
(RESMARCH: PRINCE J.S. GOV'T, P.H.S.)
             Engl sh
LA
             Abri ge 2
                                                       / Jus Journals; Priority Journals
FS
EM
                                              Ente ed
ED
             Last Jr
                                                                          May .001
                                                            la 2001
             Ente 3d
                                                                     TEDLE On STN
L11 ANSW R
Full Text
                                                      - N.
             2001121
AN
             PubM :1 :
DN
             What ir ..
                                                            protoescregens in treating menopausal symptoms?.
TI
                                                                of Australia, (2000 Nov 6) Vol. 173 Suppl, pp. S97-8.
             Murk or A
UA
             The colora
SO
                                                          14. TSSM: 0025-729X.
             Jour al dor
Aust al :
CY
                                   i,
                                                              TOT MAL PRINCLE)
DT
             Jour al A
             Engl sh
LA
             Pric it: 5
2001 2
FS
EM
                                                      2.11
             Ente ed
ED
             Last Up' ..
                                                      : 2 Mar 3001
             Entered 1.
                                                              Feb 2001
L11 ANSW TR 11.6
                                                                     MEDLINE on STN
Full Text
             2001 19912
                                                   . INE
AN
             PubM i ID:
Rand mired A c adfuvant tamoxifen and/or goserelin in premenopausal brea tour a land physiological effects and symptoms.

Nyst it 4; A land G; Bolund C; Brandberg Y; Fornander T; Rutqvist L E
DN
TT
UΑ
                                                       cog: Radiowhemmet, Karolinska Hospital, Stockholm,
CS
             Depa in t
             Swed 1.
             Acta and 's a Stac't olm, Gweden), (2000) Vol. 39, No. 8, pp. 959-68. Journal and Stac't olm, Gweden), (2000) Vol. 39, No. 8, pp. 959-68.
SO
             Norw '
CY
              (CLI ...C.
DT
             (CON AR) TO Journ A
                                                             NOT MAR TOTICLE)
              (RAI CU ZEL + . . (REC NE H
                                                                OT U.S. COVIT)
             Engl : L
Pric : L
2001 :
LA
FS
                                    J.
EM
                                                      2 11 1.
                                   T
ED
             Ent∈ 3€
             Enterson 1 2 11 Mar 1001 Enterson (etc.) 1 Feb 2001
L11 ANSW R . . . .
                                                                     TEDLINE on STN
Full Text
             2001 78% a
                                                          I = I N E
NA
             Publica 10:
                                                    treloxifine on bone mineral density, bone turnover, the in early postmenopausal women: three-year data from low zed, elacebo-controlled trials.

Threson R H; Cohen F J; Shah A; Lindsay R; Mitlak B H;
TΤ
             Long to n
             and 21 n
2 dc 51 -b
        John to C
AII
                                                     Trison R H; Conen r U; Shan R; Dinara C; Christiansen C; W; Farper K D; Heath H 3rd; Gennari C; Christiansen C;
             Hust r
             Arna d' D'
CS Indi ia n
                                                   Gott of Medicine, Emerson Hall Room 421, 545 Barnhill
             Dr. ndin -
                                                                I + 202, USA.
                                                   n . d dicina, (Dec 11-25 2000) Vol. 160, No. 22, pp.
             Arch ver o
             3444 0
             Jeur
                                                        0. ISSF: 0003-9926.
CY
             Ur.it
              (C. .
DT
                                                                OF WATER PRICES
FOR THE CONTROL OF T
             Jo::
              (P.:
                                   3E
                                  i , . .
              (RI'.
LA
             Eng
```

```
Abrilged It in Archive Journals; Priority Journals
       2001 1
EM
       Entered Mer 3 1. Jan 2001

Entered Mer 3 1. Jan 2001
ED
L11 ANSWER 128 F :: MEDLINE on STN
Full Text
                           ......N2
       2001 541 7
ΑN
DN
TI
UΑ
       School of the Canterbile University, Nashville, TN 37240-0008, USA. Semi arc in the Cartering, (2000 Aug) Vol. 16, No. 3, pp. 214-25. Ref:
CS
so.
       67
       John Boom
Unit will at
John all At
(RES DROTES
                                   38. ISSN: 0749-2081.
CY
                                   TOT NATIFICATION (NATIONAL ASTROCT)
DT
       General Ret
       Enal sh
       Prichity Je
2000 h
                              · Jurning Journals
FS
EM
                        2001
. De 2001
. De 2000
       Entered . To
ED
       Last Upc ter
       Ente of her
                                        EDLINE on STN
L11 ANS. R 129
Full Terr
AN 20 52:35
       Pu'll of 10: in a
       Ralo mifone y or orine.
TI
       Snyder K R: Street N; Malinowski J M
Department i by acy Practice, Wilkes University, Wilkes-Barre, PA
1876; USA: Wilkesledu
American jo by ach health-system pharmacy: AJHP: official journal of
the American Scribby of Health-System Pharmacists, (2000 Sep 15) Vol. 57,
No. 8, mp. 716 7; quiz 1675-8. Ref: 27
John all doc 1980-823. ISSN: 1079-2082.
UΑ
CS
SO
       Unit of Stat
CY
       John All Ar
                                 JOURNAL PRINCLE)
       \mathsf{G}_{\mathsf{C}} := \mathsf{C} \cdot \mathsf{Re}^* \cdot \mathsf{C} \cdot \mathsf{C} \cdot \mathsf{C}^\mathsf{T} \mathsf{E} \mathsf{U} \mathsf{C}
       En . . !
T.A
       P1 :t. Jr
FS
EM
                         2001
1 : 30 Mar 2001
1 ar 2001
       Enterva 3T1
       Last Upfate
       Erice rad Tec
L11 ANAW TI 10
                                       TEDATES on STN
Full To to
                         \sim 0.01
NA.
       20
       Publication:
DN
       A broof return productable of
                                 the surmen' breast cancer prevention trials and
ΤI
                            ... and tals.
       Culla de 6
UΑ
                           na. Cos, Statistics and Epidemiology, Imperial Cancer inceln's on Fields, WC2A 3PX, London, UK..
       De no ment
CS
       Rown of Francisco
                            <u>ur</u>
corpor (Omford, England : 1990), (2000 Jun) Vol. 36,
SO
                             •
       Nc. 0, υp.
       John al coche
ENGLAND: Un
John al : Ar . . .
                             73. ISSN: 0959-8049.
CY
                                    ್ರಡೆಂಗ
                                    OU MAL ARTICLE)
DT
       Eng. sh
Prompt Ju
LA
FS
                          n\epsilon
       2
EΜ
       Et : 3T
                                   2 0
. 1 Atroj
               i at
                                                  0.0
                           )
                                    ា ១១១៩
                  1e
L11 A: 32
                                         TDI-I or STN
```

```
Full Text
           79
79:
70:
      200
                       Λ
                              -N\Xi
ΑN
                    0815
DN
      Pu':
                    ne i
                             ost enopossal patients with breast cancer experiencing
ΤI
      Oral
                            hot tlashes: a University of Rochester Cancer
      tamo ifen-:
                    duc.
                           t initial Optology Program study.
      Cent of Comm
                    nit.
      Panc J J J J Pil To
                             TS T F; T ynn P J; Hynes H E; Rosenbluth R J; Kirshner
                    ₹au.
ΑU
                             ~ga in V; Morrow G R
                    4 I:
      Univ a cy
Researc. B
                     R
                             stor Candar Center Community Clinical Oncology Program
CS
                             To: 14542, USA.
      CA37 :: 0 (N
NC
                            medicine, (2000 May 16) Vol. 132, No. 10, pp. 788-93.
      Anna c O_{2}^{2} lend Jour All dos : 01 Unit All Staff s
SO
CY
      (CTITICAL T IAL)
DT
      Jon 177, A2
(R. 7 ZE1
                    icle
                            JOURNAL ARTICLE)
                     CONT
                             ED TRIAL)
     (R'S AWH S
Encl ah
Ab. Ter In
                    PPOI
                             U.S GCV'I, P.H.S.)
LA
                     ex 1 Journals; Priority Journals
FS
EM
      2000
      Ente ad 37°
                      25 7 290
ED
                          . 200 Aug 1111
1 200
      Last a it.
Ente of la
                     on
                     .ne
L11 ANS:
                     11
                                  EDBILL on STN
               3.2
Full T
      2.5
AN
                              ^{-}N
              · ):
      P
DN
                    0732
            1. 7 c
                     trog
                             mer ptor rodulators (SERMs) in clinical practice.
ΤI
      S∈
ΑU
                             US edical Endocrine Division, Indianapolis, Indiana,
CS
      El.
                    d Co
      U. ..
     John will of the same aty for Gynecolo 7, N. 1 St. pl, S3%-46. Ref: 1 Journal 200: 9 - 06. TSSN: 1071-5 Unit 1 100 A victor TOUTMAN ARTICLE) Genc al Review; 1 */IF*)
End of:
                    he same sty for Gymecologic Investigation, (2000 Jan-Feb) Vol. pl, or SNs-46. Ref: 103
SO
                            -06. TSSN: 1071-5576.
CY
LA
FS
      P ( In J. rnal
          . :
EM
      2
      Ε,
           1.4 ST
                      5 Ì
                             3000
ED
                   on 7 : 5 May 2200
      Low Treat
                    ine: . . Apr. 2000
      Елсио Ме
                             HEDLING on STN
L11 AT W T 152
                    7 1
Full Taxt
      2000 - 7-17
                              ENT.
AN
            : 2:
DN
      P. oM
                     )71.
                            the former of the comprection and tamoxifen treatment for breast
                     ocia
      C ( - 10)
           2" - 1"
                     :mei
                            Pisch Vierramese women.
                            i; 'Cuye: 2 B; Nguyen V D; Havighurst T C
is asia Comprehensive Cancer Center, Madison, USA.
ΑU
      Ι. .
                     ıyeı
                    :y c
CS
      T
               30
             , 54
      1 "
NC
              111
                             and and assatment, (1999 Dec) Vol. 58, No. 3, pp.
SO
      E
                    r re
      2
      J.
                    : 8.
                             4. ISSM: 3167-6806.
                70
      Ν·,
CY
             . · 10
             CT T.
      (:---
                     IAL'
                            .UCHUMAI SVICLE)
      J. ir
                     icla
                             GEOURIA
... GOV (. P.H.S.)
      (PAN - M 33
                     CON'
      (. 35
                     οPO.
      E ]
LA
      Pir
FS
              ...
                     :nal
EM
      2
      Ε.
ED
                37
                      21
                            - 5
                      on : Apr 1100
ne: A: 200
                35
      Ι.,
      E
                AC.
                     ine:
L11 A' 5 7 154
                    F 1.
                               WEDLINE on STN
Full T
```

```
0687 :
tion ' had Ideades reported by healthy postmenopausaling omtion placebo during osteoporosis prevention
                     2000 %
PinM. Wi
 DN
  TΙ
                      Charmatteni
                      wise inde
                      tra . .
                     Cose F 7:
Lill : T. Te
 ΑU
                                                                                                   ndianapolis, IN 46285, USA...
                                                                       ch ?
 CS
                     7.C: 2001 34, No. 1, pp. 65-73.
 SO
                                                                     : 71 · · ·3. T55<sup>w</sup>: ·378-5122.
                      Irel - d
  CY
                       (COM. PRETT
                                                                          ST( )
 DT
                                                                                              /JOHANN METICLE)
                      Journa": Ar
("ES" III : :
                                                                       \mathtt{icl}\epsilon
                                                                       PPOF
                     E 31 i.
 LA
                     F for thy C
 FS
                                                                       rnal
                     20.015
 EΜ
                                                                   12 1 2000
on 11 May 1000
ine: May 2000
                     Ende ad ST
Lat Macat
 ED
                      Ente ma Me
 L11 ANSWWT 135 F 18
                                                                                            MEDLINE on STN
 Full Text
                     20.0 110.7
PubMe . 10:
                                                                               -1 , N \oplus
 AN
                                                                       0680
 DN
                                                                                                    Fig. 1.75 to a der in the older patient.
 ΤI
                     Chemon 5.575
                                                                       ion
                     Mint . : 5
 ΑU
                                                                                                 n. W. We Moffitt Cancer Center and Research Fey T south Florida, Tampa, USA.

clinica of North America, (2000 Feb) Vol. 14, No. 1,
                    Doa ::
1 st :: ',
                                                                       niv
                    He has the problem of the problem of
                                                                       nco"
                                                                                                Re
                                                                     : 8 ·
 CY
                                                                       s
                                                                                          : AC TRAINS TICLE)
                                                                       iclo
 DT
                    G 10 : 20
E: 1 :: 20
                                                                       ew;
 LA
                     P: 0 1 2 3
2000 3
 FS
                                                                       rna.
 EM
                                                                         27 25 25 00
on 3 7 27 May 300
                     E teird ST
 ED
                     L st Tack.
                     E te
                                                                       ine. ( Not 20)
 \mathbf{L11} = \mathbf{A}^{*} \cap W \cup \mathbb{A}^{-5/5}
                                                                       F 1
                                                                                                               HOLL on STN
1...DL N/ +
                                                                       066!- 30
                     A distrog ser-unomifon, SPRMs and beyond. Distraction
 ΤI
 ΑU
                     H functa oche Ind., Mutley, NJ 07110, USA.
 CS
                     I so thightenal ew doings, [1999] Vol. 17, No. 3, pp. 285-311. Ref: 247 Journal con : 81 9300. ISSN: 0167-6997.
                     U ite 5 : J iri
 CY
                                                                   S
                                             icl∈
ew;
                                                                                            (ACCOUNT OF TICLE)
 DT
                                                                                              F***
                     G ne
                     F : 11 . . .
                     F.o + rnal
 FS
                     2 0.
 ΕM
                     E^{-1} \leftarrow
                                                                         29 <u>a</u>b .
 ED
                     I . . . . . . .
                                                                                                                       17 - - 7100
                                                                       on IN
                                             ine 17
                                                                                                                    310
                                                                                                               on STN
L11 A ....
                                                                       F 1:
 Full 7
                                                . " IC 1
 NΑ
                                                                    in the control of the
 DN
                     F M
 TI
                     A 1pt
                     7 1
1 1
 ΑU
 SO
                             11
                     F ....
 CY
                                                                       ted in .
                     I :
 DT
 LA
```

```
FS
       Priority Jurnal
       2 )0: 1
EΜ
       Elberod ST: 9 Nor 200
ED
       List Upoat ton TN: 5 Mar 3000
Else and Mo line: 24 Fe 2000
L11 ANSV
               FIGURE ON STN
Full Teve
       20 ....
ΑN
                           i DL 📆
       Pu M 1 . 1: 063. 10
       Pilot till of the earty. Clerability, and retinoid levels of
TI
       N-(4 lease phen 1) we its a le in combination with tamoxifen in patients at he is it for declaring invasive breast cancer.
Conference Shau hness S: Feindiville S; Lawrence J; Chow C; Jones E;
AU
       Marie F. C. Kais r-Thylett & T; Caruso R C; Podgor M; Goldspiel B; Venzon D: F. Month D; W. Se Worter J; Goldstein J; Cowan K H; Zujewski J
       Garaban ance Carar, Divisions of Hematology and Oncology, Department of Maicine, University of Maryland School of Medicine, Baltimore, USA.
CS
       Journal of claim al carology: official journal of the American Society of Clinical to cology, 20 0 050 Vol. 18, No. 2, pp. 275-83.

Journal of it 80 9333, ISSM: 0732-183X.

Unit of the os
SO
CY
       ( 'LIBLUAL STAL)
DT
       Jour ale A micle (COM MAL EXTICLE)
       Engl na
       Priority d. irnal:
FS
EM
       2. 10-
       Fine Fig.: 9 F b 200
List Medatel on TN: 7 Feb 2000
\mathbf{F}D
       F. e od Merline: 2 Feb 2000
L11 A 10 T 355 OF 18
                                     ! EDLINF on STN
Full 7 ...
AN 2
                             F OF N
       2 1 1 1 1.31
P 1 1 1 1 3 1
                       o550 36 pha a 17 mial of exemestane as third-line hormonal therapy
DI1
       M to entre
TI
       o potrom
Gra
                        ausa, wen a with metastatic breast cancer. Aromasin Study
       Jone 3 Morel C. Ankorpov T; Fehrenbacher L; Eisenberg P; Cooper B; Honig
ΑU
       So Poly What y is a Salle E; Tiffany J; Consonni A; Miller L

U.S. 1997 Re Barri 25 Fe for-Sammons Cancer Center, Dallas, TX, USA.

Consont flini alor plost: official journal of the American Society of

Consont floor, 10 Nov Vol. 17, No. 11, pp. 3418-25.

J 1997 L 20 21: 83 9333 TSSXx 2732-183X.
CS
SO
       U 4 3 8 2 38
CY
       DT
       (US RULE IPPOIT, NOT U.S. HOV'T)
       E 1 ...
From two urnal
LA
FS
       2 .0.
EM
      E re . STT: 31 an 1000
1 of Theat 3 on TN: 1 Sep 2001
E r . 1 Mc line: 18 Gar 2000
ED
L11 A TWO ISS OF 18 MEDLINE on STN
NA
                         1 DLTA
                      .0531 52
       Fi'
DN
TI
                                          ST.3 - ....
                        Ior: V
AII
                                      of last Co., Eli Lilly Italy, Firenze, Italy.
nvestigation, (1999 Sep) Vol. 22, No. 8, pp.
CS
         1
                        easc . ..
CZ
                        endor in-
       \epsilon
                       · 27
          11.
                                          2391-4097.
                       :: 7€ 35
CY
                                ( TICLE)
                         icle
       (
                        ew;
                                RΕ
LA
       F.
F.:
                        irna
```

```
ΕM
     19:0
      E e nú STM: 11 an DC C
Lot indated on TN: 17 Jan 2000
E e ed Medline: 17 Mars 1090
ED
L11 AN. WWW. 148 OF 18. CEDLINE on STN
Full Tem.
              F DLT
       19991
AΝ
              10520 16
       P 1 11
       [es and finite national all clinical trials with raloxifene].

Reduced to les el der der init as internationales du raloxifene.

Agnument Liu- eager ; Alexandre-Ferrante B
ΑU
               Flor te. talie. agnusdeidonato@lilly.com
endoct no restation (1999 Sep) Vol. 60, No. 3, pp. 242-6. Ref: 18
le: 01 577 (1833) 0003-4266.
       Eli
CS
       P 14.3
       Jan 1
       (TMG TGH BSTRAC )

Jour ; feticle (CCT WF FTICLE)

Gen view; RETAL
DT
       \mathbf{F} 1.31
LA
FS
       Price
                     ourna'
       1999
EΜ
              N: 11 an
2d on TN 3
3 iline: 23 3 3 3
ED
       E \cap {\mathbb C}
                                                000
       Lat
       Eite
L11 AMSW 1 43 OF 18
                                      SELECT ON STN
Full T M's

AN 1 15 1 16 1 1 10424 02

Trial of Gi
     women with metas atic beas cancer. An updated analysis.

Pick ambayam P Po Ingl. J W. Suman V J; Hartmann L C; Loprinzi C L
Mayo Charle and ource ion, Rochester MN, USA.

NOI- Tolk 44 (NC)
       Rand thizen trial of of thylatilbestrol vs. tamoxifen in postmenopausal
AU
NC
       Bread concer no earch and seatment, (1999 Mar) Vol. 54, No. 2, pp.
       117- 1:
       Jourtal mode: 87 1104. ISSV: 0167-6806.
       Netherlands (CLT SF CRIAL)
CY
DT
                    sticle (CC. MAD **TICLE)

CONTOLIS CANA

SUPPOR , I. THE CT, P.H.S.)
       Jou!
       II (AS.)
       ( 'F'
              ٠٠(
LA
       Eg.
              1
       Pri ·
              :7
FS
                     ourna?
EM
       199.
                     N: 21 ap :
ad on TN
dline 3.
       Ent .
                                         7-5 799
       Las:
       Ent·
                                      : Cn STN
L11 ANS:
               OF 1:
Full Text
       1997 If the TODETWO Public To 10402 75

Tat the acute estimate difficiency and psychiatric syndromes in breast
DN
TI
       can relients.

Duf Green ere in a sachusetts General Hospital Cancer Center,

Bos (1.14, Uf)
ΔĦ
       Psychotics, 1909 Markey) Vol. 40, No. 4, pp. 304-8.
                     de: 01 65 %. SOT: 0033-3182.
       Unit
CY
                    tes
DT
       Journ
                    rticle
                               (.C FIL HITICLE)
       Engl . .
LA
FΘ
              ____ournal
       Pric
E. :
       199
               1 V: 27 ug : 1

2 ed on TN: 1959

1 line: 17
EΔ
       Ent.
       Las
       Fnt
L11 /NS
                OF 1
                                .: : on STN
F::11 7 2X
```

```
1999 101 N DL
PubM I 10214 33
                                                                             i DL ..
AN
DN
                     Adversa ments mooth to by jostmenopausal women in controlled trials with
 TI
                     ralow'fers.
                    Davis G ; Hust r M & In ; Plouffe L Jr; Lakshmanan M Lill Re arch M books ries. Eli Lilly and Company, Lilly Corporate Cent. I diana; lis, addison 46285, USA.

Obstantia and c new Mr. 1999 Apr) Vol. 93, No. 4, pp. 558-65.

Journal T de: 04 1177. ISSN: 0029-7844.
 SO
                     Unite States
 CY
                    (CLINICAL TRIAL)
(COMPARTMENT Y)
(CONTROLLED CLINICAL TITAL)
JOURNAL; Article (JOY FAL ARTICLE)
(RAM TITALD CONTROLLE TRIAL)
DT
LA
                     Abri
FS
                                            ed Index & dict Journals; Priority Journals
                     19991
EM
                     Ente i N: 1 i n
ED
                     Last
                                              )(
                                                              ed on TN.
                                                              dline 20 ' ' '
                     Ente l
                                                                                                         TENER ON STN
                 ANSW.. 5 . OF 18
L11
Full Text
                                                         Y DL Y
ΑN
                                                       10191 65
DN
                     Pub∷
                    Ask ctor. Iv a ching tamoxifen for several months after compact treaten to law st cancer. My doctor prescribed it primarily to law my rish of employing cancer in my unaffected breast. As a result
TI
                   of concentration of the management of the state of the st
                     stop: no the tak wide. And there ways to deal with the side effects?.
ΑU
                    Nichosco C R
                   Harveries men's eath satch (1999 May) Vol. 6, No. 9, pp. 8. Journal code: 94 3177. ISSN: 1070-910X.
SO
                   Uniter States
Journal: Article (JOU WAL ARTICLE)
CY
DT
LA
                    Cons : .: Tealth
FS
EM
                     1999
                   Entered C.N: 12 Jul 1:0
Last Speaked on TN: 1 Jul 1999
Enter 1 Tidline: 22 On 1899
ED
L11 ANSW
                                           3 1 OF 12
                                                                                                                       I'll E on STN
Full Sext
                                           FIGURE 10068 18 Figure hydrochloride in women.
MA
                     1999
DM
                     PubM-
T:
                     Clin
                                                                                                                        • .;
                                            Trait W; hole
Α; ,
                    University of Californ A. For Francisco, and Veterans Affairs Medical
CS
                     Cen 121, t A.
                                                               NIDDK;
NC
                     DK 4
                   Zhni
SO
                                                              inter: 1 m: 2012 (1999 Mar 2) Vol. 130, No. 5, pp. 431-9.
                    F∂f:
                                                               de: 01 23.1 14.11 0003-4819.
                     Jour -
 CY
                    Unit
                                                              tes
                                              W . VE STUY)
D^{m}
                     (COM
                                               rticle (AC - DTICLE)

(C SUPPOI , TO TO AC ACVIT)

C SUPPOI , TO TO ACVIT, NON-P.H.S.)

C SUPPOI , TO TO TO TO TO THE SUPPOI , TO TO TO TO TO THE SUPPOINT T
                     čour:
                                         . .30
                      (RESI
                      (REJ
                                                                                           RE:
                     Cana
                                                               view;
                   Fig
Lir:
LA.
                                                              FS
F. .:
                     1.9.
                                                         N: 16 ar 10 company and a most allowed and a most a
                   Ist.
                    I it
L11 TIST
                                            I OF 1. OF THE ON STN
F: 11 'x'
```

```
1999 :
                                     10DITE . 9928. 5 differ nt d var therapy strategies on quality of life in
\Delta N
DH
             PabM
             Impa· c
TI
             licea. c
                                     cer sı vin r.
           Recent rults: c.c. arch. Fortschritte der Krebsforschung.

Programs ler recent uit le cancer, (1998) Vol. 152, pp. 396-411.

Journal de: 00 46 1. 75 2. 0080-0015.

GERMANA Lermany Friends sublic of (COMIC VE STI Y)

Journal of the cancer of
ΑU
CS
NC
SO
CY
DT
            Journ
             Journ rticle (T UF VAL TICLE)
(RES. RG. SUPPOI , NAN-A.S. JOY'T)
(RES. RG. SUPPOI , U.S. GO'T, P.H.S.)
            Ingli h
LA
FS
             I rio . Nournal
             1 199.
E:
             Enternal 3 N: 26 Lar 1915
EL.
             Last 'no red on 'TN: 26 Mar 1999
             Fate : dline: 12 Man 10.4
L11 ANSWY 5. OF 18
                                                               NUMBER ON STN
Full : xt
AN 3 -99
                                                JI E
DN
             11d: 1
                                       9881. 1
                            of earch name on tiestrogens in a rat model for hot flush.

' ler I Finch (1988) (M; Carver J M; Lundeen S G; Ghosh K;
TI
             : ie
          Mirc
LΤ
                           1 *
            ! nr
                           j.
                                      C
                                      Morpl low I'm, Women's Health Research Institute,
          Linc
                           Σ.
                                     st Rec are , Mile M, PA 19087, USA. Merchel@war.wyeth.com (1997 No. 160 70 30, No. 3, pp. 307-16. de: 70 737 . 60 .: 6278-5122.
           Tret N
           r tu
                           7.4
            Jan.
CY
             Irel
             Jours L.
                                     rticle (MUF / TRICLE)
\mathtt{DT}
            Englin
LP.
F. .
            I ic
                                     ourna.
            1 799
Eiv.
                                    N: 13 pr .99
            Fite
            list '
                                  ted on TN: 13 Tr
                                                                                    559
             late i dline: 26 Lai Li
L11 / JSW : 3 - OF 18
                                                              Notice W on STN
F: 1 | x | 9 |
                                      I DI ME
                           9881. 3
            I bi:
DN
            Last our mausal omen and outcoporosis: available choices for maintenance of some out heal h_{\rm s}
'JA
             Serming 3 D; Work M
            I ll" Remarch I bonate what Eli Lilly and Company, Indianapolis, IN
C.
                           · 3 .
            z 528:
                                     (1996 No. 16 30, No. 3, pp. 241-5. Ref: 42 de: 7: 73 . 14 (378-5122.
SO
            r tu
            c .ur
CY
             .el
                                 inticle (C. UF to D. TICLE)
DT
            cour
                                     view; RT EV
            Cinc
L.
             : g]
                            1
F.
                 ic
                                      ourna.
\mathbf{E}
                90
                                     ED:
               t€
             . s.
             : item
                                       OF 1
                                                                N. n STN
L11 / .!S'
F. 11 5 -xr.
A:
                 90
                                     9861 3
placer. it
                                                                E
DI.
                b.
· T ·
             r
                                                                h\epsilon
                                                                         breast cancer: revisiting the issues.
A::
                                                                7
                 Gi.
                                      M W; 21
                                                                       to, University of California, Sacramento
C
            I pr
                                      of I 2r + 1
                . 8 7
                                      . <u>mw 11</u>
3 (NI: 5)
                                                                                <u>a∵is.edu</u>
                                                                 <u>01</u>
             1 137
                                     3 (NII
```

```
SO
            Unit ... tes
CY
                                 .rticl. ( 'UR , ATICLE)
SUPPOI , S. 65 7 , P.H.S.)
DT
            Journ
            (REST
                                    view; RF TEW
            Canet
            Figl: 1
LA
FS
            Frior
                                    ourna?
            1999
EΜ
           Enter : N: 15 an 99 Last ed on TY 15 an 1919 Enter : dline: 6 an
L11 ANSW OF 19
                                                               M on STN
Full Text
            i. DI . 'E
AN
                             98151 1
            Fibly. 98155 4
Plas Tudy ( voroz) o 283842), a new aromatase inhibitor, in
DN
ΤI
            postune rusal wimer with thanced breast cancer in progression on
            C ss [ ] Clark M. Ameur [ Weizel H A; Wadden N A; Crump M; Walde D;
AU
           Tre I :: The Cost of Fig. Bray and S J. Erean Cost of the Toronto Hospital, Toronto, Ontario, Canada M5G 2C4.
Clinical cancer research: in official journal of the American Association for Cancer Research (1905 Par) Vol. 1, No. 3, pp. 287-94.
Journal mode: 95 2510. 198 % 1078-0432.
SO
CY
            United Contes
           (CLICA TRIAL)
(CLICAT TRIAL, PRASE CONTROL OUR CANADA CONTROL OUR CANA
DT
                                                                                  TICLE)
                                 ER STO I
             LUL.)
                           STORY SUPPORT OF THE STORY TO
            ( DES
            F gl
FS
           I ic
                                   ourna.
EM
            1 99
                                   "N: 23 al 199
            F.t∈
                           I st
                                                                                    909
            F.te
                                                              M . . . . oa STN
L11 AMSW
                                  2 OF 10
Full 7 xt
                          1 198
AN
DN
            Fibl*
                         as adj ward alter surgery for breast cancer and tamoxifen or
ТT
            T mo
            place of the chemicare into the healthy women: different compliance with
            t eal :
UA
            Vr
                                  o; Pizm chemita de la Ferlante M A; Zottar M; Magri M D; Crivellari
            I I we es
CS
            ľ vi
                           at of Preventive Omcology, Centro di Riferimento Oncologico, Aviano,
            I al…
                              1998 Ma -Chi) Folk (4, No. 3, pp. 372-5. code: 07 13 %. FASTA 0300-8916.
            T mc
SO
            Jour :
            ī al··
CY
            / LIT I
                                 TRIAL)
DT
                                                      (COUR TO I
            ĩ ur
                            rticle
                                                                                 RTICLE)
           ("A"
E g'
F ic
                            I ID CONT DI D . .
LA
FS
                                   ourna o
            1991
ΕM
                                   "I: 20
            E 15.
                                                                99
            I \in \mathcal{C}^{-1}
                                                                20
                                     ad on
                                                                                    993
                                    ∃line:
            F to
                                                               .ug
                                                                M
L11 F 'S!
                                   3 OF 10
                                                                                     cn STN
Full ' 3' A I
                                                               Έ
D^{-1}
            I bl
                                      9617
                                  sc II. 10 of 2-19 in patients with advanced or recurrent correspond to 2012 dose finding study.
           F rl
ΤI
            } ∋,
                                    Tomin
                                                            · ¥
ΑU
            I y
                                                           ic
CS
                                   orger:
                                                                             √ageγa Hospital.
```

```
Gan to it take my how Cartest & chemotherapy, (1998 May) Vol. 25, No. 6, pp.
SO
      853-6
                  ode: 78 0034. ISSI: 0385-0684.
      Jour::/
CY
      Japara
       (ULIYURA TRIAL)
(CLIYURA TRIAL PERSECTI
       (:NGI
                  BSTRAC.
                  rticle DUR ARTICLE)
      Jari
      (UL.
      Japan .
I_{i}A
              · Journa!
FS
      Frio:
EΜ
      1398
ED
      Fite
                  TN: 25
                           <sup>-1</sup>1. 199
                  ted on 11 25 htt. 1993
edline: 11 Jun 13 8
      Last
      Inte
L11 AMSW"
                  . OF 1:
                                M NE on STN
Full 7 xt
                        I DI NE
      1 98
NA
      F 15H 1
                 : 95801 -4
      Tree 1 a and I to zol
                                     for advanced breast cancer.
TI
ΑIJ
      F on:
      Te with all lett to a down and therapeutics, (1998 Apr 10) Vol. 40, No.
SO
                  43-5.
      1)24.
                code: 29 52 OR. 11'N: 6025-732X.
      Court
CY
      Unit did ates
      Jury : Article (DURL & ARTICLE)
DT
T.A
      F.ql
      Forigo Index M digus Formals; Priority Journals
FS
      1 '98 '
EM
      F to 1 (TN: 20 ) ay 1998
I st Undited on TM: 20 May 1998
E ter 1 redline: 12 May 30/8
             " 5 OF 18
L11 A. SW
                                 MININE on STN
Full Tout
AN 1 38. 2 in N NE
DN F bN 7 " : 9576% 2
              es in presente al women treated for breast carcinoma:
e, sevente, con plates, management, and relation to quality of
      F t
TI
      ] fe
                J S; P Brokow M A; Cordova M; Cunningham L; Studts J; r D; Slc i c; M co R t of Bo co prafessionnee, University of Kentucky, Lexington
UΑ
      C rp
                                        M A; Cordova M; Cunningham L; Studts J; McGrath
      E \in K
CS
      I pa
                  5, USA
      4 50
                                Vo . 2, No. 9, pp. 1682-91.
                 1998 Ma
SO
      C ha
      J in
U ill
C in.
                  oda: 03 1/3. // 1: 0008-543X.
CY
                 ates
DΤ
                 Article 'OUR' ARTICLE)
      1 gl ...
I di ... Index II di lus de Linals; Priority Journals
L.A
FS
EiM
      1.38
      Finte ( .TN: 29 to 199
I st in ted on 7.1 29 to 1998
Finte ( ... edline: 4.5 May 198
ED
                                M : NE on STN
L11 F 'SW . S OF 18
Full
              1.8 1.01
1.95225 7
                       I. DI TNE
NA
              of let a soletime a commatase inhibitor for the treatment of breast
      7 :::
TI
      C 1.3
                   alKhor .
ĽA
      ł
      5 10
                  Fharm
                                1ar
                                        bb Fandolph Cancer Center, West Virginia
C3
                                       6-9520, USA.
                  y, More
      v_i = J
                                ٧n
                                        system pharmacy : AJHP : official journal of
SO
                  jourae
      1 25
                                ıea
                                        1th System Pharmacists, (1998 Mar 1) Vol. 55,
      t e
                  den Bei
                                of
                 \epsilon_{x}=(\frac{1}{2}|\epsilon_{x}|)^{\frac{1}{2}}=\frac{\epsilon}{2}
      ŀ
                                ₹ef.
      Jur
                 ode: S!
                                3.
                                        : 1179-2082.
CY
      ιit
                 ites
                  Anticle
DT
      Č 1.
                                JUF.
                                        ARTICLE)
                   SUPPO.
                                     . . GOV'T)
                                - MC
```

```
General aview; ? TIEW
 T.A
       Figl. .
 FS
       Fic : Journal
       1 98
 EM
                         37 199∃
T 29
 ED
       L ter.A -TN: 29
                            29 / 1998
       I st Twited on
      I te dline:
                             May 8
 L11 F !SW 7 OF 15
                            M LNE on STN
 Full Text
       IC. I
 DN
 TΙ
       Voro:
                 (Rivizo
                         ٠:
                                  ve and well tolerated new aromatase inhibitor
                             aп
       f.r '.
                 reatmen
                              admined breast cancer patients with prior
       timo 😁 🚁
                             Inv gational Drug Branch of the European
                 exposi
       C galary ion for the earth and Treatment of Cancer (EORTC) Breast Cancer
              ' ve Groi
       C or
                            m A ... M; Klijn J; Houston S J; Beex L V; Vinholes J; m A ... ngenaeken C; Van Glabbeke M; Piccart M J Gas ... sberg, Leuven, Belgium.
 UA
       Fri
              1 R; Ro
                 Van Vi
       I ni:
 CS
       L· iv.
                 y Hospi
                             199 n) Vol. 9, No. 1, pp. 29-35.
 SO
       I ti- n er druc
                             3.
                                    ·: 0039-4973.
                 ode: 91
       c ur
 CY
       I GL.
                 Jrited
                             nof.
       LII
 DT
                 TRIAL
       (::LI: :/
                  TRIAL,
                             ЗE
       ( OM / R IVE STO
       Journa
                             OUR : ARTICLE)
                 Article
       (MUL " DO DER STU
       Frgland
       Frichty Journal
 FS
 E/4
       3 98
       Fiter I IN: 30 or 1997
Instituted on 170 30 And 1998
Fiteres redline: No Apr 1198
 ED
1 L11 / SWEET . 3 OF 13
                             M. T. NE on STN
 Full 7 xt
       1 98109515
 NA
       P.bM. : 9469. 4
 DN
 TI , L fe of t break
                          nce: inderstanding women's health-related quality of
       lile w sexual
Com III Rowlan
                          tic :
                            H;
                                    iond K; Meyerowitz B E; Wyatt G E
 ΔH
 C.3
       t iv
                 / of Ca
                                    os Angeles, School of Medicine, Jonsson
                             rni
                                    , 90024, USA.. pganz@medl.medsch.ucla.edu
                 sive Ca
       C ar
                             C∈
                 35. BE
       F 1
                 f clin:
                                  y : official journal of the American Society of
 SO
         177
                             onc
                                   b) vol. 16, No. 2, pp. 501-14.
                             199
       Cin
                 Ondolec
                                  : 0732-183X.
         ur
                 ode: 8
                             3.
       l it.
 CY
                 ates
             ... Articl
        Ir.
                             JUC
                                     ARTICLE)
             C - SUPPO : ,
       ( ES
                             . S .
                                    ∵T, ⊃.H.S.)
         gl en
 LA
       F
 FS
                 Journa?
       1 ; 5
 EΜ
       E to.
             i
                 IN: 12
                         : 199
       I:3'
                 ted on (11: 12
                                    : 1993
                 edline: ? ar
                 3 OF 11
                             V_{\perp}
 L11 /
                                    INE on STN
 Full
         .... F.
 ΝA
                             ΝE
 D:1
        111 :
                 : 94691
                 ze eva¹ ··
 TI
         ٥£
                             on 🗠
                                    mitamin E for hot flashes in breast cancer
         rv
                            C reguella S K; Sloan J A; Veeder M H; Egner J R; ; Strond D K; Vaught N L; Novotny P
 UA
       F rt
                 L; Lope n
       1 43
                 Ste_1
 CS
                 ic and an
                              For tion, Rochester, MN 55905, USA.
                 IDM)
 NO
         - :
       (
         - .
 SO
                 131
                                  y : official journal of the American Society of
                             onc
```

```
Clin's Dracks 199 (b) Vol. 16, No. 2, pp. 495-500. Journ (bde: 31 1.3. 1 7: 0732-183X.
     Tit Tites
CY
     (AS" TO DETS.
(LIU. 18 TRIAL)
Cur de Article
DΤ
                            OUR - ARTICLE)
     AN' ED COM'
(ES 1 16 SUPPO)
                           .ED .T)
      ( .ES < 30
                           '.S. /'T, P.H.S.)
                SUPPO.
     Engli.h
     Priority Journal
FS
     1998:3
ΕM
     Enterna TTM: 12 on 199
Last United on TTM: 12 Nor 1993
ED
     Entered ledline: 2 dar 1953
L11 /"SW" 7 OF 12
                           MILLINE on STN
F:11 T &t
AN 1:38
                         , , NE
            9335
     P pM
                finalc. In elo
     E fe "
                                   one mineral density, serum cholesterol
     conc
               tions, a ute
                                   endometrium in postmenopausal women.
AU
     Delm .
                ); Pia.
                            n N
                                   Mitlak B H; Ravoux A C; Shah A S; Huster W J;
                C117^{-1}.
     Drap .
                           ∍n
                douarro
CS
     Норі
                            iot
                                   TSERN Research Unit 403, Lyons, France.
     The
SO
                na]env
                            na]
                                   medicine, (1997 Dec 4) Vol. 337, No. 23, pp.
     1.11 . .
               2.
     č.cur
                                   f: 0008-4793.
CY
               រ. មេខ
     Uit
     1 51
                TR^{-}M
               រងគេ នា
                            OUF .
                                   ART CLE)
      .. JI
                JER SW
     (PAN AUTHOR COMPLETED AL)
               SUPPO ON- GOV'T)
     Engl : a
T.A
     Abri sec Index : dous comals; Priority Journals
FS
EM
     1997
     Entered TTN: 9 Cm 998

Last Tor led on 17 3 2 2000

Entered eddine: 4 Tec 27
ED
L11 / HSV . 1 OF 18
                          MRO. THE on STN
Full : xt
          117 j m 3
1 9342. s
                      10 J NE
     F oil
     Threshold in the littinop will breast cancer. Efficacy, safety and cost.
TΙ
     M. en (Depa
               \mathsf{U}_i \; \Lambda_i = \mathsf{si}^{\mathsf{T}}
ΑU
               t of C
                           ric. and Gymecology, University Hospital, Tampere,
     Dєра
     Finl . .
     Drug 🗀
SO
                ging
                            Oc.
                                   Tol. 11, No. 4, pp. 261-70. Ref: 53
     Joui ...
                າດວະ 11
                           4. : 1170-229X.
CY
     New ·
                ı.ci
                Autic :
                            OUF ARTICLE)
DT
     Jour a
                artiore.
                            IEV
     Gene
     Engl
               المراجبين المراجبين
\mathbf{F}
     Eric
F 1
     1.97
     E t∈
                ∷: છે. ે 99€
E \supset
                Legis To
     I st
                        . 9
                                   1909
               Cacline. - 'ed
     E.te
             7 7 OF 1.
                          NE ONE STN
L11 ANSW
Full
     Tex*
     974:
AN
               . 2211
     Publ
                ាក់និង ប្រ
                                   1 of tamoxifen versus ovarian ablation for
TT
     A ra
                            er
                1 327
     meta
                            1C€
                                   primenopausal women: a report of the National
               atiftar.
     (and
                            Car
                                    Clinical Trials Group (NCIC CTG) trial MA.1.
               A"I
                                   Shelley W; DeBoer G; Paterson A H; Meakin J W;
     S WF
                            K
     : tl
                amyb.
CS
     '. rc
                            egi
                                     Cancer Centre, Ontario, Canada.
SO
     F 321
                11 21 10
                            ch
                                 treatment, (1997 Jul) Vol. 44, No. 3, pp.
```

```
211-7.
       Jour &
                  .au: 10 . 1. . . 1: 0167-6806.
CY
      Nath .
                   ς;
       (JLITTA
                   778.77
DT
                  *****
       (LOM
                  TO COMPANY (SED LL)
                            OUF . DARTICLE)
       Jour
       (RAET TE
       Engliss
LA
      Priority
FS
                  Tours
EΜ
       19971(
      Entered IN: 13 to 199
Last Up Sted of IN: 13 to 1997
Entered spoline: 1 ot + 7
ED
L11 ANSWAT COF '
                                 M TNE on STN
Full 5 ext
       9 736
      9/36 74 MW III 1
PubM 3 To: 92201 7
A:1
DN
      Fitter and two sites of stronger. For the treatment of hot flashes.
TI
      Lace to a specific stray W M
      Department of Pl rricy Sarrices, University of Massachusetts Medical Center, Mordester ( 655, USA.

The Annels of plane cota tapy, (1997 Jul-Aug) Vol. 31, No. 7-8, pp. 915-7.

Journal offer 1997 1. 1994: 1060-0280.
·SO
                 nt es
CY
      Unit:
      Jour. 51; Antida
                              OUF ARTICLE)
DT
      Fig. : .
Fic :
LA
                  forturn (
FS
      1 197
EM
                 777: 3
      Fite · ·
                                199
                  e 1 0
                                3
                                         2000
      I .st
                  4.5
      l it∩
                                Ser
L11 / 'S''
                  or :
                                 Not in the on STN
Full ' ::
      3/30 175 N. A
      Tublid : 9165: 1
VA
DN
                                es .
TI
                                        coremifene.
      F + η<sup>m</sup> :*
ΑU
                            ill. Aliant Health Systems, Kentucky, USA.
Par (1.Y.) (1997 May) Vol. 11, No. 5 Suppl 4, pp.
      University of T.
CS
      Clackers Milli
SO
        anni i
                            9. 1: 0390-9091.
       Cour
      thit stands
communication (RES ARC SUPPO),
CY
DT
                                OUF
                                       ARTICLE)
                                ON-'... GO'.'Τ)
      Consol Pariow; Rollew
E.g. sa
LA
      Fric ity Journal...
FS
EM
      Entaied CTM: 5 Prop 1997
Last Uprolocal on The 5 A . 1997
Enter Circle adlance . Jul 107
ED
                    ~ r. -
L11 / NSF 3
                                     INE on STN
                                 N.,
Full 7 2 42
AH 42
DN F
                                £ (
                                         .694... (fadrozole) versus tamoxifen in
TI
      Α.
                  . ...
      p:
                                 рc
                                        mora sal patients with metastatic breast
      C Tall 1.
ĽA
      Fal
                                 Η
      Dep:
                                         ogy, University of Pretoria, South Africa.
                                1 C ·
C.3
                                         al firmal of the European Society for Medical Vol. 7, No. 5, pp. 465-9.
                                of.
SO
      F.n.
      Clack of the
                                36
      c u··
                                5. .
      lat!
CY
DT
      SE
                                         ART " TLE)
                                JUE
       C U111
                                       . L)
       (. . .
                                ΞD
                                          GCT (T)
       (F
                                NC-
```

```
LA
                                 English
                                 Prior to Tourns
   FS
                                 1996 ∄
 EΜ
                                Enterna fill 25 c
Last Judge of Judge
Enterna fills
                                                                                                                                             . 1967
·ED
                                                                                                                                                          28 'n 1997
                                                                                                                                                           į.
                                                                                                                                                                                               NE on STN
 L11 ANSW:
   Full Text
                                 ΑN
                                                                                                                                      Er mifene (LY139481) HCl: impact on bone turnover ile hea thy postmenopausal women.

DF: ister W J; Neild J A; Harper K D; Arnaud C
                                 A control and the
   TI
                                                                                            1.51
                                  and arm
                                 and from the Fig. Draper, I de Fig. Lillo Rolling.
   ΑU
                                                                                                                                                           ator 3, Ela Lilly and Company, Indianapolis, Indiana,
   CS
                               Jour Common min . . research : the official journal of the American Schiologic Bound Mineral Research, (1996 Jun) Vol. 11, No. 6, pp. 135-1.

Journal . de: Total Color 
   SO
   CY
   DT
                                                                                                                                       OUNT ARTICLE)
                                 Journal; Artis! (RAM NII II. COV)
                                 Engl
  LA
                                 Friouty
   FS
                                                                                    curre
   E:4
                                 1996 %
                                 Ente ad TTM: 28 or 1997

Last The Led 2 TT 3 3 3 7 2000

Ente d 4 12 4 5 Dec 7 96
   ED
  L11 ANS
                                                                                                                                                              N. INE on STN
Full Cext
AN 1620 111
DN Publ 7
                                                                                                       Public 7 . 46.7 Fact of the composition of the comp
                                                                                                                                       nro ent in the breast cancer prevention trial at a cer r during the first year of recruitment.
rno W; Frankowski R F; Weber D M; Bitsura J M;
   TT
                                  Yech - : -
   ĽΑ
                                 Vogr
                                                                                                                                                        Hot . Health Science Center, School of Nursing, USA. Vc . 76, No. 1, pp. 46-56.
                                 Uni.
   C.3
                                                                                                                                                         Vc . 76; No. 1, pp
5. 100: 0008-543X.
                                 Cand .
   S.)
                                 Jou ... .
                                                                                           :
                                Unit of it Journal ; if a life of the life
   CY
   DT
                                                                                                                                                           OUF
                                                                                                                                                                                     . ARTICLE)
                                                                                                                                                        ON- .. GOV T)
                                  inglich
   LA
                                 Abri coc Index I cas In mals; Priority Journals
   F3
   F! 1
                                  99
                                 Ent. 61 77: 1 195 

Mas 6 7 7 7 15 70 1996

Ent. 6 7 7 15 70 1996
   ED
                                                                                                                                                     11 5
   L11 ANSE F 7 CF CF
                                                                                                                                                                 M. INE on STN
   F 11 'ex'
                                 Public II . PGII.
Pro cost o face
   DH
                                                                                                                                            n \varepsilon 1 by women with metastatic breast cancer treated hal is of patients entered on four prospective
                                  wit. For a follow
                                 lim limited of the desired J + Tha S S; Mailliard J A; Wieand H S
   A'J
                                  lvi im
                                                                                                                              . Onc ;y, Mayo Clinic and Foundation, Rochester,
   C.3
                                 : in
   NC
                                 1-62
                                 (-\mathcal{L}_{-})
                                 E-F. )
                                                                                                                                                                                               77, No. 4, pp. 683-90.
   S٦
                                 Canc
                                                                                                                                                           1.
                                 c'our
                                                                                                                                                             ī.
   CY
                                  lai.
   \mathbf{D}^{-1}
                                       CLI
                                         201
```

```
Journal, India Duf - ARTICLE)
(RAN CMI of 10 ED I AL)
'RES MARC' - MARTICLE ON-1.5. GOV'T)
RES MARC' - MARTICLE
ON-1.5. GOV'T)
English
T.A
              Abri ged Indom II to us Journals; Priority Journals
FS
               1996.5
EM
                                                                       195
ED
              Ente S.G.
              Last ":c
                                                                        20 Jun 1996
                                       . . .
              Enterd
                                                                                 1.5
                                                                       :1n
                                           - :
L11 ANSWER 1
                                                                       F TNE ch STN
Full
              Text
AN
              9617 530
              Pub! - I
DN
              Ther per adv. co.c
                                                                                     archatase inhibitor fadrozole hydrochloride in
TI
                                                                       ο£ .
                                             er.
              Bonn Doi
                                                                                      owsett M; Trunet P F; Houston S J; da Luz R J;
AU
                                                                       I I··
                                                                                         owles T J
              Rube : F
                                                                       ₹(•
                                                                                      Institute of Cancer Research, London, UK.
CS
                                                                      al -
              cit il
                                                                                        (1996 Feb) Vol. 73, No. 4, pp. 539-42.
SO
                                                                      anc.
                                             .
                                                                      5. J. M: CCC7-0920.
              SCOT ...II
                                           зdс
CY
                                        1724
               (CLINICA
DT
               (COMPARE
              Gournal; "MULTICE" (RAI ONLE Engl. 51
                                                                       OUF : ARTICLE)
                                                                       ED ( "YT)
LA
              Prichty June?
FS
               . 99 ;
EM
              Thite ed (TM: 1/2 or 1993)
Last Modered to (1.6 Tet 1998)
Entered to Giffer ... Apr. 1096
ED
L11 ANSV C 1 1 OF 1
                                                                         MUDITUE on STN
Full faxt
              53073813
AN
              Fiblid I
DN
              "igh das
                                                                         for titro in and progesterone receptor negative
              retaint
                                                                        nce : place II trial of the Cancer and Leukemia
              (-rei .
                                                                     ; V MAR R Be Hayes D M; Duggan D B; Henderson I C y-Creakogy, Comprehensive Cancer Center of Wake Forest Salar NC 27157-1082, USA.
ΑU
               7 . 17
CS
                  .00 L L
              111 711
NC
              C 42 ( ) C 43 3 3 3
              Treast control of the Streethment, (1995) Vol. 36, No. 1, pp. 35-40.

1. Junal of the Streethment, (1995) Vol. 36, No. 1, pp. 35-40.
SO
               Tathurla 👉
CY
             CLITIM

CLUTTER

COUNTY, THE COUNTY ON-THE GOV'T)

CLUTTER

CLUTTE
DT
LA
FS
EΜ
              Inte nd
                                                                       199
ED
                                                                      24 . th 1996
              ist Upc
Lite ea
                                                                       30
L11 / ISU R 1
                                                                        I 'NE ~ . STN
Full 2"
ΑN
                   3
DN
                  1_
TI:
                                                                       noi
                                                                                           I er stoms in women with breast cancer.
ĽA
C3
             · ...
                                                                                       Hist . rginia School of Medicine, Charleston
                                 •
                                                                       te:
```

```
Division IS...
      The West Wirgin Condic: journal, (1995 Feb) Vol. 91, No. 2, pp. 54-6.
SO
      Journal 302: 1.3.7. 1977: 0043-3284.
      Unit i Siwan
Journal; A three
CY
DT
                               OUF ARTICLE)
      English
      Priority curt
FS
EM
      1.99538
      Entered Time 1 1977
Last Upon Add 1 27 27 21g 1995
Entered Adding Aug 1395
ED
L11
      ANSWER 1 OF THE OR STN
      <u>0 -xt</u>
9:27 098
Full
      AN.
                             tic 3 associated with a high rate of ymm 1003 in male breast cancer patients.

; K N; Lebwohl D E; Borgen P I

y, prial Sloan-Kettering Cancer Center, New York,
TT
      Anel : T
AIJ
      Departme.
CS
      New Tork
                                V 4, No. 1, pp. 74-7.
6. 7. 1: 0008-543X.
      Cancer,
Journal -
SO
      United S
CY
                   n 2
                                OUT ARTICLE)
      Journal;
DT
      Eigl sh
      A mi Wed I de:
                               rus commals: Priority Journals
FS
E:1
      1.94
      Fite od . . .
                             19:
ED
                           Ju 194
      I st pd on o
E te d on.
                   OL ...
L11 ANSWER I
                                 FED INE on STN
Full Text
                    11.79.17.5
    9410:991
      PubMed Io: 32811 5
      Fnase I hal which
                               blockione in patients with metastatic breast cancer.
TΙ
      Buzdar A The Katt
                            : Fortchagyi G N; Theriault R L; Booser D; Holmes F A;
      Walt us to Krant
      Tupa timeset of No.
                             of Cocclogy/Medical Breast Service, University of Texas
      I D. And wor dies Cesser, Houston 77030.
      Characteristics of and mearmacology, (1994) Vol. 33, No. 4, pp. 313-6.
Characteristics of and mearmacology, (1994) Vol. 33, No. 4, pp. 313-6.
Characteristics of and mearmacology, (1994) Vol. 33, No. 4, pp. 313-6.
Characteristics of and mearmacology, (1994) Vol. 33, No. 4, pp. 313-6.
SO
      CY
                   ******
      ('LI'ECF
                                SE.
     ( TI ICI
                                 OU ARTICLE)
ON GOV'T)
      IO. NO.)
                                TI
      C ur al;
(.ESTARC
                                NC
      Figlish
      Pricity ...:
FJ
      1194 ::
EΜ
      Fith d
List pc
Fith od
                    E\Box
                                 19.
                                      1. 1 1999 .
                                 2.
                                 ₹e}
                                 I ONE CA STN
L11 A''S'' 3
Full T xt
      $ 09 .52
A.J
      F bM i I
                    zi : O'Fallon J R; Veeder M H; Miser A W; Mailliard ose 4; Rowland K M Jr; Burnham N L
      n an dei
TI
     C lo arg
ΑU
      Chis nge
                   C3
                                'ncc 'ye' Program, Danville, PA.
      C :-1 183
C :-1 :24
NC
      (4-5 ,04
      Jurial and once gy: Afficial journal of the American Society of Call tal and a 190 and Vol. 12, No. 1, pp. 155-8.
Jurial and 3. Triony 2-183X.
Line 6
```

```
(CLI...CA
DT
      Jour 1;
                              DUE!
                                      ARTICLE)
      IM IIA, )
                              ED
                                           T.H.S.)
      (RES 3RC
                              . S
      English
T.A
      Frio ity
FS
EM
      1994-1
                              19.
ED
      Fnte ed
      List "po
Enter d
                              3
                                     1998
                                    594
                              Ja:
                                11 TINE or STN
L11 ANSWIR 1
                   1
Full Text
      9320 19C
AN
      EmbE 1 10
                   2.5
DN
                             ∍p! '
      Crin cal
                                     response in a minority of patients with
                              glies a treated with high-dose tamoxifen.
      redu Jer
                             . м
      Coul wel
G R; Jon
                                  DeGicrgio C M; Weiner L P; Hinton D R; Ehresmann
AU
                             .20
                              og: .. ' Surgery, University of Southern California, Los
      Departme
CS
                   ·f
      Ing. es.
                             Mar' Jol. 32, No. 3, pp. 485-9; discussion 489-90. 4. 3. W: 0348-396X.
     F mount
SO
     Cour 1
Unit + 8
CY
     3 2 2 11;
                                      ARTICLE)
DT
                              DUI .
      F ~1 ::h
      F · · ity
FS
EM
      1999
     Enth id
Luit Tpe
ED
                              3 9
                                      198.
      Ente d
                              Αp
                                     ;3
L11
     F157 A 1
                                     TNE of STN
F:11 7 7 All 1.0.
      Fabilia I
DN
            ī.
                             em:
TI
     F
                  11 1
                                     a in patients with advanced cancer.
                   . ...
                                    er P C; Haller D; Green M; Shemano I versity of Louisville, KY 40292.
ΑU
     I nm
                             , I
            · me
CS
                             ne
                                    gy: official journal of the American Society of Ov) Vol. 9, No. 11, pp. 2036-41.
SO
           al
                              onci
     ا ن ت
      ( in dal
                              19^
      c un al
                              3. .
                                    M: 0732-183X.
     2 : " ; ; ;
CY
      ( L.T. ECZ-
DT
      coural;
                  • • • -
                             ·OU:
                                      ARTICLE)
      ( ) OMI
                711 C
                             ED : AL)
                 4777
     ( .... ARC
Fagl th
                             ON G. S. GOV'T)
LA
     Paid ty
FS
           ٠:
EΜ
      1
            .d
ED
     F
                              19:
            īpc
.d
                                     1 1802
                              2
                              ec
L11 FWW- C
                                      UE of STN
F:11
      č
A:I
            356
     Fil
           i I
D\Box
     F .
             I
                                     and and pharmacokinetics of toremifene in
TI
                               t
            ts
AU
     } ).
             F
                                      Tit; DeGregorio M W; Shemano I; Tormey D C
                                     it ... Madison General Hospital, Madison, WI
CS
            ..me
                             .ne.
            - C
SO
                             -ch
                                      treatment, (1990 Aug) Vol. 16 Suppl, pp.
            -.1
                                      1: 117-6806.
                             4.
           ··la
CY
            TCF
            OI
                               T
            11;
                             υo.
                                      AP "(LE)
            TCE
```

```
JED 1 - AI,
     IMC MAS)
LA
     I yl sh
FS
     I no ity
     3 391 3
EH
     Ent∈ ed .
ED
                         .99
     1 at Upd
                               19.7
                         : 3
                              I 1
     Int∈ ≥d
                         Ma
L11 FUSV R 1
                          JOSEPH C. STN
Full c xt
    $ 729 385
    I ibk J I
DΝ
                         ison . Assestrol acetate (MA) and medroxyprogesterone
TI
     1 ra dom
     a ret te
Vill mse
                               with advanced breast cancer.
                         :ie
                         er I by E; Sleijfer D T; Tjabbes T; van Veelen H
                         CG
     I∋pa ime
     I ath rlan
SO
     Fire ean
                         ca: ::: (Cxford, England: 1990), (1990 Mar) Vol. 26,
     γэ. . , р
     cour al
                         /3.
                              -54: 00E9-8049.
     ENGL ND: " :
CY
                        . ido:
     (CLITICA TANK
(TOKEARA TANK
ALAMATAN TANKA
DT
     Jour al;
                         JOU! J. ARTICLE)
     (PAIL DAIN : CT
                         2ED : ,27F)
     Figlish
    1 in ity
FS.
E 1
     Inte ed :
I st Jpd-
                         199
                         : 3
                               1007
                             . 20
     Fitte ed :
                         Ju
L11 # 4SW R 1
                          i walls or STN
Fill 5 :t
All (13: 400
     I b' i I
    I ... ber
                         they are themohormonal therapy in women with
TI
                         a direct
     r., pos
     7 - + n - - r D
                          Tay 1 3 G (th; Knuiman M; Olson J E; Cummings F J
ΑIJ
     776
N :
     (1-4 115
     C.-7-318
                         oub litter of the National Cancer Institute, (1986)
SO
     onc II I
     10. , p
     Jan al
                         I ii d S
L ICA
LON ARA
L m al;
Cv
                - -
                         TOU : C ARTICLE)
      U. DMI --
                        TUED (CAL)
               100
     (OL. ARCH
                         J.S WOY'T, P.H.S.)
     F J. sh
I ir ity
LA.
FS
                12 .
     i sac a
E. 1
     Fith ud.
                         199
                               7.222
     I st Upd
                         : 3
     Fite ed '
                         Эес
Lil Figur R 1
                          N OL STN
    -<u>--</u>-
F 11
                         3
          384
     E = e^{-\frac{1}{2}}
D:1
           l I
     " ትጥ "
                                 result -- blind adjuvant trial in elderly women
          fe
ΤI
                         CE.
          :ta
                         : C
                                Tormey D C; Harris J E; Falkson G G;
Α''
     ( ------
           :qs
           au
           47
           15
     ( -:
           18
                              f the National Cancer Institute, (1986)
     onc I! I
SO
                         oub
```

```
Journal c. . . Unit of C.
                         .34. ISSM: 0893-2751.
C^{\vee}
     United St
D '
      (CLITICAT
     Courral;
                          JOUR MATE ARTICLE)
      CAN OMI
                          TLED TO(ATA)

J.S. GOTTER, P.H.S.)
     (REG: ARC
     Eigl sh
Esictity
LA
FJ
     1386 3
E!I
                          99
     Enteled
                       DqU dag I
     Fitered -
                           INE or STN
L11 / ISW R 1
F 11 5 X 7 362
D.J. I 15 1 15
TT 5 ife
                          3
                           in a treatment of advanced breast cancer.
                          ; B : Maschein G R; Hortobagyi G N : V = 37, Nc. 1, pp. 40-3.
     I. 16 '1 W;
ĽA
    Cancer,
                        . 36. WY: 0708-543X.
     Jour al : :
С.
     Unit i S (CLT ICA
D.
                          JOUN W ARTICLE)
     Cour al:
      IMC ...
     Figlish
LA
     7 ři ged
1930 3
                     cus . wrnals; Priority Journals
FS
Ε:
     Into ed .
                          19 .
     Last Upd
                         : 6 . 1995
     Fitte ed ( ) die
                          Fel 3.583
LN1 LISV R 1: 1 1
                         I DIME on STN
F 11 T ::

A. 8.2. 513

D.J. Fib. d. I

TI / pl. se

& v. red
                         .3
                          lvac :: tamoxifen citrate in the treatment of
                          ade: : m. foma.

ne folkant J
ATJ
     corr all
    (A) C 113
(A) C 255
(A) 255
(A) 251 Jan
NC
SI
                          cl.
                               ancology, (1982 Apr) Vol. 5, No. 2, pp.
     54.
                               - T: 0.177-3732.
CY
     t it d S
     ( A RE J w al;
D
                          JOUR AN DETTICLE)
      ARCI
                          J.S
                               (C7'7, P.H.S.)
     ig, sh
FS
     1 % ity
     Lit ed
ED
                          19
      s'. Ipd
                          : 3 1 1997
     I thod I
                           Auj 1932 1
=> d a: t' au
                       124 172 135 161 163 170 171
                          TOTAL ON STN
L-1 / JSW R 1. - - -
..01 541
                          INE
     Fot las
T
                          ir
                               regement in breast cancer.
    (rr te
S)
    : rs
                       r (2000 Aug) Vol. 16, No. 3, pp. 214-25. Ref:
                               749-2081.
The relevant to defining and managing hot
     ı ur
           .1
                          ∃8.
    J IV
ΑЗ
                          W
     f as os
                                DATA SOURCES: Published literature
                          :h
     cib 5 f
                               reast cancer and in healthy women.
                          om€.
                                ot flashes is influenced by several
     U USI
                          .0.
     1 01 1 C
                          1er
                                d factors. Hot flashes are a prevalent,
```

```
can repatively impact quality of life. Certain women for at flashes following breast cancer treatment.

porto the safety or effectiveness of treatments in
         severe process of the contract of the contract
          women wit . in:
                                                 anc : IMPLICATIONS FOR NURSING PRACTICE: Implications
         include the r. A improve patient education, perform comprehesemptom a course and counsel women about various treatment atternations.
                                             im move patient education, perform comprehensive
         Fot lash 12 3
                                              Fir to Expement in breast cancer.
TI
                                              ew literature relevant to defining and managing hot the literature cancer. DATA SOURCES: Published literature
          C3JE"TIVT
          flashes ' ''
          cahot filman
                                              ome with breast cancer and in healthy women.
                                               iole and hot flashes is influenced by several
          CONCIUSIC .
                                               men related factors. Hot flashes are a prevalent, car relatively impact quality of life. Certain women
          hrea t cm
          suvere pr
          ate t ĥ
                                                for of flashes following breast cancer treatment.
                                                por the safety or effectiveness of treatments in
          litter
                                                                    Walications for. . . .
          vomen. wit
                                                 anc.
CT
AE, adverse e.
             int neo
                                                           Teamoral: TU, therapeutic use
                                                  ıts
          * ire st
                                                  CO, prolimations
            Bre st
          Bre st
                                                  ϽT,
                                                           n 7 therapy
             lot Fla.
                                                  nem ally induced
            Tot Fla
                                                  dio jy
             to: Fla: .::
                                                 he:
             um ns
             Tid le /
             at ent
             )ua ity
             Jo Fac m
           *Jam xife : All
                                           of verse effects
          Tem xif 3... %*
1.51 -29 (%*)
                                            rapritid use
                                           . :. en)
RN
                                                     : DLINE on STN
L11 FISTUR 15 OF
         3 9 417
T . ife:
Full_
                                              · INE
                                                 it : ler surgery for breast cancer and tamoxifen or
TI
          pac-bo
                                                vent or in healthy women: different compliance with
          t ea men'
          \ i esi
I: lad
                                             stt Ma; Merlante M A; Zottar M; Magri M D; Crivellari
ΑU
          1 amori,
                                              un) 151. 84, No. 3, pp. 372-5.
SO
          וו יניכו
                                             s so dy two to investigate whether tamoxifen toxicity it is at last differed in the adjuvant versus
          All1: The
AΒ
          and trea
                                                            TITHODS: At our Institutions 119 postmenopausal
                                                tin 4000008: At our Institutions 119 postmenopausants are rendomized from August 1987 to March 1995 to
          chem pre
          l-1 c
                                          in - jurant studies (International Breast Cancer
          t ife
                                                 VI at 1:1) and 202 healthy hysterectomized women aged ndc zel from November 1993 to May 1996 in a -bl d, placebo-controlled chemoprevention study are millon Study). The tamoxifen dose was 20
          € u ·· Gr
          î ⋅- ˈye
                                            · -bl
          rult: den
             ta ian '. '.
                                            ∂re
          r /3 y fr - ·
                                                            1 studies. Median age was 66 years (54-85) in the
                                               in
                             ٠٠١,
                                             ð 5
          a'ji ant
                                                            years (37-69) in the chemoprevention study.
                                               rat in this 238 and 120 weeks, respectively. RESULTS: this acjuvent studies experienced more hot flashes,
          Fatints
Viginal
                                                 nd/ bleeding, bone marrow depression and weight gain
          t ai. tho.
                                               in
                                                            a chemoprevention study, consistent with the fact
                                         f which in the latter study were receiving placebo.
          ta<sup>+</sup> ap
                                            nat in pecurred in 2.5% of patients in the adjuvant of the in the chemoprevention study (difference not fic. t). Permanent discontinuation was more frequent
             m car
                    cs
          s sti
          i ' 3 C
                                                           make than in the adjuvant ones (26.7% vs 15.1%--P<
                                               ion
                                            : I summary, our data show that, although the toxicity
          0.01.
                                              ch special in the two settings, a larger proportion che special in discontinue treatment spontaneously. Iir name of the chemoprevention study, the impact of
          xor t o
          c. " men
          I e o t
          t : 'xi
                                                oxi a sec compliance in the chemopreventive setting
          c ni i b
                                                  ъd.
```

```
ter surgery for breast cancer and tamoxifen or
ΤI
     Tamo"ife
                         nt.
                         vent or in healthy women: different compliance with
     plac :bo
     trealmen'
     AIM: The
                         s so My war to investigate whether tamoxifen toxicity
AB
                         nti lations differed in the adjuvant versus
     and treat
                              4ETHODS: At our Institutions 119 postmenopausal
                        tin
     chem bre
                              ere mandomized from August 1987 to March 1995 to
     reart c
                         its
                               it dam's studies (International Breast Cancer and FT) and 202 healthy hysterectomized women aged
     tamorife:
                        ·in
     Sudir Gr
                         VI
     30-7" ye
                       ando zel from November 1993 to May 1996 in a
     milt cen
                              d, placebo-controlled chemoprevention study
                       -bl
     (Italian d mod
                       Pre attion Study). The tamoxifen dose was 20
     ma/q. A t. 2 .
                       in a t studies. Median age was 66 years (54-85) in the
                               the chemoprevention study. Median treatment
     duration was - duly weeks, respectively. RESULTS: Patients treated
     with high man
                      die: experienced more hot flashes, vaginal
                       sed rg, hone marrow depression and weight gain than
     disciarge
                         e d'incorevention study, consistent with the. . . to is (26.7% vs 15.1%--P< 0.05). CONCLUSIONS: In how that, although the toxicity of tamoxifen is
     tios tre
     than in '...
     sump ry,
     sp imp
                         ıe
                             o setsings, a larger proportion of women treated
                              it has treatment spontaneously. Due to the
                         Ris
     a clamo
                               ne or emoprevention study, the impact of the
     dul e-b
                 Ţ
                         o f
     t xi ity
                 t
                         3n
                               on compliance in the chemopreventive setting
                 30
                         ed.
CT
therap"
     * re st :
                         ₽C,
                               ie vion & control
                 Σ.
      ir st
Che oth
                         SU.
                               un (ord
                 ).
                         ·rar.
      Hu: ns
      Mi. le
     *Pat ent
      F. pec
                         3
                         ers at a ts
     *Tar xif
                 7
                         . rap - ii o mae
                 ( 7
RN
     105: -29
                         en)
                           : DITME on STN
L11 ANST R 1
                 OF
     T XI.
<u>Full</u>
          358
                         INE
                         men ausal women treated for breast carcinoma:
     H t las!
     plevilens
1 f.
                        Ty, Threlates, management, and relation to quality of
                 Ę
     Corp nter
P; ' nad
                         yko: ki M A; Cordova M; Cunningham L; Studts J; McGrath
AU
                         7; '.nr'F
'V' 30 No. 9, pp. 1682-91.
SO
     C n
     J a al
BAC. ROU
                         36.
                               35 ₹: 008-543X.
                 ≥.
                               nc: Hashes (HFs) after the diagnosis and
AΒ
                . F
                         ı c
                 E
                         ca
                               in the (BC) is scarce. To our knowledge, this
     tre men
                     tl.
                               second study of HF prevalence and severity in
     res- tch
                 or
                 30
                               mais sudy of 1) correlates of HF prevalence and
          wi
     we m
                     . 1e
                       HF
                               artaement strategies, and 3) the relation between
     s v ity
                 )
                 1:
                               (() among women with BC. METHODS: Eligible
     E and
                          if
                               n structured telephone interviews. RESULTS:
                        sic
     w -:
                1.5
          (n
     C: : : 1
                               train interviewed, 65% reported HFs, with 59% of
                20
                        oau:
                               The symptom as severe. Multivariate
                43
                         74
     w: wi
         sis
     a .
                               Which were most common in women with a high school
                         hat
                               DED TO were younger at diagnosis and 2) HFs were
     € '
          -io
                         nd
                               1 - F gher body mass index, those who were younger
     n .. ..ev
                         T = U
     a .
          ıgn
                         10.1
                               regraining tamoxifen. Among women with HFs, 37%
                               napprent strategies and 63% expressed interest in
                         TF
                ir
     ver not
                               1 strategy. HFs marginally were related to QOL using the SF-12 Health Survey (P <
     lest ing
                 r€
                         iir
                         1 1
     d.c
          ase
                 er
                               marrits of the current study significantly
                 CI
     C = 1
          lbu
                               ce panding HFs in women with BC and support the
                 tc
                         3CiC
                               offic clinical trials evaluating interventions for
          Cor
                 re.
                          101.
                               publishion.
and women treated for breast carcinoma:
          vin'
                 ₹£
                         .is
     r
     F t
ΤI
           asi
                         1(0)
          en
                               mala.es, management, and relation to quality of
                         7,
     ŗ
                        {\tt i} c {\tt ic} flashes (HFs) after the diagnosis and
AB
           OU.
```

```
da dirona (BC) is scarce. To our knowledge, this
     treatmen
                           to section. . . were most severe in women with a
     i.se rch
     lylrb
ræfrin
                          12::
                               thate who were younger at diagnosis, and those
                 t
                                or promen with HFs, 37% were not using any HF expressed interest in learning more
                 41
     runa ome:
                 j
     ı ga dir.
CT
                 nε
      Adu t
      7.juli
7.ge.1, 8
                 nc
     *3re st '
                          II, ne = 10 alonely induced
                [g.
                        . 3P, pidumiology
      Bre st :
                 pl
                          TH. held,
                 ρl
      Pre-st
     *"ot Fla
                 s:
      of Fla
                          piā iclogy
                 5:
      Fo: Fla
                 s:
                         . ier
      Hur is
Mic le
Mul iva
                  Ŧ
                 t€
                         sis
     *Pos men
                          phy iclogy
                 us.
      "rimale:
      Dua ity
                  L
L11 AMSVIR 1
                               DI IF on STN
                 OF
Full 7 3
     1.38 019
                          INE
     T rrrife
                               onest breast cancer. Efficacy, safety and cost.
TI
                 ir
                         . .m::
                          -33)
-250
UΑ
     l ⊳er…a
SO
     L 14 &
                              ... fol. 11, No. 4, pp. 261-70. Ref: 53
     July 1
                               35 H 170-229II.
                          7 ...
                          . 5 . ..
                               Test moxifen analogue that is indicated for
     Thro life.
     t.e 'mea
                               of its 1 hormone-dependent breast cancer. It
                          atar
                 nt
     computes \epsilon from the
                 th
                          ರೆ≐೧
                               for a trogen receptors and has growth-inhibitory
                                cells. At concentrations < 10(-6) mol/L,
                 МC
                          1 F t
                                reversed by estradiol, but at higher
     t is gro
                 j
                          .or
                          ٦i-~
                               a is sytotoxic. In dimethylbenzanthracene
     c nc ntr
                 or
                          73771
     ( MI )-i:
                               ander in rats, toremifene has been shown to
                 ce
                               aw turours and to inhibit the growth of existing
                       . · of
     dicr ase
                 е.
     time is.
                         The character owth inhibition by suppressing mitosis and
                 .or
     i idi ina
                               nach nism by which these events occur may involve
                 or.
     t is idu
                         ens. noting growth factor-beta 1 and inhibition of
                 O.
                          fa break (mecasermin). Toremifene is primarily an
     insv in-
                 Э.
                                Example estrogen agonist properties in
                          . 1
     anti tr
                 η,
                               the latter are reflected by the fall in luteinising
     ; ost end
                 3
                          1.
                         2008 intending hormone levels and the rise in sex
     lorm ne
                 di
                         . oul
                               levels that are associated with its use in most
     lorm ne-
                         men riming, toremifene 68mg administered orally has a milar antiestrogenic effect on the vaginal
     v men. /
h er fou
                 er ·
                 tc
                               milar antiestrogenic effect on the vaginal
                          and ausil women as tamoxifen 60mg. The half-life of
     epit eli
                 ir
                          a i 5 days, and the drug is > 99% bound to plasma
     t re ifer
                 in
                          me -bolites of toremifene are N-demethyl-
     ot ins
                 Th
     thre ifer
                 ar
                          inc hoxy-toremifene. Altered liver, but not
     } dr 7,
                 ct
                                the charmacokinetics of toremifene.
                          Ĩ£C
     Thre fe.
                                as effective as tamoxifen 20mg daily in the
                 5(
                          71
                          C
     t 'ea' .en
                                32 - Dermone-dependent breast cancer, producing a
                                to minute. Soft tissue and visceral metastases
     1.sp .sc
     : sp nd
                           \tau
                                han bonc metastases. Most of the adverse
     ∈ f∈ †s
                                      ted to its activity at estrogen receptors
                                al discharge and nausea. Although
     a d mol
                  ì
                           11
     t re ife
                               the bin III levels slightly, the incidence of
                  )£.
                                s low. Thus far, no carcinogenic effects
     t rc loc
                 li
                               preclinical data are mostly reassuring.
tots on serum lipids, and thus has
                           • :: •
     } v∈ sec
                 ot
     T re Te
                 'nε
     ; te lia
                                ry ry hear disease. Although toremifene is
                 :n
     : me :at
                                than tamoxifen, toremifene is an
                 r€
                               lternative to tamoxifen in the treatment ormone-lependent breast cancer. No form
     \in : f \varepsilon - \text{liv}
                                   ormone-lependent breast cancer. No formal f torem fene and tamoxifen have yet been
     cīp tn
par.cc
                 ٦ē
                  10
     jubl lie
                                   t intially safer than tamoxifen in relation
                              to tects on serum lipids.
     to curci
TΙ
                 1.1
                               reast cancer. Efficacy, safety and cost.
     Tore ife
     The 'fe
                               t moxifen analogue that is indicated for
```

```
nt
                           stra opansel hormone-dependent breast cancer. It
      the trea
                 ·th
                                 for estrogen meceptors and. . . breast cancer
      cump tes
                           tio
                                ₹ < %7(-6) mol/L, this growth inhibition can be
      C:11:
                 CC.
                           iti
                           of, but at higher concentrations toremifene is
                 . €.
      reversed
                  Ĩ.
      cytotoxi
                                 en an thracene (DMBA) - induced mammary cancer in
     rats, to
                 .if
                                 A shown to decrease the number of new tumours
                               Toremifene causes growth gair sis and inducing apoptosis. The mechanism will y involve the induction of transforming indication of insulin-like growth factor-1
      and to i
                  ъi
                           .3.4
     inhihiti
                 ρ'n
                           -:-
                  eε .
     by which
                           . .
     growth f
                           if a rimarily an antiestrogen, but it has some the latter are
                  ) .
      (nec.ser
     estro jer
                  Oľ.
                                 and he rise in sex hormone-binding globulin
     reflette
                  У
                            and the rise in most women. After estrogen
     luvela t
                  5
                       GE
ic
                         . 68
                                administered orally has been found to exert a
     r sir ing,
                 re
                                ffur on the waginal epithelium in postmenopausal
     simi ar
                 iε.
                           50m . The half-life of toremifene in plasma is 5 as 39, bound to plasma proteins. The main
     v me i as
                 · mc
     days, and
                 he
                          with a rea N-demethyl-toremifene and
     metaboli
                 · c:
                           it : : F tered liver, but not kidney, function
     c :am 'noh
                 .ox
                         ) 'T
     \varepsilon fects
                                tills of toremifene. Toremifene 60mg daily is
                 . p
     as effect
                 re
                         round in line daily in the treatment of postmenopausal
     hormine-
                 en.
                          "Co
                                cancer, producing a response in about 50% of
     r ti ats. So
                          ...tue
                                nd wisceral metastases respond better to
     thremifers at the do of its activity at estrogen receptors and include but flash a, and declarge and nausea. Although toremifere commasses into the point III levels slightly, the incidence of threme boes all the point is as low. Thus far, no carcinogenic effects
     h we bee
                          hum s, and preclinical data are mostly reassuring.
     Tirriife
                           area a effects on serum lipids, and thus has
                 ha
                           - : -
     rote tia
                                 accounty heart disease. Although toremifene is
                 n
     s m∈ hat
                                 to the than temoxifen, toremifene is an
                 re
     e fertiv
                           0:
                                 ated lternative to tamoxifen in the treatment
                 .nc
                 pг
                           1771.7
                                with ormone-dependent breast cancer. No formal
     plan rico
publishe
                           apa uscas of toremifene and tamoxifen have yet been
                 no
                                 s printially safer than tamoxifen in relation
                 T'
                           in h
                                 arl a fects on serum lipids.
     to circin
                 er
*Breas : N .pl
'l' ica
                                 . <u>j</u>. . . . . .
                           . * * . . . . .
                 r:
                           . -
       Ti ca
                  ri
                           1 :
       ur as
                  F.
                            Dr. drug therapy
      * 🕮 las
     * J. aera
       Tau mif
                           161 ... 1.1e
                 T
                           imi liye
ino ind
       Tor mif-
                 ٠:
       o mif
                 :
       or mižr.::
                          arm oblinerics
                 * or mif
     1.3541-29-
RN
L11 AUSW R 11
                  OF
                             DISTRIB ON STN
Full 7 m
           65
                          11 -
AN
TI
                         amog for the treatment of hot flashes.
           hat.
                .5
                                .4
     I 2.
UΑ
                 1
                           25.7
           n 1.
     T .a
                                190 mm (1997 Jul-Aug) Vol. 31, No. 7-8, pp. 915-7.
SO
           ..na
                 of
                           · CC
                           2.1
                                35 1: 060-0281.
     C no
           , 1
                 e:
                           . .
                                nite ing hot flashes in whom estrogen
AB
     F - nc
                           me district have alternatives available to them;
     i com
                 i
                                afined treatment modality. The literature natives has serious limitations, which men enrolled and lack of comparative studies
                           ٠.,
           r,
                  er
     si
                 ma 🕜
     j : e '
                 ٤٠
                                 meads to be assessed in terms of her current
     k-tv n
     · lications, and the degree to which vasomotor
                  t١
                                 oryday activities. The literature suggests id may provide significant relief. Women
                  5
           ---
     t t
                 rc
           t
                                       te must be told in advance that the effects
                  us.
     v 1 .0+
                                artical rly if tamoxifen is used medromprogesterone may constitute potential
                 f
            ÷ +
                 1;
     C
           .at
                                       not he able to tolerate the adverse
                  S,
```

```
that lack of literature supporting their clinical use,
              effects. ec
                                                                  This E and ginseng need to be approached cautiously.

In all this ting some of the complications associated

in a heart disease and osteoporosis, but its effect on
                                           h
              options
               Ferrise s
              with men, us
neur tra: it
trea men f
                                                               no ormanic concentrations, and how this relates to the
                                                                      each there not been characterized. Patients should
                                                                     to the first activity, a balanced diet, avoidance of
              hatuld t
                                                                      in sign as reduction may be of additional help in the children of hot flashes.
                                             C
               alco ol
                                             va
s
              decr: asi
TT
              Alternat
                                             .sa
                                                                       the explaining hot flashes in whom estrogen
            Postmano
                                                                        The source have alternatives available to them;
              ruplamen i
                                             ei
              however,
                                                                                    efined treatment modality. The. . .
                                                                                      the pe told in advance that the effects will not be also be told in advance that the effects will not be also be told in advance that the effects will not be a second that the effects will not be a second told be a second to be a s
               tius, n
                                              st
              lat t
                                               ec.
                                                                      one may constitute potential alternatives,
to tolerate the adverse. . . heart disease
to or neurotransmitters and hormone
lates to the treatment of hot flashes
Patients should be told that regular
               Con in
                                             ກເ
s
                                            s
rc
or
              \begin{array}{ccc} \text{but} & \text{.tl} \\ \text{and} & \text{te} \end{array}
              concolti
hav tot
rays tal
                                                                    Patients should be told that regular diet, avoidance of alcohol and caffeine,. .
                                             ·tj
L11 FASWTR 1
                                                                       on STN
                                               ЭF
I g'i los
                                                                   which is gen and progesterone receptor negative
                                           bı
              retritat
                                                                       : : ase II trial of the Cancer and Leukemia
              C to B
                                             .LG .
              Fer J
                                            Βε
                                                                  T.; Miss T B; Hayes D M; Duggan D B; Henderson I C
ΑU
              Franc c
                                                                    when no impatment, (1995) Vol. 36, No. 1, pp. 35-40.
                                             er
SO
                                                                 31. SS 4: 3167-6806.

1. t \in J \subset inical studies, high doses ( > or = 200
               Jan . d
              J1 : 3-C
                                            ic
th
. r
AB
              r 1/6 -)
                                                                        har, at ylane derivative toremifene showed activity
                                                                                   1) negative and ER-unknown metastatic breast cancer
               ii estro
                                             . r
               alter pr
                                                                        to bringer, and a mechanism of action independent of
                                             es
              lorm he .
thin' (C)
populati
lace of
                                                                      the speculated. The CALGB conducted a Phase II to a set the efficacy of high dose toremifene in a transfer in a hormone receptor-negative, metastatic
                                              er .
                                             -B
                                              of
                                                                                     or chemotherapy exposure, good performance
Twenty eligible patients received
                                               ei
                                               1
                                                                                       'y 20% of the patients, lightheadedness by out flasses by 15%. There was no grade
              † r [6
1 11.. 1
2 1.. el
                                               at
ai
                                                                                       sponses were observed, and 5 of 6 patients developed progressive disease at 11 to 33
               3 . . . x2.
                                               у.
                                                 C
                                                                        100 mg/day) is well-tolerated but imparts
100 mg/day) is well-tolerated but imparts
100 mg/day) is well-tolerated but imparts
               v.€`.
                                               'n
              rocled
                                               1\epsilon
               cand w.
              i di nios
i finatati
                                                                         gen and progesterone receptor negative
 TI
                                               Ol
                                                                      The transe Hi trial of the Cancer and Leukemia
               Con B.
                                                                        inical studies, high doses ( > or = 200
              1 1 ...
AB
                               - C.
                                               ic
                                                                        ne derivative toremifene showed activity tive and ER-unknown metastatic breast cancer
               1 1/
                                              t!
                              . :: c
                                              3
                                                                        to a life t, and a mechanism of action independent of
                            ភា ខ្ម
                                                                        peculated. The CALGB conducted a Phase II
for the efficiency of high dose toremifene in a
form to hormone receptor-negative, metastatic
                                e.
                                              eŗ
               t 'i. (C
                                              -3
                                                                       hormone receptor-negative, medasually to the hormone receptor-negative, medasually controlled to the hormone receptor exposure, good performance controlled to the hormone receptor exposure, good performance controlled to the hormone receptor exposure and the hormone recepto
              r r ti
                                               of
                                ti.
                                               er
               ._at .,
                                               n.
                                                                      in the liverity eligible patients received a constant of the patients received as a constant of the patients, lightheadedness by the patients of the patients, lightheadedness by the patients appears were observed, and 5 of 6 patients accelerate progressive disease at 11 to 33
               torollife
                                                at
               r nº al.
                                               `ลเ∗
                     , wei
                              xc
                                                у.
               1 .th 152
                                                (
                                                                                            (0) romay) is well-tolerated but imparts
              • €
                                                ٦.
                                                                                                         one receptor-negative, metastatic breast
Breas :
```

η.

```
lumin s
       വ്റ് പല
                  ď
       lec las.
                  et
      · lec .: to
                                        ysis
                  E
      1 lecinto
                                        analysis
                                 ts.
      formaif.
                           13.1
      *Torrighter:
                           37%
                                 . 1.1. . . . . 13e
     2re - Umo
83777 - 26
                  Out
RN
                  (T.
                           17. 3
L11 FISHIR 1
                                12. 11
                  ΟF
                                       on STN
Full :
NA
     g to man
                                 . F .
                                       imptoms in women with breast cancer.
TI
                  er
     C No bie
υA
                  Ĺ.
     r ie .∈ch
SO
                                       nal, (1995 Feb) Vol. 91, No. 2, pp. 54-6.
                                      043-3284.
                  e:
          , ar
      . .t_
                  at
                                        woman with breast cancer presents the
                                 : with respect to hormone replacement
lished meta-analyses have been consistent in
     ς ....
           ie
                  it.
     tar y
                  Τ).
     E 10 13
                                 postmonopausal estrogens for greater than
     c no r 1
                  hc
                                   been no published placebo-controlled of HT in women with a history of breast
     10 wear:
                  Нc
     Z i i sal.
                  i٠
                                       be balanced against the theoretical risk of
          ÷.
                  ЭÌ
                                        f oster-protic and cardiac risk factors
                                       family Listory, hyperlipidemia) should
                  iı
                                       alternatives to estrogen replacement such as Bellergal or vitamin E for hot
                  hғ
     10° 6
      ° a. ⊤s,
                  £
                                 alcium, anabolic steroids, and calcitonin
                  rc.
                           Fig. 1 8 ...d influence the decision. Valid
AB
                 эq.
                           continuous coment include low-dose progesterones such
continuous hot flashes, and biphosphonates,
           ·.at.
                  s
           ∴ ∈.
                  1
     calcium,
                 aŀ
                          and as and calcitonin for osteoporosis.
     Check Ta
CT
                 : F
     in st
                 p]
           act
                  C
           27
                  eŗ
                                 3 : .
            123
                  £
            .1 .
                  115
            ٠. ت
                  r.
                                      . €
=> file topta
COST 14 F 3.
                                                        SINCE FILE
                                                                          TOTAL
                                                             ENTRY
                                                                        SESSIÓN
FULL I ' .T"
                                                                          91.04
                  Э.
                                                             61.88
FILE ' . ' '''
                                   . : ON 3 MAR 2007
CAN CUMICAL SOCIETY (ACS)
CA INT II
FILE
                                 Can CFUMICAL SOCIETY (ACS)
                                       T 30 MAR 2007
CA IN
=> d i
YOU HE TO THE
                                 FOR CONTINUE? (Y) /N:y
'HSI' (S ' OT .
                                        R 'MEDI NE'
                                 Э.
The f.
The d
ABS -
                                        , CM, CM, DT, LA, FS, NCT, OS,
A.L -
                                          CN. Th
CY, T, LA, FS, NCT, OS, EM, ED
BIB --
```

```
T. CY, DT, LA, FS, NCT, OS, EM, ED to Deessing
IALL --- II,
                   de
                                        :cls
          .В,
IBIB ---
                                  .im. .∴∈ls
                   d٠
IND -- - F,
                                      TRIAL --
 (SAM,
HIT --
                                  g i coms
                   10
HITIND - IID
KWIC --- II
                            1 1 2 1 1 2 3 on either side
OCC ---- list
                                 do taining hit terms
                  C.
Hit terms il
                 е :
                         is all available fields except CM and
Ρί.
                        and the display field the display field the property of the codes, enter 'HELP DFIELDS'
To display a portion
codes. Ta
at an arm / m
                            or of hid codes, enter 'HELF DILLL'

or in of formats include: 'BIB';

format fields in any order,
                 st.
                   Ιq
                   Yε
and the for
                                  is and in the same order as the
                   i.
format s 📝
                   -
                                 TIND, WIC, and OCC) may be
The same
           · c.
                                the cord for a
used wit .
                   Зì
speci ie i
                   i. (
ENTER D.
                                  tall
                   31.
                   77
'USPA' ALT' IS
                   T
The follows:
                   O
The d-fair.
                  1
A39 ----
                                 NO CM, CM, CY, DT, LA, FS, NCT, OS, WILLIAM CY, DT, LA, FS, NCT, OS, EM, ED CY, DT, LA, FS, NCT, OS, EM, ED COST CRESSING
ATL ---- T.
BIB ----
C113 - ---
L111 - --
L112 - ---
                            .- .
                  13
                   tŀ
                           . .
                               emit coels
lemi chels
IAII - --
                  'de:
           , d∈
                           100
I:13 ---
I II ----
TXIAL --
                              - 4
                          · 37
(
                                 ||Cr||_{L^{\infty}} \in \mathbb{N}^{N}
H 17 - --
E AIN - -
                                  g in terms
K::C ---
                                  o either side
000 ----
                   ſ
                                         maining hit terms
Hit to me of:
                  е
                                          avai able fields except CM and
F .
To dia.
                                   ds. enter the display field
cws.
                                          codes, enter 'HELP DFIELDS'
a.an n
            ٠ ،
                                         of formats include: 'BIB';
                                         format fields in any order, in the same order as the
| : '; !C
an. L.∋
fima:
                                         TIND, KWIC, and OCC) may be this ty the record for a
T + s ae :
ured lt'
syri le
                   ic
F ER
                   ₹:
' ' I: î
                                          "HEDI TI"I"
                   Ţ۲
Tag fold
                   3
              + -
T at de
- - -
```

```
TO CM, CY, DT, LA, FS, NCT, OS,
A T L ----
                                     CN, GEN
CY, DT, LA, FS, NCT, OS, EM, ED
CY, DT, LA, FS, NCT, OS, EM, ED
B. B ----
C - B ---
D 'L ---
                                13412
                 2]
                                       ocessir.g
I ... S ---
I ' L ---
I IB ---
                 d
                                122
                                       ) = 1.S
II.D ----
                                77
TRIAL --
 (SAM, T
HIT ----
                                       erms
                  10
                                Ĵ
H TIND -
                                     to on either side
K . TC ---
0 .C ----
                 10.
                                   - Laining hit terms
H t term: 11
                                in the available fields except CM and
                 эe
                                c: ' :lds, enter the display field
f      codes, enter 'HELP DFIELDS'
T displ:
                 t:
c des.
                 s'
a' an ar 🕢 🖰
                               mp to of formats include: 'BIB';
                 pt
and the second
                               fry to format fields in any order,
                 Υc
                                displaced in the same order as the
                 ic
firmat s
                 t.
                                HO TITIND, KWIC, and OCC) may be
T e same
u ed wit
                 Si
                                7.16
                                       o display the record for a
s - cifie
                 31C
E ER Dl
                 DR:
= file " "
C.TT.71
                ^{\circ}L.
                                                       SINCE FILE
                                                                        TOTAL
                                                            ENTRY
                                                                      SESSION
FILES
           77
                  J.
                                                             2.94
                                                                        97.25
                                       ON 30 MAR 2007
F IE ''JS
C INDEN
                 RI.
                                       TOAN CHEMICAL SOCIETY (ACS)
FIEUR
                               1:.
                                      * 30 MAR 2007
                 T:
                                TO AN CHEMICAL SOCIETY (ACS)
C INI L
= · d ] . E
     ( ?T
                                3' '- 16 ON 30 MAR 2007)
                 31
                           ₹ .
                 STI
                                40
                                      : £6:57 CN 30 MAR 2007
     FII
           1 F.
                 E
                                Ţ
L
                 S
                 Ε
                                CP
                 S
                           45.
                                CI
                 Ε
                 S
Ι..
                                HV FILZON
                 Ξ
L
                 S
                                       1:34 CM 30 MAR 2007
     FII
                 IN:
                                r
                                       RELECTIVE ESTROGEN RECEPTOR MODUL? OR SERM)
L
                 S
L
                 S
                                       MITTEN OR TOREMIFENE OR TRIPHENYLETHYLENE)
                 ε
T
           1.€
            3
                 ?
                 3
L
I.
                 S
L
     FILT
                                        TAT 13:12:20 ON 30 MAR 2007
                 N!
                                        :32 ~ 30 MAR 2007
     FI
                 F
                                       " AT 13:12:46 ON 30 MAR 2007
                 T.
                                        ". AT 23:12:52 ON 30 MAR 2007
     FII
```

```
office of memifene or triphenylethylene)
THE RESERVE OR TOREMIFENE OR TRIPHENYLETHYLENE)
  => s (tamoviif
                    Ο..
 L12 4
                    (T.
                                        remifers or triphenylethylene)/clm
  = s (ta: xi'
                     03
                                         FNE OF TORFMIFENE OR TRIPHENYLETHYLENE)/CLM
 I 3
             13
  => s (antips:
                                           ragen receptor modul? or serm)
                     6:
                                            TIVE ESTROGEN RECEPTOR MODUL? OR SERM)
 L ·
              .8
  => s (an* los.
                                            reger receptor modul? or serm)/clm
                                            TITLE ESTROGEN RECEPTOR MODUL? OR SERM)/CLM
                     A.
 L 5
  => s hot fla
 L:5
                    :C
 = s hot fla
L = 2.
                     C
                    EC.
  = s 112 r
 L :
                     1.
  = · s 116 md
 M ^SIN >
            To
                                    the contains terms or the by a logical operator.
 T e sear ... r
                    . 1€
 nested t rs
                    ìt
\cdot = \cdot s 116
 L19
              3 . 1(
  = s 113 r
             15
                    il.
  = s 117
              ï.ď
  = d 1 - 2
 L 1 7 18 17
 F 1
                     9
  Ã,
             ٠.
                                           and Commental Venlafaxine (ODV) or its
  T
          7
                     o.
                                     3
              ្តព
          \mathbb{T} \leftarrow \tau p
  Ι.,
                                            TITEL STATES
                                            T, TITED STATES
THES U.S. corporation)
             Π,
 P
             t.h
                     d.
           : 0
 F
                     40
                                            1308
          Ţ
                                            2005 (11)
          ŗJ
  A
   · I
          1 - 70
                                            :50'
  P
                     1:
            · i:
  \Gamma
                    . 01
  F
 I .. CNT
              ' M '
  I Ch
                     4
 N = 1.
              ٠:
                     4
                     11
                                     , I
 L 1 A.....
   1172
 F
                    ,4
  Ţ
                                            rices containing O-Desmethyl Venlafaxine
                    ıa.
                     ÷ •
  Ĩ.
                                            WITED STATES
              1.
                                            IJ, UNITED STATES
THEE U.S. corporation)
                     F
  Ŀ
                                             3 ) 8
  Ŧ
                                             . 05
150
                                                   1)
 I
    ·I
 L
 F
   . CNT
  I.
              1.
```

```
NCIM: 4, 1
1 5: 4/
                                                                      A]: ... K0031-138 [I,A]
I ·
                 1 (1
                                  · '11''.
            AMS 111. 3
                                      . ..
T. 1
                                                            a en al et etn
                     . , 4
            F
                                                         18 j
                                                                        \ensuremath{\text{mg}} : ng gonadotropin hormone releasing hormone \ensuremath{\text{SW}} : RLAND
                 I hot.
                                                              2.5
T
                                      nc
                                                                                         RTAND
                 P - ch
                                                              ....
Ι
                                      H\epsilon
                                                                           τ, . . . . .
                 It inga
                                      · er
                                                                                         neuve, SWITZERLAND
                                                                        .15 17
                  C = \widetilde{V}
                                      oth.
                                                                                         SWITZERLAND
                 L. ...ev
                                                                        tion
                                                                                         WITZERLAND
                                        6
                 U 30 %
PΤ
                                         2'
                                                                                          1222
                         301
Α
                  Ü
                                         34.
                                                                                          (430 (10)
                           0.7
                                         3'
                                                                                        430
                                                                                         1922
                                                                                                       PCT 371 date
                         ~°C:
                                        В.
P-:I
                 V,
                  Ţ
                          it
L
                            1.
F
                                        0.
     . CNT
                Я
I.
1
      1.
                           .1.1
                                         4,
                                                                          4
                                                 )
                         ! ::
                                        4,
N :
                                         4
                                                                                          -0.0
                                                                                            M0031 56 [I,A]; A61K0038-24 [I,A]
Tr.
                                         11
I 1 ANS TO 1
                                                                         L· ·
F
                       C 1:1 1 81
A
                       h r ic
                                                                        eatler, as inhibitors of 17beta-hydroxysteroid
T
                           retructions.
                                                                          i /, "ITED STATES
                                                           er i
I.
                                      F. I dien
an E
                                                                         Yar www, PA, UNITED STATES
                      ti tene
                 Ŧ
                                                        to the interest of the states 
                          ī,
                                     . j ::
                         ∵∂,
                                                               Michaeville, NJ, UNITED STATES
                                     Sqcty
                                       ารีศาวิ
P:
                  ſ,
                          .0 55
                                                                          ): (60)
                                         55 →..
                          .00.
P.
                         202
    1 I
F
                  U
                       · ic
                  ſ.
T.
                          ...T ...
F
     .CNT
I.
                                                                                            10; 104/027.000; 514/492.000; 514/263.310;
                                                                         4
                                                                                            co; 5'4/049.000; 514/102.000; 424/649.000;
                                                                                           100; 514/449.000; 514/365.000; 514/002.000
                                         4, 3.
                      • ::
N ...
                                                                                           00; 514/002.000; 514/027.000; 514/034.000;
                                                 5
                                                                                             00; 5:4/102.000; 514/263.310; 514/269.000;
                                                 į
                                                                                          100; 534/449.000; 514/492.000; 564/152.000
                                                 5
                                                                                         Ţ
 Ţ٠
                                                                                           A61K) 31-522 [I,A]; A61K0031-519 [I,C*]; 
3K003 -66 [I,A]; A61K0039-395 [I,A];
                                         1.
                                                 )
                                        .1.
                                                                                         K0038 43 [I,C*]; C07C0237-28 [I,A];
                                       - 11
                                         7.
                                                                                           1K063.-165 [I,C]; A61K0031-513 [I,C];
                  1
                                                                                            1K0011-519 [I,C]; A61K0031-522 [I,A];
                                                                           , I = \cdot
                                         1:
                                                                                          :K0031 66 [I,A]; A61K0031-7042 [I,C];
:61K0001-7076 [I,A]; A61K0038-43 [I,C];
                                        . . .
                                         11
                                                                         I.
A
                                                 01
                                       1F 0I
                                                                                         1K0039-395 [I,C]; A61K0039-395 [I,A];
                                                                                      'C0237-28 [I,A]
                                         3.
                                                              7
                                                                         . 7
                          ••G
                                        L.
                                                T.
                                                                                          "ATENT.
CA- INDE
                                                                          ŭ :
             Ţ
I
F
                            :::
7
                                                  7
Т
                            \subset :
                                                                                          has reductase inhibitors and SERMs and
                                                 3
                                                                                            TWN, TN, UNITED STATES
TO NITED STATES
TN. NITED STATES
I.
Р
                                                                                             125
```

```
A.
        פחר יש
                                               721
                                                    10)
           15
D
         U
             .I
F
         Þ
L IN
    CNT
        1
            . M:
         Ι
                        1:
            ...,S:
                    ÷ 5
         1
N :
        N
                    ·;
                        1,
         ŀ
                        ō
                     .F 0.
                                     , ;
                                              1K0031-47 [I,A]
Ι
         Ι
                  - 11 01
                                    .,,
,...]
T
                                              %1K0031-138 [I,C]; A61K0031-47 [I,C];
         Ţ
                   FILT 0.
                    AuvII
C/ INDE" "IG
                                              PATENT.
      INS ... 6
L
      <u>F</u>
             · : ·
                    73
                        Ţ
                    . DIT : E
                                     738 B
Т
                                               treating diseases
         (
             :05
                                             ide, CA, UNITED STATES
ew, CA, UNITED STATES
                                      7/ 5
I.
             .ba
                    Jna
                                      . . . .
                        1
         ŀ
             ran
                     •
                                     :- <sub>(</sub> ...
                                               CA, UNITED STATES
         F
              on.
                        77
                                               Walley, CA, UNITED STATES
             .ma:
                                              THURD STATES
             dc.
        ŀ
                        ٠.5
             ..00
                    :: 0
:: 3
Р
         U
                                              ·201 (11)
         U
              0.0
Α
                    1
                                              0.5
              . 0
P
         Ţ
             ir
\mathbf{D}
ŀ
         Z
I.
    "N".
         1
I.
         1
                                             +10; 514/397.000; 514/649.000; 514/509.000
              S:.
                        1.
                    1. 0:
_{\rm N}
             .:
                                      Ç. 3
                                              00; 514/397.000; 514/509.000; 514/649.000
                    .4/
                        1.
Ι'.
                        3′
         I
                                              TT; A61K031-4178; A61K031-137
                    ±F 3
                                     370
                                      £.~
                                              K0038-08 [ICS,7]; A61K0031-5377 [ICS,7];
                    ·1F 01
                                              [*]; A61K0031-4178 [ICS,7]; A61K0031-4164
3T [ICS,7]
                                     LEC. I.
                    1k 0.
                                     100
                    CΣ
                                     , (
                                              A61K0031-137 [I,A]; A61K0031-4164 [I,C*];
         ľ
                    1...
                     1 II
                                              %61K0001-5375 [I,C*]; A61K0031-5377 [I,A];
                        ıÒ.
                                     C^{2} .
                    1K. 00
                                              %1K0038-00 [I,A]; A61K0038-08 [I,C*];
                    TIK OF
AT TI
                                     ĵ۸.
                                    3 Tr.
                                             "ATENT.
C'I INDY
             G
      : 7
                                             * 13.7
L
F
        ÷
\bar{A}.
              : 9
                        ۲J.
                                      \mathbf{T}
             . th
                     C
                         ÷.
                                              tion induced osteoporosis
                                              com, TN, UNITED STATES
1
             - 11:1
                    Μi
              ::'.·
         ۲,
                    K∂
                                                TT, NITED STATES
         F
                    hε
                                               613
P۳
         τ
                    0-
                                              07. 00)

Ma. MC 2004-778334, filed on 17 Feb 2004,

Ma. Mc 2003-609684, filed on 1 Ju
A
         ι
                     4 -
             . ; .
                    i·
R
         (
              _ 1
                     ٠,
                                              er Seg. No. US 2003-609684, filed on 1 Jul
                                              repair of Ser. No. US 2002-305363, filed on
              νC
                                                = ( )
F
              0.0
              it
L
                     1.
F
I.
  . :N'.
              ·::
1
         1
                    4/5
Ν
         N
                    4/
I
                     1F
                        7
                              ذ
                    1 F
                              1
                                              #TIM0731-138 [I,A]
                     11
                              1
                                      . 4
                     AV II
C
        וכי
                                              ATENT.
               2
        Tr
                      2
L
F
A.
              : 7
                        `J:
```

```
M~ . . . . . . . .
                                                the for predicting the effect of compounds
\mathbf{T}^{+}
                     20 %
               ot
         C .
                     as. :
                                                 UNITED STATES
UNITE STATES
                     in,
I
              in,
                      ..€
             . n
                                                 ED ST.TES
         Z
                      Sn
             - 00
                      44 ?
P
         U
              -
-
-
-
-
                     70 3
         U
                                                        ຶ ວ)
A
Р
         U
                     79
\mathbb{D}
         U
               i.
         Α
                     "ON
F
              TIC.
T,
         3
         I_{1}
Ι
                     5/ 0
                    5/ -01
-5/ -0:
         I,
              S:
                                                 50; 514/319.000; 514/651.000
\mathbf{N}
         ľ
             . :
                     ·5/:0°
                                                100; 514/319.000; 514/651.000
         ľ
1
         [
                     120102
         Ι
                                1. 1.
1. 1. 11,
1. 1. 15,
                              15 × 114
                                      7; A61K031-56; A61K031-445; A61K031-138
11, ; :01N0033-53 [ICS,7]; G01N0033-567 [ICS,7];
         I
                     1M 33
         Ι
                     .2Q(0)(
                     1K103
                                             : .51K0031-445 [ICS,7]; A61K0031-138 [ICS,7]
                                                51K0031-138 [I,A]; A61K0031-445 [I,C*];
         Ι
                     51K 101
                                                11K0033-56 [I,C*]; A61K0031-56 [I,A];
                     51K 0:
                                                300001-68 [I,A]; G01N0033-53 [I,C*]; N0033-567 [I,C*]; G01N0033-567 [I,A]
                     12Q10.
(1N10).
                     AV. II
                                                Yunkhin.
C
     HUDE
       1.1.
                     . 2
L
<u>F</u>
                     177
A
              .:2
                     1 v
                                                T
         ŀ
               100
I.
              116
                     e1 e.
                                                PA FA UNITED STATES award reville, NJ (U.S. corporation)
                          ٠, ٠
                      F.
P
         V
                     ma
                                                 . : 5
P
         Ţ
                     .98
À
         Ι.
              .0.
                     '81. ?
                                                 Th. WS 2003-369823, filed on 19 Feb 2003,
         C
                     io -
R
              1i.
             TY
         Þ
D
F
         Α
                     ON
     INT.
I
I
              : i:
                     4/,2:
                    14/.2
ľ
                     1K' 31
                                      1K: 01
                                                  A61K 031-551 [ICM, 7, C*]
         Ţ
                     11K/ 03
                                                 61K0001-5513 [I,A]
     IMDE
                     AVIII
                                                 ATENT.
C*.
       , NS
                    OF 10
                                                 TN
L
\frac{\mathbf{F}}{I}
        22
                     ?75 T
         2
                                                 rature with (R) - 2,3-benzodiazepines
c, PA: UNITED STATES
c. PA: UNITED STATES
Ŧ
                    · 10 We
         F
I
                    , Ster
               17
                       RC >6
F
         []
                     49.3
                                                 111
                                                 (0) (a) (a)
I.
         Ţ
                     2783.
                                                 Th. H 2004-781422, filed on 17 Feb 2004,
R
         C
              i:
                      ion -
                     on':
                                                 or 5000 No. US 2003-369823, filed on 19 Feb
                     DII
\Gamma
F.
                     ON
1.
         1
             • • • •
                     4/12
4/12
Ι
ì
                     1K(3)
                                                  3-1% 031-351 [ICM,7,C*]
                     1K( ):
                                  1
                                                 RECO.
                                                  200
C
     Il Di
                     AVET?
\mathbf{L}
       \mathcal{N}_{i}
                     2 10
                                  J
F
```

```
A`'
         2 - .
                                   Fī.
                     396 T
T
         N.
                     for t:
                                   ·γ
                                                   1:13
                                                   TN, UNITED STATES
TO VNITED STATES
TO UT TED STATES
I
         Ç
                      Mitcl
                                   3
         R
                     hai a:
                      Kai e
         U
Ρ
                     4857
                                                  100)

100 2003-747691, filed on 30 Dec 2003,

100 30 No. US 2003-609684, filed on 1 Jul
                     .7833
A
                     fion-
R
                     Cont in
                                                    wart of Ser. No. US 2002-305363, filed on
                     IDING
         2
                     .02, 1
Ъ.
         IJ
              . c·
                     33373-
\Gamma
         U
         Þ.
                     NCI
F
Ι
                     14/651
I
Ν
                     14/€51
I
                     4 1KC31
         1
                     31KC90
                                                  U1K0001-138 [I,A]
                     - 1KC03
      تار. `I
                                                  T.TENT.
C
               ر'
                      AVA II
\mathbf{L}
       7 NS
                     F 20
                                                   TiJ
Ţ
         12
                   :49 T
                                i PUT i
                                nç
7
         1.
                     For ti
                                       100
                                                  thes and gynecomastia
                                                  CVM, I'N, UNITED STATES
TN, UNITED STATES
TN, UNITED STATES
TO US TO STATES
TO US 2003-609684, filed on 1 Jul 2003,
TO US 2002-305363, filed on 27 Nov
                                        141 -
               1.
                      Mitc!
                                   S.
                     . harat
                                   1 .
               r
                      Karet
                     3841
P
               0
                     747€9
Į.
F
         C
                     ior-
                      ont u
         I
                      DING
               1
Ρ
                      33734
Τ.
F
                      ON
     \mathcal{N}
T
7
                      4/45
                      4/641
                      1/45
\mathbf{N}
               :
                     14/64
Ι
                     J1KC3
                     1KC0:
         Ι
                                                  09-20 [ICS,7]
| Krd:1-138 [I,A]
                      1K(0.
                                   ;
                      1K()
C,
                      AV# II
                                · ATTITE
                     DF 20
                                                 .:77
Ι
                                   30
                     +27 · I
                                              - - of flashes
                                   atr m:
T
                     .e f.o:
               ٧,
                                              A fille, IN, UNITED STATES
                                   de . I
Ι
                      Ow∈n
                                                coolin, in, united states
         'n
                      Timot
P
                      2733
               ( ·
                                                   1 (10)
Į.
                      7363.
                      S51 l
D
               ;
F
                      ИC
I
I
                      4/33
                      1/4
ř
                      4/33
                      1/4?
1
                      LKC
                      1K( ·
                                                    31-3:1 [ICS,7]
30(-1-38. [I,A]; A61K0031-452 [I,C*];
                      1KC Y
                      1K( )
                                                    1 01.-565 [I,C*]; A61K0031-565 [I,A]
                      1KC)
```

```
CIT I DE
           ٠,٦
                  AVATI
                             F( ' '
                                         PATENT.
                 OF 20 M. ATI LA
                                         BTN
Τ.
      112
<u>F</u>
                 359 T.
                             7UI
           ; <u>:</u>
                                          formonal variation, including hot
T
                 tro
                              18.
                                         on antagonist or, NY, UNITED STATES
            1.
                  usine
                             17]
           ٠.;
                  Thoma
1
                  623
F
                  091'
                                          72 ( 0)
I^{:}
                                          : -8 9390, filed on 12 Jun 2001, PENDING
                  ior
R
Ρ
  : I
                  111 .
D
F
                  NC -
   -,,,
I.
            . .
I
                  4/17
                  4/1
                  1KC:
                              [:
                  51KC01
                  1KC?
                                       F(03:-00 [I,A]; A61K0031-395 [I,C*];
                  JIKCOI
                                        ... N:03"-40 [I,C*]; A61K0031-40 [I,A];
                  •1KC ):
                                          1.100.1-401 [I,A]; A61K0031-403 [I,C*];
                                        F0031-404 [I,A]; A61K0031-405 [I,A]; 100031-445 [I,A]; A61K0031-451 [I,C*];
                  ILKCO'
                  1K(0)
                             5
                                        . 1K0031-4523 [I,C*]; A61K0031-454 [I,A];
                  >1KCO
                             L
                                      % 1 M 0 C 3 1 - 47 [I, C*]; A 6 1 K 0 O 3 1 - 47 [I, A];
                 1KCO.
                             45
                                      ; A61K0031-496 [I,A]; A61K0031-5375 [I,C*];
                             .6
                 31KC03
                                      - 351K0038-12 [I,C*]; A61K0038-12 [I,A]; - 1K0045-06 [I,A]
                 SIKCOD
                            .77
                             [:
                 -1KCO-
                            FC
                                       · TATENT.
   . I ),
                  AVAII
(
                  `F 20
                             ATI T
                                         T
F
                  7 75
                             JUI
7
                  es "
                              rc in
                                         coulators in combination with estrogens
                                          CALIADA
                 .err .
                             air
                                           r roration)
                  rcl
F
                  50C
F
                                        1.32 (10)
                  13€
7
                               2
                                          (1-711180, filed on 26 Jan 2001, PENDING
\mathbf{F}
                 io1 .
Ŀ
   Ţ
                  780
Ι
Ţ
                  NC
  . CN
I.
                   1/3
                  4/3.
                                           5 1/456.000; 514/651.000; 514/622.000;
                             : [
                  4/600
                  4/3
                  4/3
                            . . .
                                           5:4/456.000; 514/602.000; 514/622.000;
                  1/(
Ţ
                  1KC?
                                       7; A61K031-165; A61K031-137
11K0631-38 [ICS,7]; A61K0031-353 [ICS,7];
                  1K( -
                            A
                              IKCC.
                             3 ້ ເຕ
                  1K( ^.
                                           ; A61K0031-165 [ICS,7]; A61K0031-137
                  [CS,7]
                  . 1KC)
                                        ACIKO031-35 [I,A]; A61K0031-565 [I,C*];
                              [ ]
                  1K( ^
                                           KC04F-00 [I,C*]; A61K0045-06 [I,A]
                                          MINT.
                              FC
C
 3 7
                  AVA II
                                         .17
Ι
                  F 20
                             TTE
I
                              TI
                   1
                                           relators in combination with estrogens
                   er
                              r€
                                           ATATA
                              ۹ir
                   eri
                                           regrettion)
F
                   cl
                   )5
ŀ
Z
                   38:
                                              171180, filed on 26 Jan 2001, PENDING
F
                   io:
   Ι
                   78
```

```
FS
       APPLICATION
LN.CNT 2854
INCL
       INCLM: 514/177.000
       INCLS: 514/178.000
NCL
       NCLM: 514/177.000
       NCLS: 514/178.000
IC
       [7]
       ICM
               A61K031-56
               A61K0031-56 [ICM, 7]
       IPCI
               A61K0031-35 [I,C*]; A61K0031-35 [I,A]; A61K0031-565 [I,C*];
       IPCR
               A61K0031-565 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L21 ANSWER 17 OF 20 USPATFULL on STN
Full Text
AN
       2003:29916 USPATFULL
       Soy formulations and their use for promoting health
TΙ
       Tabor, Aaron, Winston-Salem, NC, UNITED STATES
US 2003021859 A1 20030130
IN
PΙ
                             A1 20020930 (10)
       US 2002-260993
AΙ
       Division of Ser. No. US 1999-356167, filed on 16 Jul 1999, GRANTED, Pat.
RLI
       No. US 6482448
       US 1998-92985P
US 1998-105797P
                              19980716 (60)
PRAI
                             19981027 (60)
DT
       Utility
       APPLICATION
LN.CNT 1339
INCL
       INCLM: 424/757.000
       INCLS: 514/027.000; 514/456.000
       NCLM: 424/757.000
NCL
       NCLS: 514/027.000; 514/456.000
IC
        [7]
       ICM
               A61K035-78
               A61K031-7048; A61K031-353
       ICS
       IPCI
               A61K0035-78 [ICM,7]; A61K0031-7048 [ICS,7]; A61K0031-7042
               [ICS,7,C*]; A61K0031-353 [ICS,7]; A61K0031-352 [ICS,7,C*]
               A23L0001-20 [I,C*]; A23L0001-20 [I,A]; A23L0001-29 [I,C*]; A23L0001-29 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
       IPCR
               A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0031-35 [I,C*];
               A61K0031-35 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A];
               A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-7042 [I,C*];
               A61K0031-7048 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L21 ANSWER 18 OF 20 USPATFULL on STN
Full Text
       2002:192152 USPATFULL
AN
       SOY FORMULATIONS AND THEIR USE FOR PROMOTING HEALTH
TI
       TABOR, AARON, WINSTON-SALEM, NC, UNITED STATES
IN
PΙ
       US 2002103223
                             A1 20020801
                             B2 20021119
A1 19990716
       US 6482448
       US 1999-356167
                                  19990716 (9)
AΤ
                              A1
       US 1998-92985P
                              19980716 (60)
PRAI
       US 1998-105797P
                              19981027 (60)
       Utility
       APPLICATION
FS
LN.CNT 1339
INCL
        INCLM: 514/310.000
       NCLM: 424/757.000; 514/310.000
NCL.
       NCLS: 426/629.000; 514/027.000; 514/028.000
IC
        [7]
        ICM
               A61K031-47
               A01N043-42
        ICS
               A61K0031-47 [ICM,7]; A01N0043-42 [ICS,7]; A01N0043-34 [ICS,7,C*]
       TPCT
        IPCI-2 A61K0031-70 [ICM,7]; A61K0033-00 [ICS,7]; A23L0001-36 [ICS,7]
               A23L0001-20 [I,C*]; A23L0001-20 [I,A]; A23L0001-29 [I,C*]; A23L0001-29 [I,A]; A23L0001-30 [I,C*]; A23L0001-305 [I,C*]; A23L0001-305 [I,C*]; A23L0001-305 [I,C*];
              A61K0031-35 [I,A]; A61K0031-352 [I,C*]; A61K0031-352 [I,A];
               A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-7042 [I,C*];
               A61K0031-7048 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L21 ANSWER 19 OF 20 USPATFULL on STN
Full Text
       2002:27435 USPATFULL
AN
       Method of treating symptoms of hormonal variation, including hot
ΤI
       flashes, using tachykinin receptor antagonist
       Guttuso, Thomas J., JR., Rochester, NY, UNITED STATES US 2002016283 A1 20020207 US 2001-879390 A1 20010612 (9)
IN
ΡI
ΑI
                             20000612 (60)
       US 2000-211116P
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 590
       INCLM: 514/001.000
INCL
       NCLM: 514/001.000
NCL
IC
       [7]
       ICM
               A61K031-00
       IPCI
               A61K0031-00 [ICM, 7]
               A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-395 [I,C*];
       IPCR
               A61K0031-395 [I,A]; A61K0031-40 [I,C*]; A61K0031-40 [I,A];
               A61K0031-401 [I,C*]; A61K0031-401 [I,A]; A61K0031-403 [I,C*];
               A61K0031-403 [I,A]; A61K0031-404 [I,A]; A61K0031-405 [I,A]; A61K0031-445 [I,C*]; A61K0031-445 [I,C*]; A61K0031-451 [I,C*]; A61K0031-451 [I,A]; A61K0031-454 [I,A];
               A61K0031-4545 [I,A]; A61K0031-47 [I,C*]; A61K0031-47 [I,A];
               A61K0031-496 [I,C*]; A61K0031-496 [I,A]; A61K0031-5375 [I,C*];
               A61K0031-5377 [I,A]; A61K0038-12 [I,C*]; A61K0038-12 [I,A];
               A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L21 ANSWER 20 OF 20 USPATFULL on STN
Full Text
AN
       2001:191165 USPATFULL
       Method of treating symptoms of hormonal variation, including hot flashes
TI
TN
       Guttuso, Jr., Thomas J., Rochester, NY, United States
       University of Rochester, Rochester, NY, United States (U.S. corporation)
PA
ΡI
       US 6310098
                             B1 20011030
       US 2000-620979
ΑI
                                  20000721 (9)
PRAI
       US 1999-145061P
                             19990722 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 625
       INCLM: 514/567.000
INCL
NCL
       NCLM: 514/567.000
IC
       [7]
       ICM
               A61K031-195
               A61K0031-195 [ICM, 7]; A61K0031-185 [ICM, 7, C*]
       IPCI
               A61K0031-185 [I,C*]; A61K0031-195 [I,A]
       IPCR
EXF
       514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
=> d an ti pi kwic 1-20
L21 ANSWER 1 OF 20 USPATFULL on STN
Full Text
       2007:62819 USPATFULL
AN
TI
       Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its
       salts
PΙ
       US 2007054964
                             A1 20070308
CLM
       What is claimed is:
       12. The method of claim 11, wherein the subject suffering from vasomotor
       symptoms experiences hot flashes.
       13. The method of claim 12, wherein administering the composition to the
       subject comprises applying a therapeutically effective amount of the
       composition to one or more skin surface areas of the subject's body
       experiencing hot flashes.
```

17. The method of claim 16, wherein the breast cancer treatment

comprises administration of tamoxifen.

L21 ANSWER 2 OF 20 USPATFULL on STN

Full Text

2007:61834 USPATFULL AN

Transdermal drug delivery devices containing O-Desmethyl Venlafaxine TΤ (ODV) or its salts

A1 20070308 US 2007053968 PΙ

What is claimed is: CLM

20. The method of claim 19, wherein the subject suffering from vasomotor symptoms experiences hot flashes.

24. The method of claim 23, wherein the breast cancer treatment comprises administration of tamoxifen.

L21 ANSWER 3 OF 20 USPATFULL on STN

Full Text

ΑN

2007:48218 USPATFULL Methods and compositions using gonadotropin hormone releasing hormone ΤI

A1 20070222 ΡI US 2007042040

What is claimed is: CLM

1. A composition consisting of: a first sustained release formulation of a gonadotropin hormone releasing hormone composition capable of . of maintaining for said period a serum level releasing. sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient,.

estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient.

estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

of maintaining for said period a serum level sufficient to reduce the enhanced loss of bone mineral density or the hot flashes that are normally caused by the administration of a gonadotropin hormone releasing hormone composition that chemically castrates a male patient,.

estrone, estrone sulfate monosodique, estrone potassium sulfate, ethinylestradiol, fosfestrol tetrasodique, hexestrol, hydroxyestrone diacetate, mestranol, pinestrol, piperazine estrone sulfate, promestriene, quinestrol, tamoxifen, toremifene, raloxifene, lasofoxifene and mixtures thereof.

L21 ANSWER 4 OF 20 USPATFULL on STN

Full

CLM

ΑN 2006:160082 USPATFULL

Anthranilic acid derivatives as inhibitors of 17beta-hydroxysteroid ΤI dehydrogenase 3

A1 20060622 PΙ US 2006135619

What is claimed is: 15. The pharmaceutical composition of claim 14, wherein said anti-cancer or cytotoxic agent is selected from tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, metalloproteinase inhibitors, inhibitors. 18. The pharmaceutical composition of claim 17, wherein said anti-cancer or cytotoxic agent is selected from tamoxifen, toremifene,

raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole,
letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide,
cyproterone acetate, gosereline acetate, leuprolide, finasteride,
metalloproteinase inhibitors, inhibitors.

metalloproteinase inhibitors, inhibitors.

. of testosterone levels in men, cancers containing at least one estrogen receptor, breast cancer, ovarian cancer, uterine cancer, endometrial cancer, hot flashes, vaginal dryness, menopause, amenorrhea, dysmennorrhea, contraception, pregnancy termination, cancers containing at least one progesterone receptor, cyclesynchrony, meniginoma, fibroids, labor induction,.

24. The method of claim 23, wherein said anti-cancer or cytotoxic agent is selected from tamoxifen, toremifene, raloxifene, droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline acetate, leuprolide, finasteride, metalloproteinase

L21 ANSWER 5 OF 20 USPATFULL on STN

inhibitors, inhibitors.

Full Text

AN 2006:22155 USPATFULL

TI Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

PI US 2006019989 A1 20060126

CLM What is claimed is:

- 1. A composition comprising a 5-alpha reductase inhibitor and a **selective estrogen receptor modulator** (SERM) compound represented by the structure of formula I, its N-oxide, ester, pharmaceutically acceptable salt, hydrate, or any combination thereof: ##STR3##. . .
- The composition according to claim 1, wherein said selective estrogen receptor modulator compound is an analog, isomer, metabolite, derivative, pharmaceutically acceptable salt, pharmaceutical product, N-oxide, hydrate or any combination thereof of said.
 The composition according to claim 1, wherein said selective androgen receptor modulator is triphenylethylene, toremifene, or a combination thereof.
- 4. The composition according to claim 1, wherein said **selective estrogen receptor modulator** compound is at a concentration of between about 5 to about 80 milligrams.
- 50. A method of suppressing, inhibiting, reducing the risk of developing, preventing or treating a subject with **hot flashes**, comprising the step of administering to said subject the composition of claim 1, in an amount effective to suppress, inhibit, reduce the risk of developing, prevent or treat **hot flashes** in said subject.

L21 ANSWER 6 OF 20 USPATFULL on STN

Full Text

AN 2005:221473 USPATFULL

TI Compositions and methods for treating diseases

PI US 2005192210 A1 20050901

CLM What is claimed is:

dysfunctions, vaginal lubrication, vaginal engorgement, pain during intercourse (e.g., dyspareunia or vulvadynia), urologenital infections, estrogen depletion conditions, menopause and post-menopause, hot flashes, preeclampsia, vulvodynia, cataract, intraocular pressure, dry eye, and diabetic retinopathy, aging, necrotizing fascitis, decubitus ulcers, anal fissures, scleroderma, Raynaud's phenomenon, . . .

. the group consisting of pilocarpine, timolol maleate, betataxolol HCl, epinephrine, dipivefrin, demecarium bromide, echothiophate iodide, A3 subtype adenosine receptor antagonist, antiestrogen, and calmodulin antagonist.

L21 ANSWER 7 OF 20 USPATFULL on STN

Full Text

AN 2005:93464 USPATFULL

TI Treatment of androgen-deprivation induced osteoporosis

PI US 2005080143 A1 20050414

CLM What is claimed is:

- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 2. The method according to claim 1, wherein said toremifene is toremifene citrate.
- 3. The method according to claim 1, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 8. The method according to claim 7, wherein said toremifene is toremifene citrate.
- 9. The method according to claim 7, wherein said administering comprises administering a pharmaceutical composition comprising said **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 14. The method according to claim 13, wherein said toremifene is toremifene citrate.
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 17. The method according to claim 16, wherein said toremifene is toremifene citrate.
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject A toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 20. The method according to claim 19, wherein said toremifene is toremifene citrate.
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof
- 23. The method according to claim 22, wherein said toremifene is toremifene citrate.
- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 26. The method according to claim 25, wherein said toremifene is toremifene citrate.

- . a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 29. The method according to claim 28, wherein said toremifene is toremifene citrate.
- 31. A method of treating an androgen-deprivation induced **hot flash** in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a **toremifene** and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 32. The method according to claim 31, wherein said toremifene is toremifene citrate.
- 33. The method according to claim 31, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . . 37. A method of reducing the incidence of androgen-deprivation induced hot flashes in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 38. The method according to claim 37, wherein said toremifene is toremifene citrate.
- 39. The method according to claim 37, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . . 43. A method of suppressing or inhibiting an androgen-deprivation induced hot flash in a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 44. The method according to claim 43, wherein said toremifene is toremifene citrate.
- 45. The method according to claim 43, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 50. The method according to claim 49, wherein said toremifene is toremifene citrate.
- 51. The method according to claim 49, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically

acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.

- 56. The method according to claim 55, wherein said toremifene is toremifene citrate.
- 57. The method according to claim 55, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 62. The method according to claim 61, wherein said toremifene is toremifene citrate.
- 63. The method according to claim 61, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 68. The method according to claim 67, wherein said toremifene is toremifene citrate.
- 69. The method according to claim 67, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 74. The method according to claim 73, wherein said toremifene is toremifene citrate.
- 75. The method according to claim 73, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. a male human subject having prostate cancer, said method comprising the step of administering to said male human subject a toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.
- 80. The method according to claim 79, wherein said toremifene is toremifene citrate.
- 81. The method according to claim 79, wherein said administering comprises administering a pharmaceutical composition comprising said toremifene and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof; and a pharmaceutically. . .
- L21 ANSWER 8 OF 20 USPATFULL on STN

Full Text

AN 2005:75165 USPATFULL

TI Methods, compositions, and kits for predicting the effect of compounds

on hot flash symptoms
US 2005064462 A1 20050324

CLM Wh

- What is claimed is:

 1. A method for determining the effect of a candidate compound on hot-flash symptoms, comprising: a) contacting a first cell that expresses an estrogen receptor or estrogen related receptor with said candidate compound; . . . b) determining the effect of said candidate compound on said first cell's expression of a panel of genes associated with hot flash symptoms.
- . of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with hot flash symptoms with a reference expression profile of said panel of genes associated with hot flash symptoms.
- . of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and tamoxifen.
- . of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with hot flash symptoms with a second cell's expression of said panel of genes associated with hot flash symptoms following contact with a compound that has a known effect on hot flash symptoms.
- 5. The method of claim 4, wherein said compound that has a known effect on **hot flash** symptoms is selected from the group that consists of estradiol, tibolone, **raloxifene**, and **tamoxifen**.
- 6. The method of claim 2 or 4, wherein said method comprises determining that said compound decreases the incidence of **hot flash** symptoms.
- 12. The method of claim 1, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by determining the presence and amount of mRNA expressed from said panel of genes.
- 13. The method of claim 12 wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, . . . 14. The method of claim 13, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a multiplexed array mRNA assay.
- 15. The method of claim 1, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by determining the presence and amount of protein expressed from said panel of genes.
- 16. The method of claim 15, wherein said cell's expression of said panel of genes associated with **hot flash** symptoms is quantified by a technique selected from the group of a western blot assay, an ELISA assay, a cytokine. . .
- 23. A method for rapidly determining the effects of a plurality of compounds on hot-flash symptoms, comprising: a) separately contacting a sample of cells that express an estrogen receptor or estrogen related receptor with each. . . of said plurality of compounds on each of said samples of cells' expression of a panel of genes associated with hot flash symptoms, thereby predicting the effect of each of said compounds on hot-flash symptoms.
- . The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with hot flash symptoms by said samples of cells with a reference expression profile of said panel of genes associated with hot flash symptoms.
- 25. The method of claim 24, wherein said reference expression profile of said panel of genes is the expression profile. . . of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and tamoxifen.

The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with hot flash symptoms by said samples of cells with the expression of said panel of genes associated with hot flash symptoms by a sample of cells following contact with a compound that has a known effect on hot flash symptoms.

27. The method of claim 26, wherein said compound that has a known effect on hot flash symptoms is selected from the group that consists of estradiol, tibolone, raloxifene, and tamoxifen.

- 28. The method of claim 24 or 26, wherein said method comprises determining that said compound decreases the incidence of hot flash symptoms.
- 34. The method of claim 23, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by determining the presence and amount of mRNA expressed from said panel.
- 35. The method of claim 34, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a technique selected from the group of reverse transcription real time.
- 36. The method of claim 35, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a multiplexed array mRNA assay.
- 37. The method of claim 23, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by determining the presence and amount of protein expressed from said panel.
- 38. The method of claim 37, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a technique selected from the group of a western blot assay,
- surface, wherein at least one of said oligonucleotides is specific for a member of a panel of genes associated with hot flash symptoms, and wherein each of said different oligonucleotides is connected with said surface in a different predetermined region of said.
- at least one of said oligonucleotides hybridizes under stringent conditions to a member of a panel of genes associated with hot flash symptoms.

L21 ANSWER 9 OF 20 USPATFULL on STN

Full Text

- AN 2004:292777 USPATFULL
- Method of lowering body temperature with (S)-2,3-benzodiazepines US 2004229866 A1 20041118 ΤI
- PΙ US 2004229866 A1 20041118
- What is claimed is: CLM
 - 13. The method according to claim 9 wherein the disorder comprises hot flashes.
 - 14. The method according to claim 13 wherein said hot flashes occur during menopause.
 - 15. The method according to claim 13 wherein said hot flashes occur during perimenopause.
 - 16. The method of claim 13 wherein said hot flashes are side effects of drug therapy.
 - 17. The method of claim 13 wherein said hot flashes occur subsequent to the removal of estrogen-producing tissue.
 - 18. The method of claim 13 wherein said hot flashes occur subsequent to organ failure of estrogen-producing organs.
 - 22. A method of lowering body temperature of an individual suffering from hot flashes associated with menopause, comprising administering to said individual an effective amount of (a) at least one compound according to Formula. . . a compound; and (b) one or more additional therapeutic agents selected from the group consisting of estrogen

agonists, progesterone agonists, **selective estrogen receptor modulators**, bisphosphonates, selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobuteric acid modulators.

- 26. The method according to claim 22, wherein the selective estrogen receptor modulator agonist is selected from the group consisting of raloxifene and bazedoxifene.
- . a compound; and (b) at least one additional therapeutic agent selected from the group consisting of estrogen agonists, progesterone agonists, selective estrogen receptor modulators, bisphosphonates; selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobuteric acid modulators.
- L21 ANSWER 10 OF 20 USPATFULL on STN

Full Text

PΙ

AN 2004:286775 USPATFULL

TI Method of lowering body temperature with (R) - 2,3-benzodiazepines

US 2004224943 A1 20041111

CLM What is claimed is:

- 13. The method according to claim 9 wherein the disorder comprises hot flashes.
- 14. The method according to claim 13 wherein said hot flashes occur during menopause.
- 15. The method according to claim 13 wherein said hot flashes occur during perimenopause.
- 16. The method of claim 13 wherein said hot flashes are side effects of drug therapy.
- 17. The method of claim 13 wherein said hot flashes occur subsequent to the removal of estrogen-producing tissue.
- 21. A method of lowering body temperature of an individual suffering from hot flashes associated with menopause, comprising administering to said individual an effective amount of (a) at least one compound according to Formula. . . a compound; and (b) one or more additional therapeutic agents selected from the group consisting of estrogen agonists, progesterone agonists, selective estrogen receptor modulators, bisphosphonates, selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobuteric acid modulators.
- 25. The method according to claim 21, wherein the **selective estrogen** receptor modulator agonist is selected from the group consisting of raloxifene and bazedoxifene.
- . a compound; and (b) at least one additional therapeutic agent selected from the group consisting of estrogen agonists, progesterone agonists, selective estrogen receptor modulators, bisphosphonates; selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobuteric acid modulators.
- L21 ANSWER 11 OF 20 USPATFULL on STN

Full Text

AN 2004:274396 USPATFULL

TI Methods for treating hot flashes

PI US 2004214898 A1 20041028

CLM What is claimed is:

- 1. A method of treating a subject with **hot flashes**, said method comprising the step of administering to said subject a **selective estrogen receptor modulator** (**SERM**) and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
- 2. The method according to claim 1, wherein said SERM is Toremifene.
- 5. The method according to claim 1, wherein said SERM is administered

- at a dosage of about 20 mg per day.
- 6. The method according to claim 1, wherein said **SERM** is administered at a dosage of about 40 mg per day.
- 7. The method according to claim 1, wherein said ${\tt SERM}$ is administered at a dosage of about 60 mg per day.
- 8. The method according to claim 1, wherein said **SERM** is administered at a dosage of 80 mg per day.
- 9. A method of suppressing, inhibiting or reducing the risk of **hot flashes**, said method comprising the step of administering to said subject a **SERM** and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
- 10. The method according to claim 9, wherein the SERM is Toremifene.
- 13. The method according to claim 9, wherein said **SERM** is administered at a dosage of about 20 mg per day.
- 14. The method according to claim 9, wherein said ${\tt SERM}$ is administered at a dosage of about 40 mg per day.
- 15. The method according to claim 9, wherein said **SERM** is administered at a dosage of about 60 mg per day.
- 16. The method according to claim 9, wherein said **SERM** is administered at a dosage of 80 mg per day.

L21 ANSWER 12 OF 20 USPATFULL on STN

Full Text

- AN 2004:273349 USPATFULL
- TI Methods for treating hot flashes and gynecomastia
- PI US 2004213841 A1 20041028
- CLM What is claimed is:
 - 1. A method of treating a subject with **hot flashes**, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide,.
 - 2. The method according to claim 1, wherein said anti-estrogen is a selective estrogen receptor modulator (SERM).
 - 3. The method according to claim 1, wherein said anti-estrogen is a triphenylethylene.
 - 4. The method according to claim 1, wherein said anti-estrogen is Toremifene.
 - 7. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
 - 8. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
 - 9. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
 - 10. The method according to claim 1, wherein said antiestrogen is administered at a dosage of 80 mg per day.

 - 12. The method according to claim 11, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
 - 13. The method according to claim 11, wherein the anti-estrogen is a triphenylethylene.

- 17. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
- 18. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
- 19. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
- 20. The method according to claim 11, wherein said antiestrogen is administered at a dosage of 80 mg per day.
- 22. The method according to claim 21, wherein said anti-estrogen is a selective estrogen receptor modulator (SERM).
- 23. The method according to claim 21, wherein said anti-estrogen is a triphenylethylene.
- 24. The method according to claim 21, wherein said anti-estrogen is Toremifene.
- 27. The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
- 28. The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
- 29. The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
- 30. The method according to claim 21, wherein said antiestrogen is administered at a dosage of 80 mg per day.
- 32. The method according to claim 31, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
- 33. The method according to claim 31, wherein the anti-estrogen is a triphenylethylene.
- 34. The method according to claim 31, wherein the anti-estrogen is Toremifene.
- 37. The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
- 38. The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
- 39. The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
- 40. The method according to claim 31, wherein said antiestrogen is administered at a dosage of 80 mg per day.
- L21 ANSWER 13 OF 20 USPATFULL on STN
- Full Text
- AN 2004:197427 USPATFULL
- TI Duloxetine for treatment of hot flashes
- PI US 2004152733 A1 20040805
- CLM What is claimed is:
 - 1. A method of treating **hot flashes** in a mammal comprising administering to a mammal in need thereof an effective amount of duloxetine.
 - 5. Duloxetine for use in the treatment of hot flashes.
 - 6. A pharmaceutical formulation containing, as an active ingredient, duloxetine adapted for use in the treatment of hot flashes.

- 7. The use of duloxetine for the manufacture of a medicament for the treatment of **hot flashes**:
- 8. A method of treating **hot flashes** in a human undergoing **raloxifene** administration comprising administering an effective amount of duloxetine to a human in need thereof.
- 9. The method according to claim 7 where the raloxifene is raloxifene hydrochloride.
- 10. The method according to claim 7 where the administration of duloxetine and raloxifene is concurrent.
- 11. The method according to claim 9 where the administration of duloxetine and raloxifene is simultaneous.
- 12. The use of duloxetine for the manufacture of a medicament for treating **hot flashes** in a human female undergoing **raloxifene** administration.
- 13. A pharmaceutical formulation adopted for treatment of hot flashes in humans comprising duloxetine and raloxifene.
- 14. A method of treating **hot flashes** in a human undergoing estrogen replacement therapy comprising administering an effective amount of duloxetine to a human in need thereof.
- 17. The use of duloxetine for the manufacture of a medicament for treatment of **hot flashes** in a human female undergoing estrogen replacement therapy.
- 18. A pharmaceutical formulation adopted for treatment of **hot flashes** in humans comprising duloxetine and estrogen replacement therapy.
- 19. A method of treating **hot flashes** in a human female comprising administering to a woman in need thereof an effective amount of duloxetine estrogen replacement therapy. . .
- 20. The use of duloxetine for the manufacture of a medicament for treatment hot flashes in a human female where estrogen replacement therapy is contraindicated.
- L21 ANSWER 14 OF 20 USPATFULL on STN

Full Text

AN 2003:335359 USPATFULL

TI Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist

PI US 2003236237 A1 20031225

CLM What is claimed is:

- 1. A method of treating hot flashes in a patient comprising: providing a tachykinin receptor antagonist selected from the group of NK₂ receptor antagonists and NK₃ receptor antagonist; and administering the tachykinin receptor antagonist to a patient experiencing hot flashes under conditions effective to treat the hot flashes.
- 13. The method according to claim 12, wherein the drug is an antiestrogen compound.
- 14. The method according to claim 13, wherein the anti-estrogen compound is tamoxifen.
- 16. The method according to claim 15, wherein the male patient experiences drug induced hot flashes.
- L21 ANSWER 15 OF 20 USPATFULL on STN

Full Text

AN 2003:93647 USPATFULL

TI Selective estrogen receptor modulators in combination with estrogens

PI CLM

What is claimed is:

1. A method of treating or reducing the risk of acquiring a condition selected from the group consisting of osteoporosis,. . . amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a **selective estrogen** receptor modulator or prodrug thereof, said modulator having the following formula: ##STR12## wherein R₁ and R₂ are independently hydrogen, hydroxyl or a. . .

amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a selective estrogen receptor modulator or prodrug thereof, said modulator being a different compound from said estrogen and being a different compound from a benzothiophene.

. amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a selective estrogen receptor modulator or prodrug thereof, said modulator being a different compound from said estrogen, further comprising the step of administering, as part. . .

- 5. The method of claim 4, wherein the selective estrogen receptor modulator has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms, . . . 7. The method of claim 5, wherein the selective estrogen receptor modulator is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.
- 8. The method of claim 5, wherein the **selective estrogen receptor modulator** is a **triphenylethylene** or diphenylhydronaphthalene derivative compound of the following formula: ##STR15## wherein D is $-OCH_{2CH2N}(R_3)R_4$, $-OCH_{2CH2OH}$, or -CH.dbd.CH--COOH (R_3 and R_4 either. . . 9. The method of claim 1, wherein **selective estrogen receptor**
- 9. The method of claim 1, wherein selective estrogen receptor modulator is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.
- 10. The method of claim 5, wherein the **selective estrogen receptor modulator** is a centchroman derivative compound of the following formula: ##STR16## wherein R_1 and R_2 are independently selected from the group. . .
- 16. The method of claim 14, wherein said **selective estrogen receptor modulator** is selected from the group consisting of: ##STR21## wherein all of the foregoing molecular structures whose stereochemistry is indicated are. . .
- 19. The method claim 1, wherein said selective estrogen receptor modulator is: ##STR22## and is optically active due to a majority of its stereoisomers being of 2S configuration; and wherein the. . . 21. The method of claim 1, wherein the selective estrogen receptor modulator has no estrogenic activity in breast or endometrium tissues.
- 24. The method of claim 1, wherein menopausal symptoms are selected from the group consisting of **hot flashes**, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.
- 26. The method of claim 2, wherein the selective estrogen receptor modulator has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms,. . . 28. The method of claim 26, wherein the selective estrogen receptor modulator is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.

- 30. The method of claim 2, wherein selective estrogen receptor modulator is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, lodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.
- 31. The method of claim 26, wherein the selective estrogen receptor modulator is a centchroman derivative compound of the #STR25## wherein R_1 and R_2 are following formula: independently selected from the group.
- 33. The method of claim 26, wherein the selective estrogen receptor modulator has the following formula: ##STR26## wherein $\rm R_{\rm l}$ and $\rm R_{\rm l}$ are independently hydrogen, hydroxyl or a moiety which is converted to. . .
- 37. The method of claim 35, wherein said selective estrogen receptor modulator is selected from the group consisting of: ##STR29## wherein all of the foregoing molecular structures whose
- stereochemistry is indicated are. . . 40. The method claim 2, wherein said selective estrogen receptor modulator is: ##STR30## and is optically active due to a majority of its stereoisomers being of 2S configuration; and wherein the.
- 42. The method of claim 2, wherein the selective estrogen receptor modulator has no estrogenic activity in breast or endometrium tissues.
- 45. The method of claim 2, wherein menopausal symptoms are selected from the group consisting of hot flashes, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.
- 47. The method of claim 1, wherein said condition is hyperlipidemia, said selective estrogen receptor modulator is EM-652.HCl and said estrogen is 17β -estradiol.
- 48. The method of claim 4, wherein said condition is hyperlipidemia, said selective estrogen receptor modulator is EM-652.HCl, said estrogen is 17β -estradiol and said additional agent is dehydroepiandrosterone.

L21 ANSWER 16 OF 20 USPATFULL on STN

Full Text

2003:57944 USPATFULL AN

TI Selective estrogen receptor modulators in combination with estrogens ΡI

US 2003040510 A1 20030227

CLM What is claimed is:

- amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a selective estrogen receptor modulator or prodrug thereof, said modulator being a different compound from said estrogen and not being a benzothiophene or a phenylindole.
- amount of an estrogen or prodrug thereof in association with administering to said patient a therapeutically effective amount of a selective estrogen receptor modulator or prodrug thereof, said modulator being a different compound from said estrogen and not being a phenylindole derivative, further comprising.
- 4. The method of claim 1, wherein the selective estrogen receptor modulator has a molecular formula with the following features: a) two aromatic rings spaced by 1 to 2 intervening carbon atoms,.
- 6. The method of claim 4, wherein the selective estrogen receptor modulator is selected from the group consisting of a triphenylethylene derivative, benzopyran derivative, HMR 3339, HMR 3656, LY 335124, LY 326315, SH 646, ERA 923 and centchroman derivative.
- 7. The method of claim 8, wherein the selective estrogen receptor modulator is a benzothiophene derivative compound of the following ##STR13## wherein R_1 and R_2 are independently selected from the group.
- 8. The method of claim 7, wherein the selective estrogen receptor modulator is selected from the group consisting of Raloxifene, LY 353381 and LY 335563.
- 9. The method of claim 4, wherein the selective estrogen receptor modulator is a triphenylethylene or diphenylhydronaphthalene

derivative compound of the following formula: ##STR14## wherein D is

- --OCH_{2CH2N}(R₃)R₄, --OCH_{2CH2OH}, or --CH.dbd.CH--COOH (R₃ and R₄ either. . 10. The method of claim 1, wherein selective estrogen receptor modulator is selected from the group consisting of OH-tamoxifen, Droloxifene, Toremifene, Iodoxifene, Lasofoxifene, iproxifene, FC 1271, and GW5638.
- 11. The method of claim 4, wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following ##STR15## wherein R_1 and R_2 are independently selected from the group.
- 13. The method of claim 4 wherein the selective estrogen receptor modulator has the following formula: ##STR16## wherein R, and R, are independently hydrogen, hydroxyl or a moiety which is converted to.
- 17. The method of claim 15, wherein said selective estrogen receptor modulator is selected from the group consisting of: ##STR19## wherein all of the foregoing molecular structures whose stereochemistry is indicated are.
- 20. The method claim 1, wherein said selective estrogen receptor ##STR20## and is optically active due to a majority of modulator is: its stereoisomers being of 2S configuration; and wherein the. 22. The method of claim 1, wherein the selective estrogen receptor modulator has no estrogenic activity in breast or endometrium tissues.
- 25. The method of claim 1, wherein menopausal symptoms are selected from the group consisting of hot flashes, vasomotor symptoms, irregular menstruation, vaginal dryness, headache and sleep disturbance.

L21 ANSWER 17 OF 20 USPATFULL on STN

Full Text

ΡI

2003:29916 USPATFULL AN

Soy formulations and their use for promoting health ΤI

US 2003021859 A1 20030130

What is claimed is: CLM

- 33. The pharmacological composition of claim 32 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.
- 36. The pharmacological composition of claim 35 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.
- 39. The pharmacological composition of claim 38 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.
- 50. The method of claim 49 wherein the menopausal like symptoms comprise hot flashes, vaginal itching, vaginal dryness, irritability, insomnia, night sweats, headaches and/or mood swings.

L21 ANSWER 18 OF 20 USPATFULL on STN

Full Text

AN 2002:192152 USPATFULL

SOY FORMULATIONS AND THEIR USE FOR PROMOTING HEALTH ΤI

A1 20020801 PT US 2002103223 US 6482448 20021119 B2

CLM What is claimed is:

- 33. The pharmacological composition of claim 32 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.
- 36. The pharmacological composition of claim 35 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.
- 39. The pharmacological composition of claim 38 wherein the medicinal composition comprises: Premarin; Fosamax; Raloxifene; Tamoxifen; or an SERM.

50. The method of claim 49 wherein the menopausal like symptoms comprise hot flashes, vaginal itching, vaginal dryness, irritability, insomnia, night sweats, headaches and/or mood swings.

L21 ANSWER 19 OF 20 USPATFULL on STN

Full Text

AN 2002:27435 USPATFULL

TI Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist

PI US 2002016283 A1 20020207

CLM What is claimed is:

- 1. A method of treating **hot flashes** in a patient comprising: providing a tachykinin receptor antagonist and administering the tachykinin receptor antagonist to a patient experiencing **hot flashes** under conditions effective to treat the **hot flashes**.
- 15. The method according to claim 14, wherein the anti-estrogen compound is tamoxifen.
- 17. The method according to claim 16, wherein the male patient experiences drug induced hot flashes.

L21 ANSWER 20 OF 20 USPATFULL on STN

Full Text

AN 2001:191165 USPATFULL

TI Method of treating symptoms of hormonal variation, including hot flashes

PI US 6310098 B1 20011030

CLM What is claimed is:

- 1. A method of treating hot flashes in a patient comprising: providing a compound which binds an $\alpha_2\delta$ subunit of a voltage-gated calcium channel and administering the compound to a patient experiencing hot flashes under conditions effective to treat the hot flashes.
- 11. The method according to claim 10, wherein the anti-estrogen compound is tamoxifen.
- 13. The method according to claim 12, wherein the male patient experiences drug induced hot flashes.

=> log y COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 60.58 157.83

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 23:30:45 ON 30 MAR 2007

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

L	BLACK BORDERS
	IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
	FADED TEXT OR DRAWING
A	BLURED OR ILLEGIBLE TEXT OR DRAWING
	SKEWED/SLANTED IMAGES
	COLORED OR BLACK AND WHITE PHOTOGRAPHS
	GRAY SCALE DOCUMENTS
	LINES OR MARKS ON ORIGINAL DOCUMENT
The state of the s	REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
' 0	OTHER:

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents will not correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox